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ABSTRACT OF DISSERTATION

MEDICATION MISADVENTRUES:
THE CASE OF BENZODIAZEPINES
For patients afflicted with symptoms of anxiety and insomnia, benzodiazepines are
generally a safe and effective short-term pharmacological treatment option. Although
considered safer than other sedative-hypnotic medications, substantial concern exists regarding
the addictive nature and abuse potential of benzodiazepines along with potentially
inappropriate prescribing and utilization in clinically vulnerable populations. These medication
misadventures can have a significant impact on public health. Examples of medication
misadventures as they pertain to benzodiazepines include the prescribing and use in clinically
vulnerable populations for whom they are contraindicated or their efficacy has not been
evaluated, the development of tolerance or addiction, abuse of the medication, and the
manifestation of negative health outcomes including cognitive impairment, withdrawal
symptoms upon discontinuation, or the reoccurrence of a preexisting substance use disorder.
In order to better understand medication misadventures associated with
benzodiazepines retrospective analyses using populations extracted from large health claims
databases are employed. To understand how benzodiazepine use may lead to adverse events
causing patient harm, the risk of exacerbations in benzodiazepine users diagnosed with chronic
obstructive pulmonary disease was estimated. The inherent risk of benzodiazepine addiction
and abuse was estimated in an HIV-infected population, a population with a high prevalence of
substance use disorders. This risk was estimated by first determining whether HIV-infected
individuals are more likely to have any benzodiazepine use compared to their uninfected
counterparts, and secondly, by examining the association between HIV-infection and potentially
problematic benzodiazepine use. Finally, in an effort to mitigate unexpected and undesirable
consequences to public health associated with the prescription drug abuse epidemic in the US,
states have implemented prescription drug monitoring programs (PDMPs) to track the
prescribing and dispensing of controlled substance medications. The effect of these programs on
benzodiazepine dispensing is evaluated on a state and national level.
Findings will provide healthcare professionals a better understanding regarding the risk
of medication misadventures involving benzodiazepines when evaluating their appropriateness
in patients with anxiety, depression, and insomnia. Additionally, policymakers will understand
the implications of PDMPs on the dispensing of benzodiazepines as they become a more widely
used tool to combat prescription drug abuse and diversion.

Keywords: benzodiazepines, Prescription drug abuse, Medication misadventures, substance
abuse, prescription drug monitoring programs
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CHAPTER 1: A REVIEW OF THE BENZODIAZEPINE LITERATURE: POLICY AND OUTCOMES.
BACKGROUND
In 1955, chemist Leo Sternbach, while working for the Hoffmann La Roche company,
created the drug chlordiazepoxide, the first drug in the chemical class of benzodiazepines
(informally “benzo”; abbreviated “BZD”).1 Benzodiazepines are indicated for use as anxiolytics,
sedatives, hypnotics, anticonvulsants, and/or skeletal muscle relaxants.2 At the time of their
discovery, benzodiazepines were comparatively efficacious and appeared to be safer than
similar drugs on the market including barbiturates and meprobamate.3 Compared to these
drugs, benzodiazepines had a lower abuse potential,2,3 produced less toxicity in acute
overdoses,2 and reduced the risk of respiratory depression.4 Additionally, barbiturates and
meprobamate often produced unwanted effects including sedation at anxiolytic dosages,
headaches, paradoxical excitement, confusion, and cognitive and psychomotor impairment.3
Hoffmann La Roche patented Sternbach’s discovery in 1959, and in 1960 the first
benzodiazepine was marketed as Librium® (chlordiazepoxide).1 Following the success of
chlordiazepoxide Roche launched the popular drug Valium® (diazepam). Between 1969 and
1982, diazepam was the most prescribed drug in the United States with greater than 2.8 billion
tablets sold in 19783 and was celebrated as “mother’s little helper” after being referenced as
such in a 1966 song by the Rolling Stones of the same name.5
The effects benzodiazepines produce result from action at the limbic, thalamic, and
hypothalamic levels of the central nervous system (CNS). Benzodiazepines bind to receptors for
the main inhibitory neurotransmitter in the CNS, the γ-aminobutyric acid (GABA), specifically the
GABAA receptor located in the synapses of neurons.6 Benzodiazepines bind to the GABAA
receptor they do not activate it directly, instead they serve to potentiate the inhibitory effects of
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GABA.6 Effects are produced after the first dose and, following oral administration, occur within
15 to 45 minutes with a duration of action of approximately seven to eight hours.2 In general,
most benzodiazepines can be used interchangeably6 and diazepam milligram equivalents (DMEs)
are used to adjust for variations in the potency between individual drugs.7 Differences in use
between benzodiazepines reflect the manner in which the drugs have been studied and
marketed by the manufacturer.2 While there is no evidence to suggest that one benzodiazepine
is more effective than any other at equivalent dosages, pharmacokinetic differences, such as the
metabolic half-life, are important to consider when prescribing these drugs.2 For example,
benzodiazepines with a shorter half-life are often preferred in the management of insomnia in
order to minimize daytime drowsiness8 while longer half-life benzodiazepines are recommended
for managing symptoms of anxiety to allow the drug to accumulate in the body.9 Drug marketing
information, therapeutic uses, and DME ratios of benzodiazepines currently marketed in the
United States are summarized in Table 1.1.
To date, more than 1,000 benzodiazepines have been synthesized,10 and remain the
most frequently dispensed psychotropic drug class.11 In 2012 benzodiazepines were the 10th
most prescribed drug class in the United States with approximately 94 million prescriptions
dispensed.12 Alprazolam was the most commonly dispensed benzodiazepine with 49 million
prescriptions dispensed in 2012 and ranked as the 13th most commonly dispensed medication in
the United States.13 Although considered safer than other sedative-hypnotics drugs, such as
barbiturates and meprobamate,2,3,6 the potential exists for benzodiazepines to be abused
because of their addictive nature. Due to their abuse potential benzodiazepines are classified as
a Schedule IV controlled substance (CS) in the classification system implemented by the
Controlled Substance Act of 1970.
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The abuse of benzodiazepines typically refers to recreational, non-medical use of the
drug in order to achieve a “high” or euphoric effect14 and frequently begins with a legitimate
prescription that is intentionally misused.15 Rarely are benzodiazepines the preferred or the sole
drug of abuse; instead abuse commonly occurs in conjunction with other substances, mainly
opioids and alcohol.16 Clinical evidence shows that benzodiazepines and opioids, when used
concurrently exert synergistic effects.17-23 Further evidence explaining the reasons for the
concomitant use of these drugs suggest benzodiazepines increase the rewarding and reinforcing
effects of opioids.24-27 Benzodiazepines with a rapid onset of action tend to be abused more
frequently.15,28,29 The exception is diazepam, while considered a long-acting benzodiazepine, it is
highly lipophilic and crosses the blood-brain barrier rapidly making it very susceptible for
abuse.15,28
Medication misadventures
Despite guidelines and recommendations regarding the appropriate prescribing of
benzodiazepines, they are often misused in the clinical setting. This inappropriate use can result
in medication misadventures, defined by the American Society of Health-System Pharmacists as
an iatrogenic hazard or incident associated with medication therapy.30 Medication
misadventures are comprised of medication errors (any preventable event that may cause or
lead to inappropriate medication use or patient harm), adverse drug events (an injury from a
medicine or lack of intended medicine), and adverse drug reactions (any unexpected,
unintended, undesired, or excessive response to a medicine).30 The literature provides several
examples of medication misadventures as they pertain to benzodiazepines.
For example, benzodiazepines are only recommended for short-term use, as their longterm anxiolytic efficacy (less than or equal to 4 months) has not been evaluated;2 however, a
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sizable proportion of the population are considered to be chronic users. Studies from several
countries have estimated that between 0.5% and 5.8% of the adult population engages in longterm benzodiazepine use of one year or more.31-33 Concerns have risen that long-term
benzodiazepine use may lead to cognitive impairment. A significant effect on cognitive functions
including sensory processing, psychomotor speed, attention/concentration, and motor
control/performance has been observed following long-term benzodiazepine use.34 Long-term
use of benzodiazepines also carries the risk of increasing tolerance to the drug’s effects and the
development of dependence. Tolerance to the effects of benzodiazepines often leads to dosage
escalation in order to maintain the same level of desired effects.28,35 This tolerance and
subsequent increase in dosage can lead to dependency although it is possible for
benzodiazepine dependency to develop within normal therapeutic ranges.34,35 Benzodiazepine
dependency can manifest physiologically or psychologically and it is has been estimated that
approximated 35% of all patients who have taken a benzodiazepine for at least four weeks
develop some type of dependency upon the drug.36
Physiologic dependence on benzodiazepines leads to the risk of withdrawal symptoms if
the drug is suddenly discontinued or the dosage drastically reduced.28,34,37,38 Common
withdrawal symptoms include rebound anxiety and insomnia, agitation, tension, dysphoria,
sweating, irritability, impaired concentration, and weight loss.2 More serious withdrawal
symptoms have also been reported such as grand mal seizures,39-41 nonconvulsive status
epilepticus,42 delirium,39,40 and death.40,43 The severity of benzodiazepine withdrawal and the
inability to taper successfully can be attributed to factors associated with the benzodiazepine
therapy along with individual patient characteristics44-46 (Table 3) and to minimize the risk of
withdrawal symptoms that benzodiazepines be discontinued gradually.47
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Benzodiazepines are also commonly prescribed in clinically vulnerable populations for
whom they are contraindicated or their efficacy has not been evaluated. Use of benzodiazepines
in these clinically vulnerable populations is a controversial practice. Some experts recommend
that benzodiazepines use be avoided in patients with a substance use disorder (SUD) history as
they may exacerbate the preexisting SUD.29,48 Additionally, patients with a SUD may be more
likely to abuse prescribed benzodiazepines. According to a recent study in the Netherlands,
patients with alcohol dependence are at an increased risk of developing benzodiazepine
dependence.49 Recent evidence also advises against the use of benzodiazepines among patients
with very severe respiratory disease including chronic obstructive pulmonary disease (COPD) as
use may lead to severe adverse events including respiratory depression50 and mortality.51
Furthermore, benzodiazepine use in the elderly population, has been associated with negative
health outcomes including cognitive impairment, falls, and fractures.52,53
The purpose of this series of papers is to review current issues related to the medication
misadventures as they pertain to benzodiazepines. More specifically, the goals of this series of
papers is to quantify the prevalence of benzodiazepine misuse and abuse, examine health
outcomes associated with the suboptimal use of benzodiazepines in clinically vulnerable
populations, and test the impact of policies designed to reduce prescription drug abuse and
diversion on the utilization of benzodiazepines. The specific aims of this literature review are to
describe health outcomes associated with potentially inappropriate benzodiazepine use in
specific populations, and to review policies that have been implemented to monitor transactions
involving benzodiazepines and their impact on benzodiazepine prescribing and dispensing.
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METHODS
The search engines of PubMed, Medline, and Google Scholar were used to search from
combinations of the following key words and phrases: benzodiazepines, drug abuse, nonmedical
prescription drug use, benzodiazepine poly-drug abuse, benzodiazepine misuse, health
outcomes, medication misadventures, benzodiazepine monitoring, prescription drug monitoring
program (PDMP), prescription monitoring program (PMP), and triplicate prescribing program
(TPP). Searches of these databases were conducted between January and April 2014. Retrieved
articles published in a language other than English were excluded from further review. Titles and
abstracts of remaining articles were assessed for relevance to this review. Additionally,
references cited in selected articles were examined and appropriate articles were considered
based on their unique contribution to this review. The reviewed articles were grouped into two
themes: prescription drug monitoring policies designed to mitigate consequences connected
with prescription drug abuse and diversion, and health outcomes associated with potentially
inappropriate benzodiazepine use.
FEDERAL AND STATE BENZODIAZEPINE POLICIES
Prescription drug abuse can be categorized as a type of medication misadventure
leading to an adverse drug event or adverse drug reaction that can lead to injuries, a declined
state of health, and death. Throughout history, several strategies have been implemented to
address problems associated with the misuse, abuse, and diversion of psychoactive compounds.
In the case of benzodiazepines, three strategies imposed by the US federal and state
governments have had the most profound impact. First was the Controlled Substance Act of
1970 that classified potential drugs of abuse into Schedules and regulated transactions involving
controlled substances (CS). Next, in 1989, New York became the first state to include
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benzodiazepines on their TPP in order to monitor their prescribing and dispensing. Finally, in an
effort to combat the problem of prescription drug abuse and diversion, many states have
implemented PDMPs to track the prescribing and dispensing of CS, with the majority of states
monitoring benzodiazepine transactions.
Controlled Substance Act of 1970
On October 27, 1970, President Richard Nixon signed into law the Comprehensive Drug
Abuse Prevention and Control Act of 1970 in response to the increasing problem of illicit drug
use, especially narcotics, which had become widespread in the late 1960s.54 Title II of the
Comprehensive Drug Abuse Prevention and Control Act of 1970, the Controlled Substance Act of
1970, created a complex regulatory system to control the distribution of drugs. The Controlled
Substance Act created a classification system categorizing licit and illicit drugs into five
categories called “Schedules” based on abuse potential, significance of abuse, dependence
liability, the risk to public health, and scientific evidence regarding accepted medical use.55
Substances classified as Schedule I currently have no accepted medical use in the United States
with drugs included in Schedules II through V considered “necessary to maintain the health and
general welfare of the American people.”55 Substances in the Schedule II category have been
determined to have the greatest abuse potential while Schedule V CS have the least. The
responsibility of adding drugs to CS Schedules and modifying the Schedules of already included
substances falls upon the Drug Enforcement Administration (DEA) and the Food and Drug
Administration. According to the criteria outlined by the Controlled Substance Act,
benzodiazepines are defined as a Schedule IV CS. A description of the CS classification system
and examples of drugs in each Schedule is provided in Table 3.
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In addition to classifying CS into Schedules, the Controlled Substance Act also led to the
regulation of transactions involving CS at the manufacturing and wholesale level. This aspect of
the legislation was in response to the growing problem of illicit manufacturing and smuggling of
CS from research laboratories to be sold on the black-market.56 Individuals and firms who
handle these drugs must register with the DEA and receive a registration number to be used on
all transactions involving CS. Authorized handlers of CS include manufactures, distributors,
hospitals, pharmacies, practitioners, and researchers. While all authorized handlers must
maintain complete and accurate records of all their CS transactions only manufacturers are
required to make periodic reports to the Attorney General.57,58 An amendment to the Controlled
Substance Act regarding the reporting of CS transactions occurred in 2008 as part of the Ryan
Haight Online Pharmacy Consumer Protection Act. This legislation requires certain pharmacies
distributing CS via the Internet to provide detailed reports of their CS transactions to the
Attorney General.59
New York’s Triplicate Prescription Program
Since the 1930s individual states have seen the need to collect and analyze prescribing
and dispensing data pertaining to certain medications. In 1939, California became the first state
to implement a PMP.60 Early monitoring programs relied upon the use of multiple copy
prescription forms and were implemented in nine states.61 These monitoring programs required
physicians to use government-issued serialized forms to write prescriptions for targeted drugs.62
Ordering physicians would retain one copy of the prescription and give the remaining copies to
the patient. Patients then would take their prescription to the pharmacy to be filled. At this
point, the pharmacy would retain the other copies of the prescription, keeping one copy for
their own records and submitting the remaining copy to the state surveillance unit.
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On January 1, 1989, New York became the first state to include benzodiazepines in their
list of targeted drugs monitored by the state’s TPP with the primary objectives of reducing
benzodiazepine diversion for illicit use and reducing inappropriate prescribing.63-65 This program
allowed regulatory agencies to track the prescribing, dispensing, and utilization of targeted
drugs by providers, pharmacies, and patients suspected of misusing these medications.66 With
the exception of certain conditions, such as panic and convulsive disorders, the addition of
benzodiazepines to the TPP limited prescriptions to a 30-day supply. In addition, refills were not
permitted, requiring a patient to visit their provider when a new prescription was needed.67
Multiple copy prescription programs were strongly supported by the DEA, citing vast
reductions of CS prescribing in states with an operational program.68 Furthermore, it was
emphasized these reductions were solely due to declines in inappropriate prescribing, in other
words, there was no negative impact to CS access for patients with a legitimate CS need.68 Early
reports by the New York Department of Health proclaimed that adding benzodiazepines to the
targeted drug list monitored by the state’s TPP had not only succeeded in reducing the abuse of
benzodiazepines and their diversion into the illicit market, but had done so without creating
access limitations for legitimate users.67 The success in reducing the abuse and diversion of
benzodiazepines was supported by drastic increases in the street price of benzodiazepines (1mg
of alprazolam rose from $1.50 to $8.50 and 10mg of diazepam went from $2.00-$2.50 to $4.50$6.00), along with reduced mentions of benzodiazepines in the Drug Abuse Warning Network
(DAWN), and a large decline in the number of Medicaid benzodiazepine prescriptions filled.69
However, the claim of the TPP accomplishing these objectives without compromising
benzodiazepine access for legitimate patients was widely challenged in a series of studies
evaluating the change in policy.
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A study by Reidenberg70 compared the estimated number of benzodiazepine
prescriptions written in New York and Pennsylvania for the years 1988, one year prior to, and
1989, one year after, the TPP implementation in New York. Pennsylvania was chosen as a
comparator state as there was no policy change regarding benzodiazepine prescriptions during
the study period. Findings showed a 57% decrease in the estimated number of benzodiazepine
prescriptions in New York with only an 11% reduction occurring in Pennsylvania. The more
interesting finding was the dramatic increase in the number of prescriptions during the study
period for alternate sedative-hypnotics that are less effective in managing symptoms of anxiety
and insomnia and/or have a higher abuse potential than benzodiazepines (i.e., meprobamate,
buspirone, chloralhydrate, and hydroxyzine) in New York with no parallel changes observed in
Pennsylvania. Similar findings were also reported by Weintraub et al.71 Changes in the
prescribing of alternate sedative-hypnotics from 1988 to 1989 in New York were assessed and
compared them to nationwide trends using prescribing data from IMS America National
Prescription Audit. While in New York the prescribing of benzodiazepine alternatives
dramatically increased during the study timeframe, nationwide prescribing trends for these
medications remained steady or declined. Hoffman et al.,64 tested the presence of a substitution
effect by examining the incident cases of overdoses reported to the New York City Poison
Control Center for benzodiazepine and non-benzodiazepine sedative-hypnotics. The findings
suggest that following the addition of benzodiazepines to the list of drugs targeted by the New
York TPP the total number of sedative-hypnotic overdoses remained unchanged, but with a
significant reduction in benzodiazepine overdoses concurrent with a significant rise in nonbenzodiazepine sedative-hypnotic overdoses. As a result of the findings from the
aforementioned studies, further questions were raised regarding the impact of benzodiazepine
triplicate regulations on public health and patient care.
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Four studies examining the effect of the benzodiazepine triplicate prescription policy on
population subgroups suggested the triplicate prescription policy might have resulted in an
unintended decrease in legitimate benzodiazepine use for patients in therapeutic need of this
newly restricted medication.65,72-74 A large controlled study conducted by Ross-Degnan et al.65
examining the addition of benzodiazepines to the New York TPP on the dispensing of
benzodiazepines observed a 50% reduction in dispensing to Medicaid beneficiaries.
Furthermore, beneficiaries were classified as either problematic or non-problematic
benzodiazepine users based on the indicators of long-term use (i.e., use greater than 120 days
duration), excessive dosage (i.e., levels more than twice the recommended maximum),
concurrent use (i.e., concurrent use of two long-acting or two short-acting benzodiazepines),
pharmacy hopping (i.e., filling a prescription for the same benzodiazepine in two different
pharmacies within seven days), and elderly use of long half-life benzodiazepine. Findings of the
study showed that after benzodiazepines were added to the New York TPP the risk of
discontinuing benzodiazepine therapy was twice as high in New York compared to New Jersey
(relative risk (RR): 2.1; 95% confidence interval (CI): 2.1-2.1). Among New York Medicaid
beneficiaries, the RR of benzodiazepine discontinuation was greater in those with problematic
use compared to those with non-problematic use (RR: 1.3; 95% CI: 1.2-1.3). However, the
authors suggested that overall, because at baseline the majority of benzodiazepine dispensing
was identified as non-problematic the number of non-problematic users that had their
benzodiazepine discontinued greatly exceeded that of problematic users. This conclusion
implies that the inclusion of benzodiazepines on the list of drugs monitored by the TPP resulted
in a barrier to appropriate medication therapy for patients with a legitimate need. Results also
demonstrated a disproportionate impact on females, and residents of predominately urban,
black, and poor areas, with these beneficiaries experiencing comparatively higher
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benzodiazepine discontinuation rates after the policy change. However, differences in
demographic characteristics between beneficiaries identified as problematic and nonproblematic users were not provided. If problematic benzodiazepine dispensing at baseline
were greater in these population subgroups then a high discontinuation rate among these
beneficiaries would be expected and potentially appropriate.
Pearson et al.74 further explored the issue of racial disparities in benzodiazepine access
after the TPP policy change in a study of New York Medicaid beneficiaries. Changes in
benzodiazepine use in white, black, Hispanic, and mixed race neighborhoods were examined
and neighborhood racial composition was used as a predictor of benzodiazepine
discontinuation. The study observed beneficiaries residing in black neighborhoods were
consistently the most likely group to experience reduced access to benzodiazepines after the
TPP policy change. This is a concerning observation as residents in black neighborhoods had the
lowest baseline benzodiazepine utilization rates and the lowest baseline odds of problematic
benzodiazepine use. Furthermore, this leads to concerns that health policies, in the process of
achieving their intended goals, may disproportionally affect racial minorities, further widening
health disparities between people of different racial backgrounds.
Evidence of a substantial impact on access to benzodiazepine therapy among clinically
vulnerable populations was detected in two separate assessments. A 2003 evaluation by
Wagner and colleagues72 examined new benzodiazepine use among patients recently
discharged from the hospital for either an acute cardiac event or cancer. Benzodiazepines are
often prescribed to relieve anxiety associated with acute myocardial infarction and in cancer
patients to reduce anticipatory anxiety and anxiety related effects associated with the
administration of chemotherapy.2 The study found new benzodiazepine use among New York
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Medicaid beneficiaries recently discharged from the hospital for acute cardiac events and cancer
declined 72.5% and 69.4%, respectively during the two-year observation period after the
benzodiazepine triplicate regulation was implemented. Additionally, Simoni-Wastila et al.73
studied patients who had a diagnosis of schizophrenia, epilepsy, or bipolar disorder, where
benzodiazepines represent an effective first-line or adjunct treatment option, and demonstrated
a nearly 50% decline in benzodiazepine use six months after the policy change. Patients with a
seizure disorder experienced a 60% decline, the largest among the conditions assessed.
However, while benzodiazepines are a first-line agent for status epilepticus and acute seizures
their efficacy in treating chronic epilepsy is limited by the risk of side effects and development of
tolerance75 which may explain the significant decline in utilization among this population.
Furthermore, clinical outcomes for the populations in both studies were not assessed.
Therefore, it is unknown if patients for whom benzodiazepine therapy was not initiated, or
discontinued, were adversely affected. However, the authors of these studies concluded access
to appropriate pharmacotherapy had been restricted by the TPP policy change.
These studies highlight the potential for health policies to produce unintended
consequences that create barriers to healthcare access for already disadvantaged individuals.
While the addition of benzodiazepines to the New York TPP did not restrict physician prescribing
of benzodiazepines, concerns existed of reduced access to appropriate pharmacological care,
dubbed a “chilling effect”. The “chilling effect” describes a situation where a patient with a
legitimate need for a CS is unable to acquire it either due to a physician’s unwillingness to
prescribe or a pharmacist being unwilling or unable to dispense the CS. The unwillingness to
prescribe or dispense a CS may be due to fear of legal investigations, fear of confidentially
violations, increased administrative burden, or confusion between the patterns of addiction and
pseudoaddiction, where patients who are not being adequately treated for their condition
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appear, on paper, to be addicts.76-79 Additionally, patients with a legitimate CS need may be
unwilling to accept the medication due to concerns they may be labeled as a drug user in the
surveillance system.79
The reviewed studies support the claim that benzodiazepine monitoring policies result
in an immediate, significant, and sustained decline of overall benzodiazepine use. In addition,
these studies identify reductions in problematic or inappropriate benzodiazepine use as a result
of the benzodiazepine TPP regulation, a primary goal of the policy amendment. Evidence of
unintended consequences, such as a “chilling effect” and a differential impact among certain
population subgroups were also supported. However, the reviewed studies only assessed the
effect of the New York TPP. Benzodiazepine monitoring policies in other states may affect
patterns of benzodiazepine use differently based on physician prescribing practices, prevalence
rates of mental illnesses, and variations in abused/misused substances. Furthermore, each of
these studies exclusively relied upon data from a Medicaid population. Therefore, it is unknown
how benzodiazepine monitoring programs affect use among privately insured populations.
Moreover, clinical outcomes of the study populations after the TPP were not assessed. Without
this information it is undetermined if patients who were discontinued from benzodiazepine
therapy experienced adverse health outcomes as a result of the new regulation. Use of clinical
outcomes would provide a more accurate depiction of the impact of the TPP on inappropriate
and legitimate benzodiazepine use, as the proxy developed by the Advisory Panel described in
Ross-Degnan et al.65 does not contain diagnostic information, thus limiting the ability to
distinguish between specific instances of appropriate and inappropriate use.
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Prescription Drug Monitoring Programs
In the 1990s, states began to rely on electronic data transfer systems to track the
prescribing, dispensing, and utilization of targeted medications in an effort to combat
prescription drug abuse and diversion. Because of these electronic systems, states have
repealed their multiple copy prescription programs in favor of PDMPs. In 2006, California
became the last state to repeal their multiple copy prescription program, which they had been
using concurrently with their electronic PDMP since 1997.61 Prescription drug monitoring
programs have an added advantage over multiple copy prescription programs as they provide
prescribers and pharmacists with the ability to request and receive a patient’s CS prescription
history with quick turnaround, allowing treatment decisions to be made at the point of care.
Reports detailing a patient’s CS prescription history can be accessed upon request, or
proactively distributed to specific healthcare providers and law enforcement officials, depending
upon the regulations of the individual state’s program. Pharmacies, along with dispensing
physician and veterinarian offices submit CS dispensing data to the PDMP on a regular basis as
mandated by state law. The majority of states require CS dispensing data to be submitted at
least every seven days with some states requiring daily or “real-time” reporting.80 Prescription
data submitted to PDMPs follows a standard format and includes patient name, prescriber
name, date of dispensing, and name, strength, and quantity of the CS medication dispensed. As
of December 2014, 49 states have an operational PDMP. Missouri and Washington DC do not
currently have a PDMP, however, Washington DC does have pending legislation.80
While all PDMPs were designed to facilitate collection, analysis and reporting of
prescription controlled substance use, in practice they take several different forms based upon
individual state legislation and differ in terms of objectives, design, and operations.58 Housing
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agencies of PDMPs vary between states with the majority of PDMPs housed within health
departments, a single state authority (an entity designated as a state’s administrative authority
responsible for the planning and implementation of statewide systems that provides substance
abuse services81), or Boards of Pharmacy.80 Seven states house their PDMP within a law
enforcement agency.80 Variation exists across states in terms of authorized users and access to
the PDMP system and PDMP reports. In most states healthcare professionals including
prescribers and dispensers of CS, along with regulatory and licensing boards are authorized to
receive the information contained within PDMP reports, however, access among law
enforcement personnel is less uniform.80 States also differ in the CS schedules monitored. While
all state PDMPs track the dispensing of Schedule II CS, some states also monitor Schedules III, IV,
and V. Some state PDMPs also have the authority to monitor non-CS under certain
circumstances.82 Relevant for this work, of the 49 operational PDMPs as a December 2014, 48
have the authority to monitor the prescribing and dispensing of Schedule IV CS which include
benzodiazepines.80,83 A list of states with active PDMPs and a description of CS Schedules
monitored is provided in Table 4. Of note, Pennsylvania is the only state with a PDMP that does
not monitor Schedule IV CS, including benzodiazepines.
The limited studies conducted regarding the effectiveness of PDMPs suggest these
programs are successful in reducing the supply of CS. One study conducted by the United States
General Accounting Office released in 2002 examined the presence of a PDMP in the ten states
with the highest and lowest per capita OxyContin prescriptions. Among the ten states with the
greatest number of OxyContin prescriptions per capita, only two (Kentucky and Rhode Island)
had an active PDMP. Comparatively, six of the ten states with the lowest number of
prescriptions per capita had a PDMP in place.58 A 2006 evaluation of PDMPs by Simeone and
Holland84 used state and individual level models to estimate the relationship between the
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presence of a PDMP, the supply of Schedule II CS, and the abuse of these medications. Using
data from the Automation of Reports and Consolidated Orders System (ARCOS), which monitors
the sale of CS through commercial channels, the per capita supply of Schedule II CS over the
seven-year study period was found to be reduced in states with an active PDMP compared to
states without a PDMP.
Conversely, PDMPs may not be associated with improved health outcomes as some
studies suggest that PDMPs have a limited impact on overall opioid consumption and drug
overdose mortality. Twillman85 conducted a review of the ARCOS database and identified a
decrease in the supply of Schedule II opioid analgesics along with a concurrent increase in
Schedule III opioid analgesics among states with an active PDMP. Paulozzi, Kilbourne, and
Desai86 also analyzed the ARCOS database and noted that during the study period from 1999 to
2005, PDMPs were not associated with lower rates of overall opioid consumption and like
Twillman85 found PDMPs were associated with lower rates of Schedule II opioid analgesic use
but not Schedule III opioid analgesics. Similar findings were reported in a 2012 cross sectional
study conducted by Simoni-Wastila and Qian87 who estimated the association between the
presence of a PDMP and the probability of analgesic use by CS Schedule among older, privately
insured adults. Results showed the odds of filling any opioid analgesic prescription were greater
in states with a PDMP. More specifically, beneficiaries in states with an active PDMP had
decreased odds of filling a prescription for a Schedule II opioid analgesic and increased odds for
Schedule III opioid analgesics when compared to beneficiaries in states absent of a PDMP.
Recently, Brady et al.88 found that on a national level PDMPs are ineffective at significantly
reducing the amount of opioids distributed per capita, but when examined at the state level
there are marked variations among the effect of programs. Li et al.89 found similar results when
examining the impact of PDMPs on drug overdose mortality. On a national scale the presence of
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a PDMP was associated with and 11% increase in drug overdose mortality, however, significant
state variations were found ranging from a 35% decrease in Michigan to a 337% increase in
Nevada. The findings presented by Brady et al. and Li et al. suggest that it is specific
characteristics of PDMPs that have the greatest impact on prescription drug abuse and diversion
as opposed to the presence of a program alone.
In clinical practice there is limited literature examining how PDMPs impact CS behaviors.
Baehren et al.90 studied how PDMP reports affected the prescribing decisions by emergency
room physicians at a university hospital in Ohio for patients presenting with non-acute pain. In
41% of cases the physician chose to alter their initial CS pain medication prescribing decision
after reviewing a patient’s PDMP report with 60% of these cases resulting in fewer of no CS pain
medications being prescribed. Green et al.91 surveyed pharmacists in Connecticut and Rhode
Island to understand how PDMPs influence their practice. Responding pharmacists reported
they used reports generated by the PDMP to screen for abuse and doctor shopping but the
effect on CS dispensing behavior was not evaluated. A 2010 independent study conducted by
Blumenschein et al.82 surveyed CS prescribers and dispensers in Kentucky and found that for
46% of prescribers and 34% of pharmacists the information contained within the PDMP report
had altered their CS prescribing or dispensing decision.
To date, studies regarding current PDMP legislation have focused primarily on the
impact concerning opioid analgesic prescribing and use. Focus on this medication class is
understandable as opioid analgesics are the primary contributor to the increasing trend of drug
overdose deaths in the United States.92-94 However, other CS, specifically benzodiazepines, have
been found to be a factor contributing to the substantial rise in unintentional poisoning
deaths92,95-97 likely related to the additive or synergistic effects when benzodiazepines are
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combined with opioids.98 In West Virginia, a forensic drug database review conducted by Shah et
al.97 found that the proportion of drug-related deaths where alprazolam was a contributing
factor increased from 7.2% in 2005 to 27.5% in 2007. An analysis of medical examiner records
from New York City found that benzodiazepine use concurrent with methadone maintenance
therapy increased the odds of an accidental overdose by 1.66 (95 % CI: 1.12, 2.45).99 Similar
results were also reported in a study of opioid-related deaths in the United Kingdom.
Interestingly, among the deaths primarily attributable to methadone in which benzodiazepines
were detected, the blood concentration levels of methadone were considered to be within
therapeutic ranges.100
Utilization of PDMPs can aid in the identification of potentially inappropriate prescribing
and dispensing involving benzodiazepine medications. In the approximately 50% of drug-related
deaths in West Virginia where opioids and benzodiazepines were identified through toxicology
analysis, the deceased had a legal prescription for both medications.97 Additionally, among the
deceased with more than one benzodiazepine detected at the time of death, the majority (63%)
had a valid prescription for each medication.97 As many electronic PDMPs allow prescribers
nearly instantaneous feedback of a patient’s CS prescription history, use of these systems can
alert prescribers to possible doctor shopping and inappropriate or risky adjunct CS prescribing.
This information allows the prescriber to intervene in suspected cases of drug abuse and
diversion by referring the patient to substance abuse treatment or conducting drug screens to
ensure the patient is taking, and not diverting, the prescribed CS, thereby reducing the risk of
unintentional poisonings.
Previous literature on benzodiazepine monitoring has centered on the New York TPP
from the early 1990s. Given the noticeable absence of literature evaluating the impact of
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current PDMP legislation on benzodiazepine prescribing, dispensing, and utilization studies in
this area are warranted. Expanding the literature on current PDMP legislation to incorporate
benzodiazepines is necessary to understand if these programs are effectively meeting their
objectives of curbing the prescription drug abuse epidemic. Assessments of how PDMP policies
affect benzodiazepines is also needed to ensure patient safety by not restring access to
pharmacotherapy options among patients having a condition where benzodiazepine therapy is
appropriate.
BENZODIAZEPINE USE AND HEALTH OUTCOMES
In the United States it is estimated that in a given year approximately one-quarter of
adults 18 and older suffer from a diagnosable mental disorder.101 Anxiety disorders, including
panic disorder, post-traumatic stress disorder, generalized anxiety disorder, and phobias, are
the most prevalent mental disorder in the United States affecting about 40 million Americans or
18% of the adult population.101 Furthermore, patients who suffer from mental disorders,
including anxiety disorders, are also likely afflicted with symptoms of insomnia.102
Benzodiazepines are generally an effective pharmacological treatment option and are widely
prescribed for the management of symptoms related to anxiety disorders and insomnia.11,103
Despite their benefits, benzodiazepine therapy is not optimal for all populations.
Commission of benzodiazepine therapy has inherent risks and medication misadventures
involving benzodiazepines are common when they are used in clinically vulnerable populations.
The abuse potential of benzodiazepines and synergistic effect when coupled with opioid
analgesics can lead to the risk of medication errors including concurrent use of benzodiazepines
and opioid analgesics, duration of use exceeding that of proven efficacy, and escalation of
dosage beyond that prescribed by a physician. While medication errors sometimes have little or

20

no potential for patient harm they can be linked with mild to severe adverse drug events and
adverse drug reactions. Adverse drug events and adverse drug reactions may also present when
benzodiazepines are used in patients with certain comorbid conditions. These avoidable
incidents can lead to patient discomfort, progression of disease state, visits to the emergency
department, hospitalizations, and death.
Misuse and abuse of benzodiazepines
The misuse and abuse of benzodiazepines is a prevalent issue. According to the 2012
National Survey of Drug Use and Health,104 the estimated number of incident benzodiazepine
abusers was 166,000. National estimates of drug-related visits to emergency departments
collected by the Drug Abuse Warning Network105 (DAWN) for the year 2011 reported that
between 2004 and 2011 the number of emergency department visits for the non-medical use of
benzodiazepines increased 149% from 143,500 to 357,800. Additionally, this report identified
benzodiazepines as the second leading cause of all emergency department visits concerning
nonmedical use of pharmaceuticals, as they were involved in 28.7% of all emergency
department visits for this cause. Another recent study by Cai et al.106 examining data from
DAWN between 2004 and 2008 reported that benzodiazepines were identified in approximately
26% of all opioid related emergency department visits. These estimates suggest that
benzodiazepine misuse and abuse can lead to serious adverse effects on individuals and caution
must be exercised with their prescribing and use.
It has been suggested that patterns of benzodiazepine misuse and abuse can be
separated into two categories: deliberate and unintentional.15 Deliberate misuse and abuse of
benzodiazepines entails taking the drug to achieve a euphoric effect, while unintentional misuse
and abuse would include individuals with a valid prescription for the medication but take higher
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than suggested doses or take it for a prolonged period of time.15 Oftentimes benzodiazepines
are deliberately abused in combination with other drugs, most commonly alcohol and opioids,16
in order to enhance the effect provided by other substances. For example, in a survey of
methadone maintenance patients, 72% of those who were also regular benzodiazepine users
indicated that benzodiazepines were used in order to increase the effects of their daily
methadone dose.107 However, patients who are receiving methadone maintenance therapy and
are also regular users of benzodiazepines experience a greater mean number of overdoses (3.3
± 0.7) than occasional-users (1.8 ± 0.4) and non-users (0.7 ± 0.2; p=0.003).108 The co-use of
benzodiazepines and opioids is also common among patients treated for chronic pain with
surveys estimating between 40-60% of chronic pain patients also regularly using
benzodiazepines.109 It is undetermined if chronic pain patients use benzodiazepines in order to
enhance the pain relieving effects of opioids or to manage symptoms of anxiety and/or insomnia
that frequently coexist with chronic pain.110,111 Despite the frequency of concurrent use, the
combination of benzodiazepines and opioids can have detrimental effects on physical and
mental health. With this in mind, physicians should be aware of patterns that may signal
deliberate drug misuse and abuse in patients using one or both of these medications.
Benzodiazepine use, mental illness, and substance use disorders
Among patients with severe mental illness, such as schizophrenia, bipolar disorder, and
major depression, benzodiazepines are commonly prescribed to reduce symptoms of anxiety,
insomnia, and agitation and to manage side effects of other medications.112,113 The use of
benzodiazepines in patients with mental illness is a controversial practice due to the high
prevalence of SUDs in this population coupled with the abuse potential of benzodiazepines. The
2012 National Survey on Drug Use and Health found that 19.2% (8.4 million) of the 43.7 million
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adults with any mental illness also met the criteria for a SUD as specified within the 4th edition of
the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV).114 Comparatively, only 6.4%
(12.3 million) of adults without any mental illness were considered to have a SUD.114 Despite
concerns, benzodiazepine use is highly prevalent among individuals with mental illness and cooccurring SUDs.112,113 Clark, Xie, and Brunette112 reported that among Medicaid beneficiaries,
the prevalence of benzodiazepine use is greater in patients with severe mental illness and cooccurring SUDs than in patients with a severe mental illness alone. Wixson and Brouwer115
found that in a privately insured population, males infected with HIV were more likely (OR: 1.68;
95% CI: 1.05-2.67) to fill a benzodiazepine prescription compared to their uninfected
counterparts. This finding is of notable concern as the HIV-infected population has high
prevalence of mental illness and SUDs116 and substance abuse has been linked to poor
antiretroviral therapy adherence.117 Furthermore, in patients with severe mental illness and cooccurring SUDs benzodiazepine use did not improve symptoms of anxiety and depression.113
These findings suggest that further research into the appropriateness of benzodiazepine use in
mental illness patients with and without a co-occurring SUD is warranted due to concerns
regarding efficacy and abuse potential.
Benzodiazepines and adverse health outcomes
The use of benzodiazepines in certain clinically vulnerable populations carries a risk of
negative effects on health outcomes. For example, studies examining patients with COPD have
found evidence of a link between benzodiazepine use and several adverse respiratory outcomes
such as decreased minute ventilation,118,119 low levels of oxygen and high levels of carbon
dioxide in the blood,119,120 and a decrease in respiratory muscle strength.118 Moreover, joint
American Thoracic Society/European Respiratory Society guidelines recommend that hypnotics
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such as benzodiazepines not be used in patients with severe COPD.121 Despite these
recommendations, a 2013 study by Vozoris et al.122 examining benzodiazepine use in older
patients with COPD in Ontario found that new benzodiazepine use is common, occurring in
roughly one-third of the study population. The study also found that incident benzodiazepine
use was more common in patients with severe COPD than less severe COPD, suggesting that
patients who are most at risk of experiencing an adverse event related to benzodiazepine use
are the patients most likely to receive this medication class. New benzodiazepine use among the
COPD population was also found to increase the risk for outpatient respiratory exacerbations
(RR: 1.45; 95% CI: 1.36-1.54) and emergency department visits for COPD and pneumonia (RR:
1.92; 95% CI 1.69-2.18) in a 2014 study conducted by Vozoris et al.123 A 2007 study by
Winkelmayer and colleagues124 found a potential link between benzodiazepine use and an
increased risk in mortality in patients with COPD.
The safety of benzodiazepines in the management of posttraumatic stress disorder has
also been called into question. According to the Veterans Affairs (VA)/Department of Defense
Clinical Practice Guideline for Management of Post-Traumatic Stress125 regular benzodiazepine
use in the PTSD population is discouraged due to insufficient evidence supporting avoidance and
dissociation symptom improvement and concerns of safety, especially respiratory depression
and over-sedation when used concurrently with other drugs acting on the CNS. Instead, it is
recommended that SSRIs or serotonin and norepinephrine reuptake inhibitors (SNRIs) are used
as first line pharmacotherapy agents for treating PTSD. Even with these guidelines, Hawkins et
al.126 determined benzodiazepines were prescribed to nearly one-third (31%) of all VA patients
diagnosed with PTSD in 2009. Their study examining the comparative safety of adjunct
benzodiazepine therapy in addition to SSRIs/SNRIs versus SSRIs/SNRIs alone among VA patients
diagnosed with PTSD found that compared with patients who only received SSRIs/SNRIs, those
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who also concurrently used benzodiazepines had a significantly greater risk for a mental health
hospitalization (adjusted hazard ratio (AHR): 1.87; 95% CI: 1.37-2.53) and for any hospitalization
(AHR: 1.52; 95% CI: 1.16-2.00). The finding of increased adverse events in concurrent users of
SSRIs/SNRIs and benzodiazepines supports the current guidelines discouraging benzodiazepine
use for the management of PTSD due to safety concerns.
Benzodiazepine use in the elderly
In an elderly population adverse drug events can lead to increases in morbidity,
mortality, and hospitalizations.52,127 Often, such adverse events are associated with medications
that are contraindicated for use in the elderly population. Benzodiazepines are identified by the
Beer’s Criteria for Potentially Inappropriate Medication Use in Older Adults53 as one specific drug
class that should be avoided in the elderly due to an increase of cognitive impairment, falls, and
fractures. Furthermore, these guidelines state the quality of evidence for avoiding the use of
benzodiazepines in the elderly is high and the strength of the recommendation is strong. The
high quality of evidence means that consistent results have been found from well-designed and
well-controlled studies, and the strong recommendation means the burden of the elderly
population using this medication clearly outweighs the benefits.
Even though the recommendations against benzodiazepine use in the elderly exist,
these drugs are still commonly prescribed in this population. It has been estimated that the
prevalence of benzodiazepine use in the elderly ranges between 10-30%, significantly higher
than the 2-5% prevalence ranges estimated in younger adults.128-131 A 2014 study conducted by
Olfson et al.132 examining variations in rates of benzodiazepine use by age found the use of
benzodiazepines, specifically long-term use defined as filling at least 120 days of supply during
the study year of 2008, increases steadily with age. Of adults 65-80 years old, 31% were
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identified as long-term benzodiazepine users compared to only 15% of those in the 18-35 age
group.
Several studies have been conducted investigating relationships between
benzodiazepine use in elderly populations and adverse health outcomes. Evidence suggests that
physiological changes associated with aging make the elderly population more susceptible to
side effects associated with benzodiazepines.2 The use of benzodiazepines among elderly
populations has been associated with an increased risk of cognitive and psychomotor
impairment.
With an increasingly aging population, problems associated with cognitive impairment
are a public health concern. Hanlon and colleagues133 suggested current benzodiazepine use
among community-dwelling elderly is associated with poorer performance on cognitive
functioning tests. Furthermore, the study results suggested a dose response and a duration
response relationship where patients taking higher dosages or who had a longer duration of use
displayed greater cognitive decline than non-users of benzodiazepines. Similar results were also
reported by Paterniti et al.134 who found chronic benzodiazepine users had a significantly
greater risk of cognitive decline than non-users (OR: 1.9; 95% CI: 1.0 – 3.5). In a large
prospective study of elderly people in France, Billioti de Gage et al.135 associated new
benzodiazepine use with an approximate 50% increase in the risk of dementia. Most recently,
Billioti de Gage and colleagues136 reported any past benzodiazepine use was associated with an
approximate 50% increase in the risk of Alzheimer’s disease among community dwelling
individuals in Quebec. The risk was increased when long-acting benzodiazepines were primarily
used and as the duration of exposure increased.
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Cutson et al.137 conducted a double blind study assessing the effects of benzodiazepines
on the balance of healthy older adults and found that after taking a single dose of diazepam,
processes related to balance control were adversely affected. Several epidemiologic studies
have been published suggesting benzodiazepine use in the elderly is strongly associated with an
increased risk for falls and fractures. Bayesian adjusted odds ratios from a meta-analysis by
Woolcott et al.138 suggest benzodiazepine use among older individuals is associated with a 41%
increase in the risk of falling. Furthermore, these falls are likely to be injurious, especially among
individuals 80 years of age and older.139 Xing et al.140 conducted a meta-analysis examining the
relationship between benzodiazepine use and risk of fractures in 18 studies where this
relationship was investigated in an elderly population. Results of the meta-analysis suggest that
benzodiazepine use in the elderly is associated with an overall relative risk of fractures of 1.26
(95% CI: 1.15 – 1.38). Additionally, an analysis of VA databases by French et al.141 found a
temporal association between outpatient benzodiazepine use and serious injuries resulting in
inpatient stays, costing $2.89 million for 297 unique patients, and outpatient visits, costing
$400,000 for 1,352 unique patients.141 Additionally, studies have shown an association between
benzodiazepine use in the elderly and an increase in the relative risk of motor vehicle accidents
in this population.142,143
Benzodiazepine use in adolescents
To date, few studies have assessed the use of benzodiazepines in adolescent
populations. Traditionally, benzodiazepines have been used in adolescent populations with
anxiety disorders, sleep disorders, psychosis, and aggression despite a lack of sound evidence
indicating benzodiazepines are an effective treatment option in this population.144 In the United
States the prescribing of CS to adolescents and children has nearly doubled over the previous
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two decades.145 At the same time that CS prescribing for adolescents has been increasing so has
the nonmedical use of benzodiazepines in this population.146 A recent study by McCabe and
West147 estimated that high school seniors the lifetime prevalence of medical benzodiazepine
use to be 4.3% and 7.5% for nonmedical benzodiazepine use. In two separate studies of
students enrolled in Detroit metropolitan area public secondary schools, medical use of
controlled medications, including benzodiazepines, was associated with an increased likelihood
of nonmedical prescription drug use compared to students who had never received a
prescription for a CS.148,149 Furthermore, the nonmedical use of benzodiazepines in adolescent
populations is of significant concern as McCabe et al.150 linked earlier initiation of nonmedical
benzodiazepine use to an increased risk of developing a SUD compared to those whose initial
nonmedical benzodiazepine use is later in life.
CONCLUSION
Benzodiazepines are an effective treatment option for many people suffering from a
wide range of medical conditions including insomnia and anxiety. Due to the abuse liability of
benzodiazepines and their synergistic effects when taken with other substances, clinicians
should evaluate the benefits and risks of benzodiazepine therapy prior to prescribing in an effort
to avoid medication misadventures associated with this drug class. The abuse liability of
benzodiazepines has led to policies, most notably TPPs, and PDMPs, designed to monitor the
distribution of benzodiazepines in an effort to reduce inappropriate use. Previous studies
evaluating state monitoring programs suggest the supply of CS is drastically reduced upon
implementation. However, the only studies evaluating the effect of state monitoring programs
on benzodiazepine use focus on the New York TPP and the impact of current state PDMPs on
benzodiazepine use is unknown. The available literature is also currently unable to definitively
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evaluate the impact of prescription drug monitoring policies on health outcomes, an important
aspect to determine the effect PDMPs have on inappropriate and legitimate benzodiazepine
use.
Evaluations of health outcomes associated with benzodiazepine utilization in at-risk
populations are warranted as many previous studies were conducted prior to the growth and
notoriety of the prescription drug abuse epidemic. As a result, little is known about
benzodiazepine use in populations at risk for SUDs. Furthermore, studies are needed to evaluate
the use and safety of benzodiazepines in clinically vulnerable populations as inappropriate
benzodiazepine use can increase the risk of medication misadventures involving adverse drug
events and adverse drug reactions which can include increased healthcare resource utilization,
morbidity, and mortality. Studies evaluating potentially inappropriate benzodiazepine use can
help disseminate information regarding the effectiveness and suitability of benzodiazepines use
in specific populations and thereby optimize health outcomes to the benefit of patients and
society.
Motivated by the evidence suggesting medication misadventures pertaining to
benzodiazepines are of significant concern, this dissertation will assess the issue in two clinically
vulnerable populations (COPD and HIV) and examine the impact of a policy designed to mitigate
their inappropriate use. The second chapter of this dissertation will examine the use of
benzodiazepines in patients diagnosed with COPD and the risk of acute exacerbations requiring
hospitalization. The objectives of this chapter will address the definition of a mediation
misadventure by describing an iatrogenic hazard or incident created through by the
administration of a medicine during which a patient may be harmed. Chapter 3 will determine
whether individuals infected with HIV are more likely to fill a prescription for a benzodiazepine
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compared to those who are uninfected with the disease. Additionally, Chapter 4 will continue
the investigation pertaining to benzodiazepine use in the HIV infected population by examining
whether individuals infected with HIV are more likely to engage in potentially problematic
benzodiazepine use than their uninfected counterparts. In these two studies the inherent risk
when medication therapy is indicated aspect of the medication misadventure definition will be
addressed as the administration of benzodiazepines in the HIV infected population is
controversial due to the abuse potential of the medication coupled with the high prevalence of
SUDs in this population. In Chapter 5 the impact of a PDMP is evaluated using the example of
South Carolina’s program implementation and the subsequent effect on benzodiazepine
dispensing. Chapter 6 will further elaborate on the topic of PDMPs by assessing their impact on
benzodiazepine dispensing using a nationwide sample. These chapters will address a policy that
has been implemented by states to curtail problems associated with prescription drug abuse,
which can lead to negative health outcomes that are always unexpected or undesirable to the
patient and healthcare professional. Examples of unexpected or undesirable health outcomes as
they pertain to prescription drug abuse include: tolerance and/or addiction, overdose, and
fatality. At the same time, these studies evaluate the possibility that PDMPs may induce a
‘chilling effect’ by limiting access to benzodiazepine therapy among patients who have a
legitimate need for the medication. The inability of patients who have a legitimate need for a
benzodiazepine to acquire it can lead to an iatrogenic hazard or incident that is created through
the omission of a medication during which the patient may be harmed, another component of
medication misadventures.
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Table 1.1. List of benzodiazepines marketed in the United States as of January 2013.
Diazepam
Milligram
Trade
Dosage Year on
Equivalent
Generic Name
Names
Forms
Market Indications
(DME)7,151
Treatment of generalized anxiety
disorder (GAD); short-term relief
of symptoms of anxiety; panic
Niravam®;
disorder, with or without
Xanax XR®; Solution,
agoraphobia; anxiety associated
Alprazolam
Xanax®
Tablet
1981
with depression
1
Management of anxiety disorder
Librax®;
or for the short-term relief of
Librium®;
symptoms of anxiety;
Limbitrol®;
withdrawal symptoms of acute
Chlordiazepoxide Limbitrol®
alcoholism; preoperative
Hydrochloride
DS
Capsule 1960
apprehension and anxiety
50
Adjunctive treatment of seizures
associated with Lennox-Gastaut
Clobazam
Onfi®
Tablet
2011
syndrome
20
Alone or as an adjunct in the
treatment of petit mal variant
(Lennox-Gastaut), akinetic, and
myoclonic seizures; petit mal
Klonopin®;
(absence) seizures unresponsive
Klonopin®
to succimides; panic disorder
Clonazepam
Wafers
Tablet
1975
with or without agoraphobia
0.5
Treatment of generalized anxiety
disorder; management of
GenXene®;
ethanol withdrawal; adjunct
Clorazepate
Tranxene® Capsule,
anticonvulsant in management
Dipotassium
T-TAB®
Tablet
1972
of partial seizures
15
Management of anxiety
disorders; ethanol withdrawal
symptoms; skeletal muscle
relaxant; treatment of
convulsive disorders;
preoperative or preprocedural
sedation and amnesia
Rectal gel: management of
selected, refractory epilepsy
Diastat®
patients on stable regimens of
Rectal
Gel,
antiepileptic drugs requiring
Delivery
Injection,
intermittent use of diazepam to
System;
Solution,
control episodes of increased
Diazepam
Valium®
Tablet
1963
seizure activity
10
Short-term management of
Estazolam
ProSom® Tablet
1990
insomnia
2
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Table 1.1. List of benzodiazepines marketed in the United States as of January 2013 (cont’d).
Flurazepam
Short-term treatment of
Hydrochloride
Dalmane® Capsule 1970
insomnia
30
Oral: management of anxiety
disorders or short-term (≤4
months) relief of the symptoms
of anxiety, anxiety associated
with depressive symptoms, or
insomnia due to anxiety or
Injection,
transient stress
Solution,
IV: status epileptics, anterograde
Lorazepam
Ativan®
Tablet
1977
amnesia, sedation
2
Preoperative sedation; moderate
sedation prior to diagnostic or
radiographic procedures; ICU
sedation (continuous infusion);
Midazolam
induction and maintenance of
Hydrochloride
Versed®
Injection 1985
general anesthesia
15
Treatment of anxiety;
Capsule,
management of ethanol
Oxazepam
Serax®
Tablet
1965
withdrawal
30
Quazepam
Doral®
Tablet
1985
Treatment of insomnia
15
Short-term treatment of
Temazepam
Ristoril®
Capsule 1981
insomnia
20
Short-term generally (7-10 days)
Triazolam
Halcion®
Tablet
1982
treatment of insomnia
0.25

Table 1.2. Characteristics of benzodiazepine therapy and individual patients that influence
withdrawal severity and inability to taper off the medication. 44-46
Characteristics of benzodiazepine therapy
Short half-life benzodiazepine
Higher benzodiazepine dosage
Longer duration of benzodiazepine therapy
Rapid taper
Characteristics of individual patients
Female
Higher baseline levels of anxiety and depression
Higher level personality pathology
History of mild to moderate alcohol or drug abuse
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Table 1.3. United States Schedule of controlled substances.55
Definition of
Schedule
Controlled Substance Schedules
Examples
No currently accepted medical use in the
United States; lack of accepted safety for Heroin; lysergic acid diethylamide
Schedule I
medical use; high potential for abuse
(LSD); marijuana
High potential for abuse potentially leading
to severe psychological or physical
Oxycodone; morphine;
Schedule II
dependence
methamphetamine
Combination products containing
Abuse potential is below that of Schedule I <15mg of hydrocodone per dosage
and II; abuse can lead to low to moderate unit; products containing <90mg
physical dependence or high psychological codeine per dosage unit;
Schedule III
dependence
buprenorphine
Low potential for abuse compared to
Schedule IV
Schedule III
All benzodiazepines; carisoprodol
Low potential for abuse compared to
Schedule IV; primarily consists of
substances containing limited quantities of Cough medications with ≤ 200mg
Schedule V
certain narcotics
codeine per 100ml/100g
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Table 1.4. States with an operational prescription drug monitoring program and controlled
substance Schedules monitored as of December 2014.80,83
Schedules Monitored
Schedules Monitored
State
II
III
IV
V
State
II
III
IV
V
Alabama
X
X
X
X
Nebraska
X
X
X
X
Alaska
X
X
X
X
Nevada
X
X
X
Arizona
X
X
X
New Hampshire
X
X
X
Arkansas
X
X
X
X
New Jersey
X
X
X
X
California
X
X
X
New Mexico
X
X
X
X
Colorado
X
X
X
X
New York
X
X
X
X
Connecticut
X
X
X
X
North Carolina
X
X
X
X
Delaware
X
X
X
X
North Dakota
X
X
X
X
Florida
X
X
X
Ohio
X
X
X
X
Georgia
X
X
X
X
Oklahoma
X
X
X
X
Hawaii
X
X
X
X
Oregon
X
X
X
Idaho
X
X
X
X
Pennsylvania
X
Illinois
X
X
X
X
Rhode Island
X
X
X
Indiana
X
X
X
X
South Carolina
X
X
X
Iowa
X
X
X
South Dakota
X
X
X
Kansas
X
X
X
Tennessee
X
X
X
X
Kentucky
X
X
X
X
Texas
X
X
X
X
Louisiana
X
X
X
X
Utah
X
X
X
X
Maine
X
X
X
Vermont
X
X
X
Maryland
X
X
X
X
Virginia
X
X
X
Massachusetts
X
X
X
X
Washington
X
X
X
X
Michigan
X
X
X
X
West Virginia
X
X
X
X
Minnesota
X
X
X
Wisconsin
X
X
X
X
Mississippi
X
X
X
X
Wyoming
X
X
X
Montana
X
X
X
X
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CHAPTER 2: BENZODIAZEPINE USE IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY
DISEASE AND THE RISK OF ACTUE EXACERBATIONS.
INTRODUCTION
Chronic obstructive pulmonary disease (COPD) refers to lung diseases, mainly
emphysema and chronic bronchitis, which obstruct air flow and interfere with normal patterns
of breathing.152-154 Prevalence estimates suggest that 12.7 million adults in the US are afflicted
with the disease.153 Currently, COPD results in more than 800,000 hospitalizations annually155
and is the third leading cause of death in the United States.152,153 One of the trademarks of COPD
is exacerbation, which is a sudden worsening of symptoms including shortness of breath or
changes in the quantity and color of phlegm. Exacerbations typically occur in patients with COPD
two to three times per year and their cause in largely unknown.155
Patients who suffer from COPD commonly experience symptoms related to insomnia,156159

anxiety and depression. Budhiraja et al.159 estimated the prevalence of chronic insomnia in

the COPD population to be approximately 27%, greater than the 10% prevalence in the general
population. Symptoms related to insomnia frequently reported by patients with COPD include
difficulty falling asleep, trouble staying asleep, and an increased feeling of sleepiness during the
day.156,160 Results from the Tucson Epidemiologic Study157 found more than 50% of patients with
COPD experience sleep related difficulties and 25% an excessive feeling of daytime sleepiness.
Additionally, studies have found a higher prevalence of anxiety and depression in patients
diagnosed with COPD compared to the general population. Utilizing a case-control study design,
Di Marco et al.161 estimated patients with COPD had a higher prevalence of anxiety (28% vs. 6%)
and depression (19% vs. 6%) than controls without the disease. Kunik et al.162 found a 51%
prevalence of anxiety and a 39% prevalence of depression in patients diagnosed with COPD
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receiving care through the Veteran’s Affairs system. These estimates exceed those of the
general population: 18% for anxiety101 and 7% for depression.163
Benzodiazepines are generally an effective pharmacological treatment option and are
widely prescribed for the management of symptoms related to anxiety disorders and
insomnia.11,103 Studies examining patients with COPD have found evidence of a link between
benzodiazepine use and several adverse respiratory outcomes such as decreased minute
ventilation,118,119 low levels of oxygen and high levels of carbon dioxide in the blood,119,120 and a
decrease in respiratory muscle strength.118 Moreover, joint American Thoracic Society/European
Respiratory Society guidelines recommend that hypnotics such as benzodiazepines not be used
in patients with severe COPD.121
To date there is little understanding regarding the impact benzodiazepine use on the
risk of adverse respiratory outcomes among patients with COPD in the US. The current literature
evaluating benzodiazepine use in this population relies on studies employing small sample sizes
and patients with greater COPD severity. As a result, studies evaluating benzodiazepine use and
their association with adverse respiratory outcomes at a population level are warranted. The
goal of this research is to better understand how patients in the US with COPD are being treated
when they have a psychiatric comorbid condition including anxiety, depression, and insomnia.
This study will also provide clarity to concerns that the use of benzodiazepines in the COPD
population may be associated with an elevated risk of adverse respiratory outcomes and thus
impact the clinical care of these patients. The aims of this study are to estimate the prevalence
of new benzodiazepine use among patients with COPD in the US and evaluate differences in the
risk of acute exacerbations among patients with COPD who are identified as new users and
nonusers of benzodiazepines.
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METHODS
This study employs a new user, retrospective cohort using medical and pharmacy claims
obtained from a large private insurer for beneficiaries in all 50 states and Washington DC
between January 1, 2007 and December 31, 2009. This claims database includes de-identified
information regarding beneficiary socio-demographics and codes related to interactions with
the healthcare system. Beneficiaries were considered for inclusion if they had continuous
medical and pharmacy benefits coverage for the duration of the study period, had a diagnosis
code in the medical claims data for chronic bronchitis (ICD-9 code: 491.xx) emphysema (492.xx),
or chronic airway obstruction, not elsewhere classified (496.xx), did not have a diagnosis of
asthma (493.xx excluding 493.2), were at least 40 years of age, and did not have a prescription
drug claim for a benzodiazepine during the 180 days prior to the index date.
Ascertainment of benzodiazepine use
Benzodiazepine exposure was evaluated using dispensing records from a pharmacy
claims database and identified through the use of national drug codes. Beneficiaries were
considered to be an incident benzodiazepine user if they had a prescription drug claim for the
medications consisting of alprazolam, chlordiazepoxide, clonazepam, clorazepate, diazepam,
estazolam, flurazepam, lorazepam, midazolam, oxazepam, quazepam, temazepam, and trizolam
following 180 days without a prescription drug claim for a benzodiazepine prior to the index
date. The index date was defined as the date of the first prescription drug claim for a
benzodiazepine following 180 days without a benzodiazepine prescription drug claim. Incident
benzodiazepine use was only considered once during the study period, at the first occurrence,
regardless if the beneficiary met the definition for incident benzodiazepine use multiple times.
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Nonusers of benzodiazepines were identified based on not having a prescription drug
claim for any of the benzodiazepine medications listed above. For these beneficiaries, index
dates were randomly assigned based on the distribution of time to the first prescription drug
claim for a benzodiazepine in those identified as incident benzodiazepine users.
The follow-up time for each beneficiary started on the index date and was extended
until the earliest of an acute COPD exacerbation, 30 days after the index date, or the end of the
study period. This approach was intended to emulate an intention-to-treat analysis similar to
that employed by randomized controlled trials.
Propensity score matching
To account for baseline differences in the severity of COPD and to estimate the effect of
incident benzodiazepine use on the risk of acute exacerbations in the COPD population, users
and non-users of benzodiazepines were matched using propensity score matching methods. The
propensity score for each patient in the study population was estimated through logistic
regression as the probability of initiating benzodiazepine therapy during the study period, based
on demographic characteristics, index date, measures of general health, and healthcare
utilization intensity. Matching was performed using the Greedy Matching algorithm164 without
replacement and one-to-one and one-to-many matching methods were explored.
Ascertainment of acute exacerbation
The outcome of interest was the occurrence of an acute COPD exacerbation within 30
days following the index date. Acute exacerbations were identified in the medical claims
database where the primary or admission diagnostic ICD-9 code was 491.21. Only the date of
the first acute exacerbation within the 30-day follow-up timeframe after the index date was
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utilized. The 30-day follow-up period was chosen as acute exacerbations related to
benzodiazepine use were expected to occur relatively soon after their initiation.
Statistical analysis
Baseline characteristics of benzodiazepine users and nonusers were compared before
and after propensity score matching. Standardized differences were calculated to compare users
and nonusers on all covariates before and after propensity score matching. The rates of
experiencing an acute exacerbation within 30 days after the index date were estimated and
compared using cumulative incidence function curves. Tests of equality of the cumulative
function curves were performed using Gray’s method.165 Cox proportional hazard models
estimated the hazard ratio (HR) and accompanying 95% confidence interval (CI) of experiencing
an acute exacerbation associated with incident benzodiazepine use within 30 days after
initiation. Sensitivity analyses were conducted to test the robustness of the results. For
beneficiaries who did fill a benzodiazepine prescription during the study period, those whose
prescription was for seven days or less were excluded to examine if the restriction of non-acute
benzodiazepine use was associated with an increased risk in an acute exacerbation. Additionally,
a second sensitivity analysis was conducted where beneficiaries were also matched on the
number of claims for an acute exacerbation in the database. Data use was approved by the
Institutional Review Board at the University of Kentucky. All statistical analyses were conducted
using SAS 9.4 (SAS Institute Inc., Cary, NC). The a priori level of significance was set at 0.05.
RESULTS
A total of 92,461 beneficiaries with COPD met the inclusion criteria (Figure 2.1). Of these
15,723 (17.1%) were identified as incident benzodiazepine users. After propensity score
matching 13,265 incident benzodiazepine users were matched to at least one benzodiazepine
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nonuser. No propensity score match was found for 2,458 (15.6%) incident benzodiazepine users.
Kernel density estimates of the propensity score distributions between the user and nonuser
groups are shown in Figure 2.2a and Figure 2.2b. The distribution for the non-matched sample is
depicted in Figure 2.2a while Figure 2.2b presents the matched sample. A comparison of
baseline demographic and health characteristics between incident benzodiazepine users and
nonusers is presented in Table 2.1. After matching incident benzodiazepine users and nonusers
were well matched on all baseline characteristics with the exception of psychiatric disorders
where the prevalence was greater among benzodiazepine users. Benzodiazepines are indicated
and commonly prescribed for these conditions and to account for these observed differences
the psychiatric disorders of anxiety, depression, and insomnia were considered in the hazard
ratio calculation.
The logistic regression model used to derive propensity scores for the likelihood of
initiating benzodiazepine therapy is presented in Table 2.2. The results indicate that among
beneficiaries with COPD incident benzodiazepine use was more likely among females (AOR:
1.34; 95% CI: 1.24, 1.39) and those diagnosed with anxiety (AOR: 5.21; 95% CI: 4.94, 5.49),
depression (AOR: 1.61; 95% CI: 1.53, 1.70), or insomnia (AOR: 3.18; 95% CI: 2.97, 3.40). Those
taking oral corticosteroids also had increased odds of incident benzodiazepine use (AOR: 1.28;
95% CI: 1.20, 1.36). Beneficiaries were also more likely to be incident benzodiazepine users if
they had a diagnosis for the comorbidities of other ischemic heart disease (AOR: 1.13; 95% CI:
1.08, 1.19), cerebrovascular disease (AOR: 1.14; 95% CI: 1.08, 1.20), lung cancer (AOR: 1.67; 95%
CI: 1.50, 1.85), cancers excluding lung cancer (AOR: 1.17; 95% CI: 1.12, 1.22), weight loss (AOR:
1.12; 95% CI: 1.04, 1.22) or essential hypertension (AOR: 1.20; 95% CI: 1.02, 1.43). Beneficiaries
with COPD who were black were less likely to be incident benzodiazepine users (AOR: 0.56; 95%
CI: 0.52, 0.61). Additionally, increasing age was associated with a decreased likelihood of
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incident benzodiazepine use (AOR: 0.98; 95% CI: 0.98, 0.98) as was a lower overall general
health status as depicted by the Charlson Comorbidity Index (AOR: 0.69; 95% CI: 0.62, 0.71).
Prior to matching 148 (0.9%) of incident benzodiazepine users and 473 (0.4%) of
nonusers had a claim for an acute exacerbation within 30 days of the index date. After matching
127 (1.0%) of incident benzodiazepine users and 272 (0.6%) of nonusers had an acute
exacerbation claim within 30 days of the index date. Results of the Cox proportional hazard
model are shown in Table 2.3. Compared to nonusers, incident benzodiazepine users with COPD
were at a 26% higher risk (HR: 1.26; 95% CI: 1.01, 1.57) for having a claim for an acute
exacerbation within the 30 days following the index date. The cumulative incidence of acute
exacerbations during the 30-day follow-up was determined to be greater for incident
benzodiazepine users versus nonusers (p<0.01) beginning immediately after benzodiazepine
initiation and continuing onwards (Figure 2.3).
The findings from the sensitivity analyses are presented in Table 2.3. The finding from
the model only examining non-acute benzodiazepine use supported the findings of this study.
When compared to nonusers, non-acute incident benzodiazepine users were at a statistically
higher risk (HR: 1.28; 95% CI: 1.01, 1.63) of having a claim for an acute exacerbation within 30
days of the index date. When all incident benzodiazepine users were considered but also
matched on the number of claims for an acute exacerbation prior to the index date the
association between incident benzodiazepine use and an acute exacerbation within 30 days was
no longer statistically significant, however, the HR and most of the 95% CI were greater than 1
(HR: 1.11; 95% CI: 0.89, 1.39).
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DISCUSSIONS
This study of a nationally representative sample of privately insured adults in the US
with COPD showed that incident benzodiazepine use was associated with an increased risk of an
acute exacerbation within 30 days of initiation. Findings from the sensitivity analyses supported
this finding. However, the point estimates were attenuated and were no longer statistically
significant suggesting the presence of confounding and selection bias related to these factors.
This observed association is consistent with previous finding that have reported a relationship
between benzodiazepine use and adverse respiratory outcomes in the COPD population. Vozoris
et al.123 recently evaluated the association between new benzodiazepine use and the risk of
adverse health outcomes among older patients in Ontario with COPD. Their findings suggested
that new benzodiazepine use is associated with a greater risk of outpatient respiratory
exacerbations and emergency department visits for COPD or pneumonia.
An important finding in the present study was the observation that incident
benzodiazepine use in the COPD population is common as we found it to occur in 17% of the
study cohort despite American Thoracic Society/European Respiratory Society guidelines
cautioning against their use.121 While this finding is less than that reported by Vozoris et al.122
where new benzodiazepine use was found in roughly one-third of COPD patients, that study
examined older patients with COPD and existing evidence demonstrates than benzodiazepines
are more likely to be prescribed to older individuals.166
The results of the logistic regression model indicate that receipt of an oral corticosteroid
prescription was associated with an increase in the odds of new benzodiazepine use. It is
possible that receipt of an oral corticosteroid prescription may be related to an acute
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exacerbation167 experienced in the outpatient setting where the patient did not utilize the
healthcare system for treatment.
This study found that new benzodiazepine use was associated with an increased risk of
experiencing an acute exacerbation within 30 days of benzodiazepine initiation; however, the
absolute risk was small, occurring in 0.9% of new benzodiazepine users and 0.4% of nonusers.
Furthermore, the sensitivity analyses revealed selection and confounding by factors related to
benzodiazepine use. Due to the high prevalence of COPD in the US, especially in states such as
Kentucky and Alabama where the prevalence is estimated to be greater than 9%, this small risk
is clinically important at the population level.
Limitations to this study exist. Due to the observational nature of this study an
association between variables does not imply causality as unmeasured difference between the
benzodiazepine user and nonuser groups may have influenced the findings. Secondly, as this
study employs data for a privately insured, continuously enrolled cohort the overall COPD
population may not be accurately represented. This study also could not account for
benzodiazepine medications acquired outside the healthcare system of paid for out of pocket.
Another potential limitation is that dispensed benzodiazepine prescriptions may not be
equivalent to benzodiazepines consumed. Not all patients who experienced an acute
exacerbation may have sought treatment from a healthcare provider and thus were not
documented in the data, however, it is expected that no systematic differences existed between
the user and nonuser groups in their propensity to access the healthcare system for this event
and thus the results would not be influenced.
The findings of this study identify benzodiazepines as a potential risk factor associated
with the occurrence of an acute exacerbation in a large sample of privately insured adults with
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COPD. This highlights concerns regarding the potential misuse of benzodiazepines in clinically
vulnerable populations, including those with COPD. Given that patients with COPD are often
afflicted with symptoms related to anxiety, depression, and insomnia, which are commonly
managed with benzodiazepines, the potential of experiencing an acute exacerbation should be
considered in treatment decisions. Inappropriate benzodiazepine use, especially in clinically
vulnerable populations, can lead to adverse drug event and adverse drug reactions, which are
potentially avoidable. These can result in a dramatic negative effect on a patient’s health
outcomes and quality of life. Based on the findings from this study further research is warranted
regarding the relationship between benzodiazepine use in the COPD population, especially is it
pertains to other COPD related health outcomes.
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Table 2.1. Characteristics of benzodiazepine users and nonusers with COPD.

a

Before Matching
Benzodiazepine Benzodiazepine
users
nonusers
15,723
76,738

Std.
d
Diff

After Matching
Benzodiazepine Benzodiazepine
users
nonusers
13,265
37,828

Beneficiaries
COPD Exacerbation
Acute exacerbation
within 30 days of index
148 (0.9)
473 (0.4)
0.07
127 (1.0)
date
Sex
Male
7,294 (46.4)
43,594 (56.8)
6,273 (47.5)
Female
8,429 (53.6)
33,142 (43.2)
0.21
6,992 (52.5)
Age
b
c
Median age (IQR )
71 (66-77)
72 (67-78) -0.13
72 (67-78)
Race
White
12,806 (81.4)
59,790 (77.9)
0.11 11,932 (90.0)
Black
877 (5.6)
7,069 (9.2)
-0.15
847 (6.4)
Other
523 (3.3)
2,191 (2.9)
0.03
486 (3.7)
Psychiatric Disorder
Anxiety
4,954 (31.5)
4,403 (5.7)
0.70
3,581 (27.0)
Depression
4,516 (28.7)
8,177 (10.7)
0.47
3,439 (26.0)
Insomnia
2,309 (14.7)
2,709 (3.5)
0.40
1,645 (12.5)
Comorbidities
Acute myocardial
687 (4.4)
2,598 (3.4)
0.05
581 (4.4)
infarction
Other ischemic heart
6,475 (41.2)
25,928 (33.8)
0.15
5,575 (42.0)
disease
Congestive heart failure
3,417 (21.7)
13,447 (17.5)
0.11
2,975 (22.5)
Cerebrovascular disease
3,788 (24.1)
13,427 (17.5)
0.16
3,212 (24.3)
Diabetes
5,724 (36.4)
25,533 (33.3)
0.07
4,970 (37.4)
Lung cancer
750 (4.8)
1,885 (2.5)
0.12
587 (4.4)
Cancers excluding lung
6,371 (40.5)
25,129 (32.7)
0.16
5,310 (39.9)
cancer
Cardiac arrhythmia
4,397 (28.0)
17,527 (22.8)
0.12
3,745 (28.4)
Pulmonary circulation
1,273 (8.1)
4,504 (5.9)
0.09
1,086 (8.1)
disorder
Weight loss
1,187 (7.5)
3,783 (4.9)
0.11
954 (7.2)
Essential hypertension
12,131 (77.2)
53,806 (70.1)
0.16 10,349 (78.1)
Any hypertension
12,322 (78.4)
54,946 (71.6)
0.16 10,522 (79.4)
Tobacco user
4,665 (30.0)
17,287 (22.5)
0.16
3,756 (28.2)
Medications used
Short/long acting β2,663 (16.9)
11,193 (14.6)
0.06
2,253 (17.0)
agonists
Inhaled corticosteroids
2,373 (15.1)
9,388 (12.2)
0.08
1,957 (14.9)
Oral corticosteroids
3,179 (20.2)
11,473 (15.0)
0.14
2,605 (19.8)
Theophylline
103 (0.7)
347 (0.5)
0.03
90 (0.7)
Healthcare utilization
Median number of
26 (14-49)
22 (11-43)
0.11
27 (14-50)
c
healthcare claims (IQR )
Median number of
prescription claims
51 (24-94)
44 (16-89)
0.11
53 (26-98)
c
(IQR )
a
Data are presented at n(%) unless otherwise noted
b
Median age assessed at index date
c
Interquartile range
d
A standardized difference of >0.10 is considered a potentially meaningful difference
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272 (0.7)

19,133 (50.4)
18,695 (49.6)
73 (68-78)

Std.
d
Diff

0.03

0.00
0.00
-0.06

33,871 (89.4)
2,598 (6.9)
1,359 (3.7)

0.01
-0.02
0.00

4,025 (10.6)
6,588 (17.4)
2,427 (6.4)

0.43
0.21
0.21

1,470 (3.9)

0.02

15,293 (40.0)

0.03

8,031
8,373
13,994
1,468

(21.0)
(22.2)
(37.3)
(3.9)

0.03
0.05
0.01
0.03

14,662 (38.7)

0.03

10,140 (26.7)

0.03

2,787 (7.4)

0.03

2,296
28,838
29,387
9,657

(6.1)
(76.0)
(77.4)
(25.7)

0.05
0.04
0.04
0.06

6,128 (16.4)

0.02

5,386 (14.3)
7,023 (18.7)
234 (0.6)

0.01
0.03
0.01

26 (13-49)

0.01

53 (22-102)

0.00

Table 2.2. Propensity score model of incident benzodiazepine use.
Variable
Year
1
Index year
Sex
Male
Female
Race
White
Black
Other
Age
Age
Psychiatric Disorder
Anxiety
Depression
Insomnia
COPD Medications
Beta-agonists
Inhaled corticosteroids
Oral corticosteroids
Theophylline
Comorbidities
Acute myocardial infarction
Other ischemic heart disease
Congestive heart failure
Cerebrovascular disease
Diabetes
Lung cancer
Cancers excluding lung cancer
Cardiac arrhythmia
Pulmonary circulation disorder
Weight loss
Essential hypertension
Any hypertension
Tobacco user
Healthcare Utilization
Total number of medical claims
Total number of prescription claims
General Health State
Charlson Comorbidity Index
1
Reference year is 2007

Odds Ratio
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95% Confidence Interval

1.05

1.02

1.09

Ref.
1.34

1.28

1.39

Ref.
0.56
1.04

0.52
0.93

0.61
1.15

0.98

0.98

0.98

5.21
1.61
3.18

4.94
1.53
2.97

5.49
1.70
3.40

0.96
1.03
1.28
1.19

0.90
0.97
1.20
0.93

1.03
1.11
1.36
1.54

0.93
1.13
1.02
1.14
0.99
1.67
1.17
1.02
1.06
1.12
1.20
0.88
1.05

0.84
1.08
0.96
1.08
0.94
1.50
1.12
0.97
0.98
1.04
1.02
0.74
1.00

1.03
1.19
1.08
1.20
1.03
1.85
1.22
1.07
1.15
1.22
1.43
1.05
1.10

1.00
1.00

1.00
1.00

1.00
1.00

0.69

0.62

0.77

Table 2.3. Comparison of hazard ratios.

Model
Study model
Matching on acute
exacerbation
Elimination of acute
benzodiazepine use

Number of incident
benzodiazepine users
13,265

Number of outcomes
among incident
benzodiazepine users
127

Number of non
benzodiazepine
users
37,828

Number of acute
exacerbation among non
benzodiazepine users
272

Hazard
ratio
1.26

95% CI
(1.01, 1.57)

13,265

125

37,763

288

1.11

(0.89, 1.39)

10,757

105

30,878

222

1.28

(1.01, 1.63)
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Figure 2.1. Sample selection flow chart.
Beneficiaries continuously enrolled between January 1, 2007 and December 31, 2009
1,080,141

Excluded:
1. Did not have COPD diagnosis
927,604
2. Had an asthma diagnosis
42,232
3. Under 40 years of age
1,436
4. Prescription drug claim for benzodiazepine
during 180 days prior to index date
16,284
5. Acute exacerbation occurred on index date
124

Study population before propensity score matching
92,461

Incident benzodiazepine users
15,723

Benzodiazepine nonusers
76,738

Study population after propensity score matching
51,093

Incident benzodiazepine users after
matching
13,265

Benzodiazepine nonusers after matching
37,828
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Figure 2.2a. Propensity score distributions for incident benzodiazepine users and nonusers
before propensity score matching.

Figure 2.2b. Propensity score distributions for incident benzodiazepine users and nonusers
after propensity score matching.
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Cumulative incidence of acute exacerbation

Figure 2.3. Cumulative incidence function curves for acute exacerbations among incident
benzodiazepine users and nonusers occurring within 30 days of the index date.

Time in days to acute exacerbation

Copyright © Sarah Elizabeth Wixson 2015
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CHAPTER 3: SEX DIFFERENCES IN BENZODIAZEPINE USE IN THE HIV-INFECTED POPULATION.
INTRODUCTION
The burden of psychiatric disorders in the HIV-infected population exceeds that of the
general US population116,168 and the 12-month prevalence of psychiatric disorders is estimated
at 48%.116 This estimate is nearly two times greater than the 26% prevalence rate estimated in
the general population.101 The most commonly detected psychiatric disorders in the HIVinfected population include major depression, dysthymia, and generalized anxiety disorder.116
Additionally, patients who suffer from psychiatric disorders are likely afflicted with symptoms of
insomnia.102 The estimated prevalence rate for anxiety disorders may be as high as 38%,169 32%
for depression,116 and 78% for insomnia,170 in the HIV-infected population. Each of these
estimates exceeds those of the general population: 18% for anxiety,101 7% for depression,163 and
30% for insomnia.171 Managing symptoms of these comorbidities is especially important in HIVinfected patients as they are associated with suboptimal adherence to antiretrovirals.117,168 High
levels of adherence are necessary to achieve optimal viral load suppression and mitigate the
development of drug-resistant HIV infection.172,173
Benzodiazepines are the most frequently used psychotropic drug class,11 and are widely
prescribed for the management of symptoms related to anxiety, insomnia, and depression.103,174
Concerns exist regarding benzodiazepine use in the HIV-infected population due to potential
interactions with antiretroviral therapy175,176. Moreover, due to their abuse/misuse potential,
benzodiazepines are not recommended for patients with a substance abuse history, a common
problem among the HIV-infected population.116 To date, few studies have compared the
prevalence of benzodiazepine use in the HIV-infected and uninfected populations. Furthermore,
no studies have examined benzodiazepine usage by sex despite evidence suggesting prevalence
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rates of psychiatric disorders differ between males and females in the general and HIV-infected
populations.163,177,178 The current study uses insurance claims data to examine whether HIVinfected patients are more likely to fill a benzodiazepine prescription than uninfected patients
and, investigate sex differences in the likelihood of filling a benzodiazepine prescription among
HIV-infected and uninfected patients.
METHODS
We established a four state nationally representative, population-based cohort using
data from a large private insurance claims database from January 2007 to December 2009. This
claims database includes patient socio-demographics and codes related to interactions with the
healthcare system. Beneficiaries were included if they resided in Kentucky, Maryland, North
Carolina, or Washington, were between 19 and 64 years of age, and had at least one healthcare
claim in 2007 followed by a subsequent claim in either 2008 or 2009. Beneficiaries were
identified as HIV-positive if they had at least one healthcare claim in 2007 with the ICD-9 code
‘042’ (Human Immunodeficiency Virus (HIV) disease). The outcome of interest was filling a
benzodiazepine prescription. Benzodiazepine fills during the study period were represented by a
claim for any benzodiazepine identified using national drug codes. We considered the following
covariates assessed in the year 2007: sex, age, race, education, state of residence, continuous
insurance enrollment, substance abuse treatment (e.g. residential or non-residential treatment
facility), and psychiatric disorders. Bivariate analysis examined the association between HIVinfection and benzodiazepine use. Multivariate logistic regression models adjusted for
covariates identified above were used to estimate the adjusted odds ratio (AOR) of filling a
benzodiazepine prescription for HIV-infected patients. We examined the presence of interaction
between HIV-infection and the covariates using backwards elimination. Statistical significance
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was considered using the Wald χ2 p-value associated with the interaction term as well as
clinically meaningful differences by comparing stratum specific odds ratios. Data use was
approved by the XXXXX Institutional Review Board. Statistical analysis was conducted using
Stata 12.0 (StataCorp., College Station, TX).
RESULTS
A total of 323,902 beneficiaries met the inclusion criteria for this study. Of these
beneficiaries 106 were excluded due to duplicate or conflicting information. Overall, our study
cohort consisted of 323,796 beneficiaries, 723 were identified as HIV-infected. Baseline
characteristics and benzodiazepine utilization for HIV-infected and uninfected patients are
shown in Table 1. Compared to the uninfected population the HIV-infected population had a
greater proportion of men (80% versus 44%) and blacks (21% versus 7%). The HIV-infected
population also had a greater proportion of patients with a diagnosis of depression (12% versus
8%) or insomnia (6% versus 3%). We observed a greater proportion of HIV-infected patients
filled a benzodiazepine prescription during the study period (24% versus 19%) with alprazolam,
diazepam, and lorazepam being the most commonly filled benzodiazepines.
Figure 1 shows the AOR of filling a benzodiazepine prescription for HIV-infected patients
stratified by sex relative to the overall estimate of HIV-infected patients. The overall AOR
demonstrates that without stratifying by sex, HIV-infected patients have 1.68 times greater odds
of filling a benzodiazepine prescription than uninfected patients (95% CI: 1.39, 2.02). When
stratified by sex, results from the multivariate regression showed HIV-infected males are 1.68
times more likely to fill a benzodiazepine prescription than uninfected males, adjusting for
covariates (95% CI: 1.05, 2.67), while no statistical difference was observed between HIVinfected and uninfected females (AOR: 1.12, 95% CI: 0.73, 1.70). Interaction between HIV-
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infection and age, race, education, substance abuse treatment, and psychiatric disorders was
considered but statistical significance was not achieved at the 0.05 level nor were there any
clinically meaningful differences between the strata.
In the overall population the likelihood of filing a benzodiazepine prescription is
influenced by the patient’s age, sex, and race, along with treatment for substance abuse and
psychiatric disorder diagnosis. With each additional ten years patients age, their odds of filling a
benzodiazepine prescription increase 21% (AOR: 1.21, 95% CI: 1.20, 1.22). Additionally, males
are less likely than females (AOR: 0.62, 95% CI: 0.61, 0.63) and nonwhite patients are less likely
than white patients to fill a benzodiazepine prescription (AOR: 0.72, 95% CI: 0.70, 0.74).
Furthermore, treatment for substance abuse (AOR: 1.27, 95% CI: 1.14, 1.42), or having a
diagnosis of anxiety (AOR: 5.99, 95% CI: 5.81, 6.18), depression (AOR: 2.48, 95% CI: 2.42, 2.56),
or insomnia (AOR: 2.78, 95% CI: 2.65, 2.90) increase the odds of filling a benzodiazepine
prescription.
DISCUSSIONS
This study demonstrates that HIV-infected patients are more likely to fill a
benzodiazepine prescription than uninfected patients. Furthermore, we show HIV-infected
males are more likely than uninfected males to fill a benzodiazepine prescription, with no
observed difference between HIV-infected and uninfected females. This difference is notable as
concerns exist regarding benzodiazepine use in the HIV-infected population due to their high
abuse/misuse potential and the link between substance abuse and poor medication
adherence.179,180
The overall difference in the odds of filling a benzodiazepine prescription between HIVinfected and uninfected patients may be related to the high prevalence of psychiatric disorders
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in this population.116 However, we adjusted for these conditions in our models suggesting
additional factors shown to be associated with benzodiazepine use in this population and not
captured within claims data, such as exposure to stressful events related to HIV serostatus and
disclosure,181 may explain the differences in benzodiazepine use between the HIV-infected and
uninfected populations. The high prevalence of substance abuse and dependence in the HIVinfected population116 should also be considered as an explanation of the observed differences
in benzodiazepine use. Few studies have compared benzodiazepine use in the HIV-infected and
uninfected populations and to our knowledge, this study is the first to examine differences in
receipt of benzodiazepines by sex. Roux et al.181 investigated factors associated with regular
benzodiazepine use in HIV-infected patients but as this study included HIV-infected patients
only, comparisons to the uninfected population were not made.
Reasons for observed differences between males and females in our study may be
related to underlying differences in the prevalence of psychiatric disorders, differences in
stigmatization, as well as differences in overall health care utilization between HIV-infected men
and women. Lopes et al.177 showed HIV-infected men were more likely than uninfected men to
have a specific DSM-IV diagnosis with no observed differences among women. Our results
support these findings as we found HIV-infected men more likely than uninfected men to fill a
benzodiazepine prescription, with no observable differences between women. Additionally,
Roux et al.181 found that individuals belonging to the injecting drug use (IDU) and men who have
sex with men (MSM) HIV-transmission groups were more likely than their heterosexual HIVtransmission group counterparts to report regular benzodiazepine use. This finding is likely
associated with IDUs and MSM group members perceiving and facing greater discrimination and
stigmatization.182 Evidence exists of differences in healthcare utilization between HIV-infected
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men and women. Hellinger and Encinosager183 found HIV-infected men were more likely than
HIV-infected women to receive antiretroviral therapy and costlier medications.
Limitations to this study exist. First, this study uses data from a private insurance claims
database for four states, and may not accurately represent the overall HIV-infected or
uninfected populations. Also, this study does not account for the number of benzodiazepine
prescriptions filled or the quantity and dosages of those prescriptions. Additionally, we cannot
account for prescriptions acquired through family and friends or paid for using cash. Finally,
while our results show HIV-infected patients are more likely to fill a benzodiazepine
prescription, we did not differentiate between appropriate and inappropriate use.
Despite these limitations, our findings demonstrate HIV-infected patients, especially
HIV-infected males, are more likely to use benzodiazepines. Our findings, in combination with
evidence demonstrating sex differences in psychiatric disorders, show the need for further
research evaluating reasons for observed differences. Furthermore, intervention studies
targeting this at-risk population to reduce the risk of substance abuse and improve HIV clinical
care are warranted.
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Table 3.1. Comparison of demographics of HIV-infected and HIV-uninfected patients.
HIV
HIV-uninfected
N=723
N = 323,073
p-value
Variables
n
%
n
%
Benzodiazepine Usage
Filled Benzodiazepine Prescription
174
24%
60,420
19%
< 0.001
State of Residence
Kentucky
67
9%
36,698
11%
0.077
Maryland
193
27%
59,635
18%
< 0.001
North Carolina
339
47%
177,680
55%
< 0.001
Washington
124
17%
49,060
15%
0.141
Sex
Male
578
80%
140,605
44%
< 0.001
Age
Mean Age (for year 2007), SDa
43.02
8.83
41.98
11.46
0.015
Race
White
483
67%
255,735
79%
< 0.001
Black
155
21%
23,085
7%
< 0.001
Hispanic
32
4%
11,501
4%
0.209
Other
49
7%
29,917
9%
0.021
Education
Less than High School
6
1%
2,023
1%
0.488
High School Graduate
237
33%
112,330
35%
0.262
Some College
345
48%
139,963
43%
0.017
College Graduate
118
16%
60,340
19%
0.104
Psychiatric Diagnosis
Anxiety
47
7%
21,386
7%
0.989
Depression
84
12%
26,026
8%
< 0.001
Insomnia
44
6%
9,973
3%
< 0.001
Substance Abuse Treatment
Receiving Substance Abuse
5
1%
1,941
1%
0.752
Treatment
Enrollment Eligibility
Continuously Eligible
284
39%
145,518
45%
0.002
Gaps in Coverage
439
61%
177,555
55%
0.002
a
SD: Standard Deviation
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Figure 3.1. Likelihood of filling a benzodiazepine prescription among HIV-infected individuals compared to HIV-uninfected individuals
stratified by sex.
Strata
Men
Women
Overall
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Adjusted Odds Ratioa (95% CIb)

4

Odds Ratioa
1.68
1.12
1.68

(95% CIb)
(1.05, 2.67)
(0.73, 1.70)
(1.39, 2.02)

2

1

0.5
Men (N=141,185)

Women (N=182,615)

Overall (N=323,800)

a

Adjusted for state of residence, age, race, education, and enrollment eligibility (e.g. continuous insurance coverage, gaps in insurance
coverage).
b
CI: Confidence Interval.
Copyright © Sarah Elizabeth Wixson 2015

CHAPTER 4: PROBLEMATIC BENZODIAZEPINE USE AMONG COMMERCIALLY INSURED HIVINFECTED INDIVIDUALS IN THE UNITED STATES.
INTRODUCTION
The misuse of prescription medications is a growing public health concern in the United
States. Results from the 2013 National Survey on Drug Use and Health184 found that prescription
drug misuse is the second most prevalent drug problem in the United States trailing only
marijuana. Prescription medications, including benzodiazepines, prescribed for the management
of symptoms related to anxiety, depression, and insomnia, are increasingly being misused by
patients who take them long-term or in larger than prescribed doses. National estimates of
drug-related visits to emergency departments collected by the Drug Abuse Warning Network105
(DAWN) for the year 2011 reported that between 2004 and 2011 the number of emergency
department visits for the non-medical use of benzodiazepines increased 149% from 143,500 to
357,800 visits. The DAWN report also identified benzodiazepines as being involved in 29% of all
emergency department visits concerning the nonmedical use of pharmaceuticals, trailing only
opioids analgesics. These estimates suggest that benzodiazepine misuse can lead to serious
adverse effects and caution must be exercised regarding their prescribing and use.
Existing evidence suggests that HIV-infected individuals are often afflicted with
psychiatric comorbidities that are associated with prescription drug misuse.53,185,186 A screening
of a nationally representative sample of HIV-infected patients in the United States estimated
approximately one-half have a diagnosable psychiatric disorder.116 Managing symptoms of these
conditions is important as they are associated with a lower quality of life and suboptimal
adherence to antiretroviral therapy.117,187 Symptom management is frequently accomplished
through the prescribing and use of benzodiazepines. In the HIV-infected population the use of
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benzodiazepines is controversial due to the high prevalence of substance use disorders in this
population coupled with the abuse potential of benzodiazepines. Despite this, benzodiazepine
use is highly prevalent among HIV-infected individuals. Vitello et al.188 utilized the HIV Cost and
Services Utilization Study (HCSUS) and found nearly one-quarter of HIV-infected patients with a
co-occurring mental disorder reported benzodiazepine use. Wixson and Brouwer115 found that
in a privately insured population HIV infection was associated with a 68% increase in the odds of
filling a benzodiazepine prescription relative to those uninfected. In a survey of HIV-infected
patients conducted in France, Roux et al.181 found regular benzodiazepine use in 16% of
patients. Furthermore, results from this study determined that psychosocial factors, including
disclosure of HIV status, are predictors of regular benzodiazepine use.
Prescription drug misuse is a common problem in the HIV-infected population. A survey
conducted by Newville, Roley and Sorensen189 of HIV-infected patients receiving antiretroviral
therapy at a San Francisco hospital found 11% of patients acknowledged misuse of prescription
medications. Most of the literature examining prescription drug misuse in the HIV-infected
population has primarily focused on opioid analgesics. Hansen et al.190 found a high prevalence
of opioid analgesic misuse in a homeless and marginally housed sample of HIV-infected adults in
San Francisco. Silverberg et al.191 determined that long-term prevalent prescription opioid use,
defined as longer than 90 days and associated with a greater than 120 total days’ supply, or ten
or more dispensed prescriptions in a year, was more common among individuals infected with
HIV compared to those uninfected. An analysis of the HCSUS database by Tsao et al.192 showed
increased rates of opioid misuse in patients having a history of problematic substance use.
Likewise, Robinson-Papp et al.193 found an association between problematic opioid use and
having a history of a substance use or dependence disorder. This study also demonstrated that a
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current psychiatric disorder and poor antiretroviral adherence were linked to problematic opioid
use.
While previous studies examining prescription drug misuse in the HIV-infected
population have concentrated on opioid analgesics, this study focuses on the potentially
problematic use of benzodiazepine medications. Potentially problematic benzodiazepine use
describes instances when the medication may be used in a manner that has not been proven
effective or may lead to patient harm. One measure of potentially problematic benzodiazepine
use involves long-term continuous use exceeding 120 days duration. As their long-term (> 120
days) anxiolytic efficacy has not been evaluated, benzodiazepines are only recommended for
short-term use, with the exception of managing symptoms related to panic or seizure disorders
in some patients.2 Additionally, long-term benzodiazepine use carries the risk of increasing
tolerance to the drug’s effects and the development of dependence.28,35 Another measure of
potentially problematic benzodiazepine use involves excessive daily dosages that are greater
than 40 diazepam milligram equivalents (DME) per day. Current guidelines regarding the dosing
of benzodiazepines in adults under 65 years of age recommend 20 DME per day as the
maximum daily dose.194 An expert panel has defined high daily dosage of benzodiazepines
indicating potentially problematic benzodiazepine use as doses greater than two-times the
recommended daily maximum (i.e. 40 DME).65 Concurrent use of prescription benzodiazepine
and prescription opioid medications for non-acute purposes also constitutes potentially
problematic benzodiazepine use. Rarely are benzodiazepines the preferred or sole drug of
abuse; instead abuse commonly occurs in conjunction with another substance, often opioids.16
Clinical evidence shows that benzodiazepines and opioids, when used concurrently exert a
synergistic effect by increasing the rewarding and reinforcing effects of opioids.17-23 Other
measures of potentially problematic benzodiazepine use include doctor shopping and pharmacy
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hopping. Doctor shopping depicts a pattern of visiting multiple prescribers to obtain
prescriptions for a controlled substance (CS) medication95,195 and pharmacy hopping describes a
pattern of having CS prescriptions filled at multiple pharmacies.196 Each of these measures has
previously been found to be associated with problematic prescription drug use.197
The aims of this study are to estimate the prevalence of potentially problematic
benzodiazepine use in a commercially insured population of HIV-infected adults and, determine
if HIV-infection is associated with an increased risk of potentially problematic benzodiazepine
use. In addition, this study evaluated differences in patient characteristics including sex, age,
race, education, presence of a psychiatric disorder, and substance use history on the likelihood
of potentially problematic benzodiazepine use among HIV-infected and uninfected patients.
METHODS
This study utilized data from a population-based cohort of privately insured
beneficiaries from all 50 states and the District of Columbia from January 2007 through
December 2009. Beneficiaries were included in the study cohort if they were between the ages
of 19 and 64 throughout the study period, resided in the same state the entire duration of the
study period, had at least one healthcare claim in 2007 followed by a subsequent claim in either
2008 or 2009, and had a claim for a least one benzodiazepine prescription during the study
period regardless of quantity, days’ supply, or dosage form. Benzodiazepine fills during the study
period were identified using national drug codes for the medications consisting of alprazolam,
chlordiazepoxide, clonazepam, clorazepate, diazepam, estazolam, flurazepam, lorazepam,
midazolam, oxazepam, quazepam, temazepam, and triazolam. HIV-infection among
beneficiaries was identified if they had at least one healthcare claim in 2007 in any position for
HIV-infection (ICD-9 code: ‘042’). The outcome of interest was potentially problematic
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benzodiazepine use. The following covariates were assessed during the first year of observation:
sex, age, race, education, state of residence, substance abuse treatment (e.g. residential or
nonresidential treatment facility), psychiatric disorders, and alcohol abuse.
Measures of potentially problematic benzodiazepine use were identified through
reviews of the literature65 and discussions with academic pharmacists. The measures employed
in this study include: duration of benzodiazepine use exceeding 120 consecutive days, daily
dosages greater than 40 DMEs, having filled a prescription for an opioid medication for a
duration exceeding seven days during a benzodiazepine episode, having a benzodiazepine
prescription written by a minimum of four different prescribers during the study period, and
filling a benzodiazepine prescription at a minimum of four different pharmacies during the study
period. The duration of a benzodiazepine episode was defined as a chronological sequence of
benzodiazepine dispensing with a break of no more than seven days between the end date of
the prescription and the subsequent benzodiazepine prescription fill. The end date of a
prescription was calculated by taking the fill date of the prescription and adding to it the days’
supply of that prescription. For each benzodiazepine prescription DMEs per day were calculated
based on equivalency rates proposed by Shader et al.7 and The American Pharmacists
Association.151 Conversion to DME dosages allowed for therapeutic comparisons between each
benzodiazepine dispensed. To calculate the per day dosage the equivalency rates were
multiplied by the quantity and strength of the prescribed benzodiazepine and then divided by
the total days’ supply. Prescription opioid fills were identified through the use of national drug
codes. The dispensing of an opioid medication where the days supply was less than or equal to
seven days were not considered as short-term concurrent benzodiazepine and opioid use may
be appropriate (i.e. opioid use for the management of acute pain in a person taking
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benzodiazepines to manage symptoms of a psychiatric disorder). Individual prescribers and
pharmacies were identified using unique identifiers within the database.
The distributions of baseline covariates between the HIV-infected and uninfected
samples were examined. Bivariate analyses tested the association between HIV-infection and
potentially problematic benzodiazepine use defined by the measures above. Multivariate logistic
regression models adjusted for covariates were used to estimate the adjusted odds ratio (AOR)
of potentially problematic benzodiazepine use for HIV-infected patients. The covariates
described previously were added to the multivariate model based on their bivariate association
with potentially problematic benzodiazepine use and were operationalized as categorical
variables. Age was segregated into two categories, ages 19 to 44 years and 45 to 64 years, based
on the mean age of the study population years. Race was divided into two categories, white and
nonwhite. The nonwhite category was comprised of beneficiaries identified in the claims data as
black, Hispanic, or other. Education was separated into two categories: high school graduate or
less and more than high school education. Effect modification between HIV and the covariates
was examined using the Breslow-Day test and added to the model based on clinically
meaningful differences between the stratums. Data use was approved by the University of
Kentucky Institutional Review Board. Statistical analyses were conducted using SAS 9.4 (SAS
Institute, Cary, NC). Statistical significance was set a priori at the 0.05 level.
RESULTS
A total of 835,025 beneficiaries met the inclusion criteria for this study. Of these
beneficiaries, 3,555 were excluded due to duplicate information (i.e., multiple states of
residence, conflicting years of birth), 181 were excluded because they resided outside the US at
some point during the study period, and eight were excluded due to incomplete benzodiazepine
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dispensing information. Overall, the study cohort consisted of 831,281 beneficiaries with 3,447
identified as HIV-infected. Baseline characteristics of the HIV-infected and uninfected
populations are presented in Table 4.1. Compared to the uninfected population the HIV-infected
population had a greater proportion of males (84% vs. 32%) blacks (8% vs. 4%) Hispanics (11%
vs. 7%). The HIV-infected population also had a greater proportion of beneficiaries with a
diagnosis of depression (24% vs. 20%) and insomnia (11% vs. 8%) compared to those uninfected
with HIV.
At least one indicator of potentially problematic benzodiazepine use was found in 45%
of HIV-infected patients and 31% of uninfected patients (Figure 4.1). Of these indicators, longterm continuous use exceeding 120 days duration was the most common measure of potentially
problematic benzodiazepine use and was observed in 28% of HIV-infected patients compared to
16% of uninfected patients. Patients infected with HIV also were more likely than their
uninfected counterparts to have benzodiazepine prescriptions written by at least four different
providers (10% vs. 7%), filled by at least four different pharmacies (6% vs. 3%), have the daily
dosage exceed 40 DMEs (7% vs. 5%), and have non-acute opioid use during a benzodiazepine
episode (25% vs. 19%).
Results from the multivariate model suggest differences in the likelihood of potentially
problematic benzodiazepine use by any measure between the HIV-infected and uninfected
populations stratified by level of education and the presence of a depression or insomnia
diagnosis (Figure 4.2). In this model HIV-infection alone was associated with a significant
increase in the odds of potentially problematic benzodiazepine use by any measure (AOR: 1.32;
95% CI: 1.20, 1.45). Stratum-specific results show that HIV-infected patients with less education
(i.e. high school graduate or less) were 1.37 times more likely (95% CI: 1.20, 1.56) to have
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potentially problematic benzodiazepine use compared to HIV-infected patients who had more
than a high school education while in the uninfected population those with less education were
less likely to have potentially problematic benzodiazepine use (AOR: 0.76; 95% CI: 0.76, 0.77).
Results show that in both the HIV-infected and uninfected populations having received a
diagnosis of depression was associated with an increased likelihood of potentially problematic
benzodiazepine use, however, in the HIV-infected population the likelihood was greater than
that observed in the uninfected population. HIV-infected patients who had received a
depression diagnosis were twice as likely (AOR: 1.99; 95% CI: 1.71, 2.32) to have potentially
problematic benzodiazepine use than HIV-infected patients without a depression diagnosis
while in the uninfected population those who received a diagnosis of depression, compared to
those without, were only 20% more likely (AOR: 1.20; 95% CI: 1.18, 1.21) to have potentially
problematic benzodiazepine use. Having been diagnosed with insomnia was also found to
increase the likelihood of potentially problematic benzodiazepine use in the HIV-infected and
uninfected populations. In the HIV-infected population a diagnosis of insomnia was associated
with an 87% increase (AOR: 1.87; 95% CI: 1.49, 2.35) in the likelihood of potentially problematic
benzodiazepine use but in the uninfected population a diagnosis of insomnia was only
associated with a 23% increase in the odds (AOR: 1.23; 95% CI: 1.21, 1.25).
DISCUSSIONS
To our knowledge this is the first study to examine potentially problematic
benzodiazepine use in the HIV-infected population. The present study demonstrates that HIV
infection is associated with an increase in the likelihood of potentially problematic
benzodiazepine use. Furthermore, among the HIV-infected population those with less education
or who were diagnosed with depression or insomnia were more likely to display signs of
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potentially problematic benzodiazepine use compared to those with more education or absent a
depression diagnosis. In the uninfected population lower education was associated with a
decrease in the odds of potentially problematic benzodiazepine use, and even though having
received a diagnosis of depression or insomnia was associated with an increase in the likelihood
of potentially problematic benzodiazepine use it was not as great as the association observed in
the HIV-infected population. The observed findings are notable as concerns exist regarding
benzodiazepine use in the HIV-infected population due to their high abuse/misuse potential.
Substance abuse has been linked to poor adherence of antiretroviral therapy179,180 and
problematic benzodiazepine use may lead to increases in the cost of treating the HIV-infected
population and poor clinical outcomes.
Reasons for the observed finding of HIV-infection being a risk factor of potentially
problematic benzodiazepine use may be related to the high prevalence of substance abuse in
this population. Evidence also suggests that chronic pain is undertreated among HIV-infected
patients as physicians may have a difficult time managing chronic pain in HIV-infected patients
due to the high prevalence of substance abuse concerns.198-200 As a result of undertreated pain,
HIV-infected patients may seek pain relief by concurrently taking benzodiazepines with opioid
analgesics in an effort to enhance the pain relieving effects of opioids. Our finding that one
quarter of HIV-infected patients had evidence of non-acute opioid use during a benzodiazepine
episode lends support to this explanation; however, it is not possible to ascertain the reasons
for the concurrent use.
This study also found that HIV-infected patients with less education were more likely
that their more educated counterparts to have potentially problematic benzodiazepine use
while the reverse was found in the uninfected population where less educated patients had a
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decreased likelihood of potentially problematic benzodiazepine use. Lower educational
attainment has been shown to be associated with both prescription drug misuse201 and HIVinfection.202 The increased odds of potentially problematic benzodiazepine use among those
with less education in the HIV-infected population may be explained by links that have been
shown to exist between education and health related quality of life. Murri et al.203 showed that
lower education levels were associated with poorer mental health where symptom
management may involve benzodiazepine use. Lower education levels may also lead to
difficulties in understanding complex HIV treatment regimens that may cause additional stress
and anxiety for the patient.203
The differences in the odds of potentially problematic benzodiazepine use between the
HIV-infected and uninfected populations based on the presences of depression may be related
to demographic or behavioral factors that are unable to be captured in the claims data (i.e., HIVrelated stigmas, psychosocial burdens, and the overall encumbrance of being HIV-infected).
Surveys using a sample of the general US population found that men who have sex with men
and injecting drug users perceive and face a greater degree of discrimination and stigmatization
associated with their HIV serostatus.182 The level of social support has also been found to be
directly related to depressive symptoms experienced by patients infected with HIV.204 Another
possible explanation is HIV-infected patients with depression may be more concerned about
their health status and life expectancy thus making them more likely to engage with treatment
providers who monitor their medications205 leading to increased opportunities to acquire a
benzodiazepine prescription. Benzodiazepines are not specifically indicated for the management
of depression however, anxiety, a condition for which benzodiazepines are indicated, is
associated with depressive symptoms.116
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In the HIV-infected population managing symptoms related to insomnia is important as
they have been linked with adverse effects on the immune system206 and medication
adherence,207,208 both which can impact disease outcomes. This may offer explanation to the
finding that among HIV-infected individuals those diagnosed with insomnia were more likely
than those without to have at least one indicator of potentially problematic benzodiazepine use.
Estimates of the rate of sleep disturbances in the HIV-infected population vary widely (2997%)209 but mostly exceed that estimated in the general population (33%).210 Existing evidences
also points to a direct relationship between sleep disturbances and advanced HIV disease
stage211-213 and longer duration of HIV-infection.206,209,214 Furthermore, a relationship between
antiretroviral therapy, specifically nonnucleoside reverse transcriptase inhibitor (NNRTI), and
sleep disturbances has been shown in several studies.215-217 These previous studies may provide
explanation for the finding that in the HIV-infected population the likelihood of potentially
problematic benzodiazepine use among those diagnosed with insomnia is greater than the odds
observed in the uninfected population.
Limitations to this study should be recognized. First, as this study employs data from a
private insurance claims database the overall HIV-infected and uninfected populations may not
be accurately represented. Additionally, we are unable to account for medications acquired
from family or friends or prescriptions paid for with cash. Due to the observational nature of this
study an association between variables does not imply causality. Another potential limitation is
that dispensed medications may not be equivalent to medications consumed. More generous
definitions of continuous benzodiazepine use have been employed elsewhere in the literature65
however, when applied results from the present study were unchanged.
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Despite these limitations the findings presented provide valuable information on
potentially problematic benzodiazepine use in the HIV-infected population. This study supports
the idea that caution should be exercised in the prescribing of benzodiazepines and other
potentially abused medications in this population. Additionally, these findings highlight the need
to adequately manage symptoms of depression and insomnia among this clinically vulnerable
population. Furthermore, social factors including perceived stigmas and social support systems
may have a valuable role in the management of HIV related symptoms. Future research should
highlight HIV related health outcomes associated with potentially problematic benzodiazepine
use. Interventions designed to reduce potentially problematic benzodiazepine use in this
population are also warranted. Healthcare providers should take care in an effort to adequately
manage symptoms of pain in the HIV-infected population while also being mindful of concerns
regarding the risk of prescription drug misuse. Additionally, decreasing stigmas associated with
HIV infection and mitigating daily stressors for HIV-infected patients may also reduce potentially
problematic benzodiazepine use in this population. As the lifespan of the HIV-infected
population continues to approach that of the uninfected population adequately managing
symptoms associated with HIV and curtailing prescription drug misuse would benefit patients,
payers, and society.
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Table 4.1. Comparison of demographics of HIV-infected and uninfected patients.
HIV-infected
HIV-uninfected
n = 3,447
n = 827,834
Variable
n
%
n
%
Sex
Male
2,886
84%
267,077
32%
Race
White
2,463
71%
657,722
79%
Black
292
8%
31,526
4%
Hispanic
389
11%
56,018
7%
Other
289
8%
75,404
9%
Age
Mean age (for year 2007), SDa
44.1
(8.4)
43.9
(11.0)
Education
High school graduate or less
1,044
30%
282,203
34%
Some college or college graduate
2,304
67%
520,314
63%
Location
Northeast
419
12%
84,623
10%
Midwest
494
14%
198,531
24%
South
1,943
56%
423,821
51%
West
590
17%
120,822
15%
Psychiatric disorders
Anxiety
676
20%
178,947
22%
Depression
844
24%
169,143
20%
Insomnia
375
11%
68,739
8%
Substance abuse
Alcohol abuse
120
3%
15,802
2%
Substance abuse treatment
35
1%
7,396
1%
a
Standard deviation
Percentage values presented may not add to 100% due to rounding or missing values.
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Figure 4.1. Measures of potentially problematic benzodiazepine use in the HIV-infected and
uninfected samples.
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Figure 4.2. Likelihood of potentially problematic benzodiazepine use among HIV-infected patients
compared to HIV-uninfected patients stratified by presence of anxiety diagnosis and age.

Strata
Odds Ratio
HIV
1.32
High school or less
0.76
HIV*High school or less
1.37
Depression
1.20
HIV*Depression
1.99
Insomnia
1.23
HIV*Insomnia
1.87

Odds Ratio

2

a

b

(95% CI )
(1.20, 1.45)
(0.76, 0.77)
(1.20, 1.56)
(1.18, 1.21)
(1.71, 2.32)
(1.21, 1.25)
(1.49, 2.35)

1

73
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High school or HIV*High school
less
or less
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HIV*Depression
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a

Adjusted for sex, education, race, psychiatric disorder diagnosis, substance use disorder (e.g., alcohol abuse diagnosis, treatment for substance
use).
b
CI: Confidence interval.
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CHAPTER 5: IMPACT OF SOUTH CAROLINA’S PRESCRIPTION DRUG MONITORING PROGRAM
ON THE USE OF BENZODIAZEPINES IN A COMMERCIALLY INSURED POPULATION.
INTRODUCTION
For patients afflicted with symptoms of anxiety and insomnia, benzodiazepines are a
generally safe and effective pharmacological treatment option. Benzodiazepines are indicated
for use as anxiolytics, sedatives, hypnotics, anticonvulsants, and/or skeletal muscle relaxants2,103
and are the most frequently prescribed psychotropic drug class.11 In 2012 benzodiazepines were
the 10th most prescribed drug class in the United States with approximately 94 million
prescriptions dispensed.12 Alprazolam was the most commonly dispensed benzodiazepine with
49 million prescriptions dispensed in 2012 and ranked as the 13th most commonly dispensed
medication in the United States.13
Although considered safer than other sedative-hypnotics drugs, such as barbiturates
and meprobamate,2,3,6 the potential exists for benzodiazepines to be abused and are therefore
classified as a Schedule IV controlled substance (CS). According to the 2012 National Survey of
Drug Use and Health, the estimated number of incident benzodiazepine abusers was 166,000.104
National estimates of drug-related visits to emergency departments collected by the Drug Abuse
Warning Network (DAWN) for the year 2011 reported that between 2004 and 2011 the number
of emergency department visits for the non-medical use of benzodiazepines increased 149%
from 143,500 to 357,800.105 Additionally, this report identified benzodiazepines as the second
leading cause of all emergency department visits concerning nonmedical use of pharmaceuticals
as they were involved in 28.7% of all emergency department visits for this cause.105 Another
recent study examining data from DAWN between 2004 and 2008 reported that
benzodiazepines were identified in approximately 26% of all opioid-related emergency
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department visits.106 These estimates suggest that inappropriate benzodiazepine use can lead to
serious adverse effects and caution must be exercised regarding their prescribing and use.
Concerns about the growing trend of prescription drug abuse and diversion have
prompted states to enact legislation to track the prescribing and dispensing of targeted CS. In
1989, New York became the first state to monitor the prescribing and dispensing of
benzodiazepines through the state’s triplicate prescribing program (TPP).63-65 Several studies
have since evaluated the effectiveness of the New York TPP on the state’s Medicaid population
and discovered that following implementation there was an immediate, significant, and
sustained reduction in overall benzodiazepine use.65,73,74 Other studies of the New York TPP
highlighted concerns that policies monitoring benzodiazepine prescribing and dispensing may
result in a chilling effect where patients with a chronic psychiatric disorder and/or a legitimate
need for benzodiazepine therapy are unable to acquire the medication.73 Patients may be
unable to obtain appropriate CS medications either due to a physician’s unwillingness to
prescribe or a pharmacist being unwilling to dispense the CS. The unwillingness to prescribe or
dispense a CS may be due to fear of legal investigations, fear of confidentiality violations,
increased administrative burden, or confusion between the patterns of addiction and
pseudoaddiction, where patients who are not being adequately treated for their condition
appear, on paper, to be addicts.76-79
More recently, states have relied on electronic data transfer systems, more commonly
referred to as prescription drug monitoring programs (PDMPs), to track the prescribing,
dispensing, and utilization of targeted medications in an effort to mitigate prescription drug
abuse and diversion. Reports detailing a patient’s CS prescription history can be accessed upon
request by healthcare providers, allowing for treatment decisions to be made at the point of
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care. Additionally, because many PDMPs allow healthcare providers nearly instantaneous access
to a patient’s CS prescription history, use of PDMPs can alert them to possible cases of
prescription drug abuse and diversion by patients. As of December 2014, 49 states have an
operational PDMP.80
In 2006, the South Carolina state legislature signed into law legislation authorizing the
state’s Department of Health and Environmental Control (DHEC) Bureau of Drug Control to
establish and maintain a PDMP with the intent of improving the ability to identify and prevent
prescription drug diversion in an efficient and cost effective manner without impeding access to
licit CS medications for patients with a legitimate need.218 The South Carolina Reporting and
Identification Tracking System (SCRIPTS) started collecting data from CS dispensers on January 1,
2008, and reporting began on February 1, 2008.219
All dispensing of Schedule II-IV CS in community pharmacy and outpatient settings are
maintained in the SCRIPTS electronic database.218 Dispensers, including pharmacists, physicians,
and veterinarians, are required to submit their CS dispensing data for Schedule II-IV at least
every 30 days, between the 1st and 15th of the month.218 Controlled substance prescription data
submitted to SCRIPTS follows a standard format and includes patient’s name, address, and date
of birth, prescriber’s Drug Enforcement Administration (DEA) number, dispenser’s (i.e.,
pharmacy’s) DEA number, date the prescription was issued, date the drug was dispensed,
National Drug Code (NDC), quantity, and approximate number of days supply of the CS
medication dispensed.218 Physicians and pharmacists may request a patient’s CS prescription
history report from SCRIPTS, which is usually available within minutes,219 in order to make
treatment decisions at the point of care; however, physicians and pharmacists are not required
to do so.218 Prior to accessing the SCRIPTS database, physicians and pharmacists are required to
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complete an online training course and granted access by the DHEC.220,221 Law enforcement and
prosecutorial officials may also request reports from the SCRIPTS database as long as they are
officially engaged in a drug-related investigation.218,221 However, these parties cannot access the
database directly. Instead, they must mail a request form to the DHEC who must approve the
request before reports will be mailed via certified U.S. Mail to the requesting official.222 In the
first complete fiscal year following the implementation of SCRIPTS (July 1, 2008 – June 30, 2009)
more than nine million prescription records were collected and more than 51 thousand SCRIPTS
reports were produced.223
Policies designed to curtail the abuse, misuse, and diversion of prescription drugs (i.e.,
PDMPs) should be evaluated to determine if they are effectively meeting their objectives.
Assessments of these policies are also necessary to ensure patient safety (i.e., permitting access
to CS medication for appropriate medical care). To date, studies regarding current PDMP
legislation have focused primarily on the impact concerning opioid analgesic prescribing and
use. Focus on this medication class is understandable as opioid analgesics are the primary
contributor to the increasing trend of drug overdose deaths in the United States.92-94 However,
other CS, specifically benzodiazepines, have been found to be a factor contributing to the
substantial rise in unintentional poisoning deaths.92,95-97 Despite the role of benzodiazepines in
the US prescription drug abuse epidemic, no studies have evaluated the impact of current PDMP
legislation on benzodiazepine use. Of the 49 operational PDMPs, as of December 2014, 48 have
the authority to monitor the prescribing and dispensing of Schedule IV CS which includes
benzodiazepines.224
The aim of this study is to evaluate the effect of South Carolina PDMP implementation
on the dispensing of benzodiazepines. This will be accomplished by testing the following
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hypotheses: 1.) Implementation of the PDMP in South Carolina will not result in a change in the
rate of benzodiazepine use 2.) Implementation of the PDMP in South Carolina will not result in a
chilling effect, defined as a reduction in the likelihood of filling a benzodiazepine prescription
among patients with a legitimate need for the medication. Results of this study will expand the
literature on PDMPs and their influence on benzodiazepine utilization.
METHODS
Using data from a large private insurance claims database containing beneficiary sociodemographic information and codes related to interactions with the healthcare system, two
identically defined cohorts, one from South Carolina (study), the other from Tennessee
(control), were extracted for the time period between January 2007 and December 2009. This
time period constitutes the 12 months prior to and 24 months after the South Carolina PDMP
was implemented. Tennessee was selected as a control state because had a PDMP in place
during the entire study period and, with the exception of race, is it similar demographically to
South Carolina225 (Table 5.1). Beneficiaries were included in the analyses if they resided in South
Carolina or Tennessee, were between 19 and 64 years of age during the entire study period, and
were continuously enrolled (≥1090 days) during the study period. Beneficiaries under the age of
19 were excluded because the prescribing of benzodiazepines in children is an uncommon
practice65 while those 65 and older were excluded because benzodiazepines are not
recommended for use in this population due to an increased risk of cognitive impairment, falls,
and fractures.52,53 Psychiatric disorders for which benzodiazepines are commonly prescribed
including anxiety103 (ICD-9 codes: 300.xx, excluding 300.4), insomnia103 (307.41, 307.42, and
780.52), and depression174 (296.2x, 296.3x, 300.4, and 311) were also identified in the database.
These conditions were used as an indicator of legitimate benzodiazepine use to test for the
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presence of a chilling effect. Beneficiaries were considered to have a specific psychiatric disorder
if they had a claim at any time during the study period with a diagnosis including one of the ICD9 diagnostic codes listed above. Benzodiazepine dispensing during the study period was
represented by a claim for any benzodiazepine during a given month of the study period and
identified using national drug codes.
To evaluate whether or not the implementation of the South Carolina PDMP had a
greater impact on the rate of benzodiazepine use than any underlying secular trend, interrupted
time series methods were employed. Time series analyses using autoregressive integrated
moving average (ARIMA) models estimated changes in the level and trend of the percent of
beneficiaries in each state who filled a benzodiazepine prescription during each of the 12
months prior to and 24 months after the South Carolina PDMP was implemented. According to
Wagner, Soumarai, Zhang, and Ross-Degnan (2002), a change in level is described as the jump or
drop in the outcome after an intervention, while a change in the trend is defined by an increase
or decrease in the slope of the trend line after the intervention compared to the trend line prior
to the intervention.226 Because some prescriptions written in 2007 may not have been filled
immediately and because reporting did not begin until February 1, 2008, January 2008 was
excluded from this analysis. The exclusion of this time period is consistent with the methods
used by Ross-Degnan et al. (2004) to evaluate the impact of the New York TPP on
benzodiazepine use.65 Moreover, a sensitivity analysis was performed to test the robustness of
the results using the proportion of the continuously eligible sample who filled an opioid
prescription during each of the 12 months prior to and 24 months after the South Carolina
PDMP was implemented.
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Panel data methods were employed to examine the effect that South Carolina PDMP
implementation had on the likelihood of filling a benzodiazepine prescription. Multivariate
logistic regression models using random effects and adjusted for presence of a PDMP, sex, age,
race, presence of psychiatric disorders, state and month specific unemployment rates, time in
months, and state of residence were used to estimate the adjusted odds ratio (AOR) and
associated 95% confidence intervals (CI) of filling a benzodiazepine prescription. The covariates,
with the exception of the monthly unemployment rates and the time trend variable, were
operationalized as categorical variables. Age was calculated based on the beneficiary’s year of
birth and segregated into two categories based on the median age of the study sample, age 19
to 44 and 45 to 64. Race was divided into three categories: white, black, and other. The other
race category was comprised primarily of beneficiaries identified in the database as Hispanic, or
other. These beneficiaries were considered together due to their individually small
representation in the study population. State and month specific unemployment rates acquired
from the US Bureau of Labor Statistics were used to adjust for the economic climate that was
especially volatile during the study period.227 The unemployment variable was operationalized
as a continuous variable representing the percentage of the states’ workforce who were without
a job, actively seeking employment, and available for work during a given month. The monthly
time trend variable was operationalized as an ordinal variable taking the values 1 through 36
and included in the analysis to capture the effects that trend in one direction over time.
The first multivariate logistic regression model takes a linear form to determine factors
that influence the likelihood of filling a benzodiazepine prescription among beneficiaries in the
study population. This model takes the form of
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Where
state

is the odds of filling a benzodiazepine prescription for beneficiary residing in
in month . The variable

in month .

indicates the presence of an operational PDMP in state

represents the state of residence for beneficiary . The matrix

identifies

demographic characteristics for beneficiary including sex, race, and age, and the matrix
represents the presence of a psychiatric disorder diagnosis including anxiety, depression, and
insomnia for beneficiary . The variable
month and

is the unemployment rate for state

in

is the monthly time trend variable. Finally, is a normal independent

identically distributed (i.i.d.) error term.
A difference in difference (DD) estimator, obtained by interacting the variables
indicating the beneficiary’s state of residence and the presence of a PDMP, estimated the effect
the South Carolina PDMP had on the odds of filling a benzodiazepine prescription among South
Carolina beneficiaries compared to their counterparts in Tennessee. To evaluate if the South
Carolina PDMP implementation had a differential impact on specific subgroups in the
population, difference in difference in difference (DDD) estimators were employed. These
second order interactions were obtained by interacting the DD estimator with each of the
demographic and psychiatric disorder covariates listed previously. This model takes the form of

Linear combinations of coefficients estimated the odds of filling a benzodiazepine prescription
among subgroups in South Carolina during the two years after the PDMP implementation
compared to the odds in the year preceding the program. Statistical significance was considered
using the Wald χ2 p-value associated with the interaction term. The a priori level of significance
for all analyses was set at 0.05. Data use was approved by the University of Kentucky
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Institutional Review Board. Statistical analyses was conducted using Stata 13.0 (StataCorp.,
College Station, TX).
RESULTS
A total of 69,738 beneficiaries met the inclusion criteria of this study. Of these, 19,034
(27.3%) resided in South Carolina and 50,965 (72.7%) in Tennessee. Baseline characteristics and
benzodiazepine utilization by state of residence are shown in Table 5.2. Due to the large sample
sizes, differences in the demographic characteristics between the states are statistically
significant but the proportions in the distributions are similar for most characteristics. A sizable
difference exists between the individual state cohorts with regards to race, with the South
Carolina cohort having a higher proportion of nonwhite beneficiaries, particularly black
beneficiaries (11.85% vs. 6.57%), compared to the Tennessee cohort. The South Carolina cohort,
compared to the Tennessee cohort, also had a greater proportion of beneficiaries with at least
some college education or a college degree (52.1% vs. 48.5%).
Overall, 18% of the South Carolina cohort and 17% of the Tennessee cohort filled a
benzodiazepine prescription between January 2007 and December 2009. During this timeframe
12,297 unique beneficiaries filled a total of 101,036 benzodiazepine prescriptions. Alprazolam
(47,501 unique prescriptions filled), clonazepam (19,612), lorazepam (13,624), and diazepam
(11,836) were the most commonly filled benzodiazepine prescriptions. The number of
beneficiaries who filled a benzodiazepine prescription in each month of the study period is
presented in Appendix 5.1.
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Interrupted Time Series Analysis
Throughout 2007, the percentage of South Carolina beneficiaries who filled a
prescription for a benzodiazepine was increasing monthly by a rate 5% (0.05; 95% CI: 0.03, 0.07;
p<0.01; Table 5.3). After the PDMP was implemented in South Carolina in January 2008, the
percentage of beneficiaries filling a benzodiazepine prescription increased at a rate of 4% (0.04;
95% CI: 0.03, 0.07; p<0.01). This change in trend of the percent of South Carolina beneficiaries
filling a benzodiazepine prescription each month was not significant (-0.01; 95% CI: -0.03, 0.02;
p=0.46). Additionally, there was no change observed in the level (0.10; 95% CI: -0.33, 0.12;
p=0.38) of the percent of South Carolina beneficiaries who filled a benzodiazepine prescription
immediately after the PDMP was implemented (Figure 5.1). In the control state of Tennessee,
no change was observed in the slope of the trend line of the percentage of beneficiaries filling a
benzodiazepine prescription each month (-0.01; 95% CI: -0.03, 0.01; p=0.25). There was also no
change observed in the level of filled benzodiazepine prescriptions (0.13; 95% CI: -0.30, 0.04;
p=0.13) among Tennessee beneficiaries at the time of the South Carolina PDMP
implementation.
The relative effect of the South Carolina PDMP based on 2007 predicted values initially
after the program was implemented was 3.1% (95% CI: -8.92%, 3.58%; p=0.36) reduction in the
percent of beneficiaries who filled a benzodiazepine prescription and not statistically significant
(Figure 5.2). In January 2009, one year after the program began, the relative effect was a 5.3%
(95% CI: -13.91%, 5.41%; p=0.31) reduction in the percent of beneficiaries who filled a
benzodiazepine prescription and also not determine to be significant. By the end of 2009 the
relative effect of the PDMP implementation was a 7% (95% CI: -18.44, 8.33%; p=0.34) reduction
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in the percent of beneficiaries who were predicted to fill a benzodiazepine prescription and not
statistically significant.
The results from the sensitivity analysis performed determined that there was no
change in trend or level of the percentage of South Carolina beneficiaries who filled an opioid
prescription after the PDMP was implemented in January 2008 (Appendix 5.2). Similar findings
were observed in Tennessee where there was no change in trend or the level of the percent of
beneficiaries who filled an opioid prescription. Furthermore, the relative effect of the South
Carolina PDMP on the percentage of beneficiaries who filled an opioid prescription was not
significant throughout the follow-up period (Appendix 5.3).
Multivariate Logistic Regression Analysis
In the overall study population, the odds of filling a benzodiazepine prescription were
influenced by sex, race, age, presence of a psychiatric disorder, state of residence,
unemployment rate, and time (Table 5.4). The odds of filling a benzodiazepine prescription were
greater for beneficiaries residing in South Carolina compared to those in Tennessee (AOR: 1.29;
95% CI: 1.18, 1.40; p<0.01), females compared to males (AOR: 2.45; 95% CI: 2.26, 2.66; p<0.01)
and beneficiaries between the ages of 45 and 64 compared to those 19 to 44 (AOR: 1.64; 95%
CI: 1.54, 1.73; p<0.01). Having a diagnosis of anxiety (AOR: 31.39; 95% CI: 28.58, 34.48; p<0.01),
depression (AOR: 4.68; 95% CI: 4,27, 5.13; p<0.01), or insomnia (AOR: 5.65; 95% CI: 5.09, 6.28;
p<0.01) also increased the odds of filling a benzodiazepine prescription during the study period.
Furthermore, the time trend variable included in the regression suggests that as time
progressed during the study period the odds of a beneficiary filling a benzodiazepine
prescription also increased (AOR: 1.02; 95% CI: 1.02, 1.03; p<0.01). Conversely, beneficiaries
identified as black (AOR: 0.35; 95% CI: 0.30, 0.42; p<0.01) or other race (AOR: 0.55; 95% CI: 0.49,
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0.67; p<0.01) were less likely than white beneficiaries to have filled a benzodiazepine
prescription. The unemployment rate was also inversely related to the odds of filling a
benzodiazepine prescription (AOR: 0.98; 95% CI: 0.97, 0.99; <0.01). Results also suggest the
presence of a PDMP did not have an effect on the odds of beneficiaries filling a benzodiazepine
prescription during the study period (AOR: 0.98; 95% CI: 0.94, 1.02; p=0.37).
Table 5.5 presents results from the DDD model evaluating whether the South Carolina
PDMP implementation had a differential impact on the likelihood of having a benzodiazepine
prescription filled among specific subgroups in South Carolina. The DD estimator was omitted
from the final interaction model due to collinearity as the correlation between the DD estimator
and the state of residence variable was determined to be 76 percent.
Adjusted for the covariates described previously, results from the DDD model suggested
the implementation of the PDMP in South Carolina differentially impacted the likelihood that
certain subgroups in the population would fill a benzodiazepine prescription. Linear
combinations of effect estimates (Table 5.6) demonstrated that in the 24 months after the
PDMP in South Carolina went into effect females and beneficiaries 45 and older experienced a
significant reduction in the odds of filling a benzodiazepine prescription compared to the 12
months prior to the program. The South Carolina PDMP implementation resulted in females
only having 85% (AOR: 0.85; 95% CI: 0.77, 0.91; p<0.01) of the odds of filling a benzodiazepine
prescription while beneficiaries 45 and older only had 87% (AOR: 0.87; 95% CI: 0.80, 0.95;
p<0.01) of the odds of filling a benzodiazepine prescription in 2008 and 2009 than they did prior
to the program in 2007.
Conversely, beneficiaries in South Carolina with a diagnosis of insomnia during the study
period had greater odds of filling a benzodiazepine prescription in the two years after the PDMP
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was implemented than they did in the year prior. South Carolina beneficiaries diagnosed with
insomnia during the study period experienced a 16% increase (AOR: 1.16; 95% CI: 1.03, 1.30;
p=0.02) in their odds of filling a benzodiazepine prescription after the PDMP was implemented.
DISCUSSIONS
In this sample of continuously eligible, privately insured beneficiaries in South Carolina
the implementation of SCRIPTS did not impact the rate of benzodiazepine use or create a chilling
effect by decreasing the likelihood of filing a benzodiazepine prescription during the two years
following the program’s implementation for beneficiaries having a diagnosis of insomnia, a
condition for which benzodiazepines are indicated. This finding is a contrast from previous
findings in New York,65 which suggested that benzodiazepine monitoring programs cause a
sudden and sustained decrease in the rate of benzodiazepine use. The findings of the present
study show that in the two years after SCRIPTS was implemented there was no change in the in
the level nor the trend of benzodiazepine dispensing when compared to the year prior to the
program. One possible explanation for this finding is that during the study period use of SCRIPTS
was voluntary among physicians and pharmacists. Physicians may not have accessed the
SCRIPTS database due to time constraints often present with evaluating patients. Another
deterrent to SCRIPTS use by physicians may be the perception that the information contained in
the report is incomplete and would therefore not impact their CS prescribing decisions. The
perception of the report being incomplete may be based on the knowledge that CS dispensers
were only required to submit their CS dispensing data once every 30 days. Of note, in June 2014
legislation passed the South Carolina General Assembly requiring daily reporting of CS
dispensing data by dispensers.228 Pharmacists may not have accessed the SCRIPTS database to
request a patient’s CS prescription history due to workflow issues and limited access to the
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Internet, especially in chain pharmacy settings. Pharmacists may have also assumed that
physicians were accessing the SCRIPTS database and therefore there was no reason for them to
do so.
Findings from this study did show that the presence of SCRIPTS differentially impacted
certain subgroups of the population. Results show that among South Carolina beneficiaries the
likelihood of filling a benzodiazepine prescription after SCRIPTS went into effect were
significantly decreased for females and beneficiaries 45 and older. However, even after SCRIPTS
was implemented females remained nearly three times more likely than males to fill a
benzodiazepine prescription and those 45 and older were nearly twice as likely to fill a
benzodiazepine prescription as their younger counterparts. As this study evaluated the impact
of SCRIPTS on the dispensing of benzodiazepines it cannot be determined if the discontinuation
of benzodiazepine therapy among female beneficiaries in South Carolina was appropriate or if
there were any adverse outcomes experienced as a result.
This study also demonstrated that having received a diagnosis of insomnia during the
study period significantly increased the likelihood of filling a prescription for a benzodiazepine
after the PDMP was implemented compared to beneficiaries without a diagnosis. As
benzodiazepines are indicated to manage symptoms associated with this condition, the finding
suggests that PDMPs, as they pertain to benzodiazepines, do not induce a chilling effect by
restricting access to pharmacotherapy options among those with a diagnosis of insomnia, a
condition where benzodiazepine therapy is appropriate.
Limitations to this study exist. First, this study does not distinguish between appropriate
or potentially inappropriate benzodiazepine dispensing to beneficiaries. However, the use of
diagnostic codes for conditions for which benzodiazepines are indicated and/or commonly
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prescribed can be used as a proxy for appropriate dispensing. Also, even though
benzodiazepines are often prescribed for the treatment of seizure disorders, they are generally
not the first-line therapy option. Because of this and the necessity of tailoring seizure disorder
treatments to individual patients seizure disorder conditions were not assessed. This study does
not account for the number of benzodiazepine prescriptions filled or the quantity and dosage of
these prescriptions. As this study utilized prescription drug claims from a private insurance
claims database, prescriptions acquired from family and friends or paid for using cash cannot be
accounted for. Additionally, this study could not account for utilization of the SCRIPTS program
by physicians and pharmacists who make treatment decisions. Finally, this a sample of
continuously enrolled, privately insured beneficiaries may not adequately represent the
populations of South Carolina or Tennessee as a whole and may not be generalizable to other
populations.
Findings from this study demonstrate that the presence of SCRIPTS did not induce a
chilling effect with regards to benzodiazepines in the overall sample of continuously enrolled,
privately insured beneficiaries in South Carolina with a diagnosis of insomnia. However,
benzodiazepine dispensing to females and beneficiaries 45 and older in South Carolina were
more impacted by the presence of the program than they were to males and younger adults. As
this study did not explicitly differentiate between appropriate and potentially inappropriate
benzodiazepine dispensing it cannot be determined if the reduction in benzodiazepine
dispensing to females and beneficiaries 45 and older was focused on those who may have been
misusing or diverting benzodiazepines or if discontinuation occurred in those who were using
the medication appropriately. Future research focusing on PDMPs and their impact on
benzodiazepine utilization should consider employing methods to identify appropriate and
potentially inappropriate benzodiazepine use in claims databases in order to evaluate if PDMPs
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are achieving their goal of reducing prescription drug abuse and diversion without impeding
access for those with a legitimate need. Additionally, exploring clinical outcomes among
patients who have had their benzodiazepine therapy discontinued can assist in evaluating costs
associated with the presence of a PDMP. Finally, future studies should explore the impact of
PDMPs on benzodiazepine use by expanding the number of states to allow for specific
characteristics of PDMPs to be analyzed and understand how they impact benzodiazepine use.
In addition, the time period analyzed should be expanded in order to observe the long-term
impact of PDMPs on benzodiazepine utilization. Considerable potential exists for PDMPs to
become a powerful tool to combat prescription drug abuse and diversion heightening the need
for more research to understand their clinical utility and ensure they do no obstruct access to
legitimate pharmacotherapies.
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Table 5.1. United States Census demographic information for South Carolina and Tennessee.225
South Carolina
Tennessee
2010 Population
4,625,364
6,346,105
Sex
Male
48.7%
48.8%
Female
51.3%
51.2%
Age
Under 18 years of age
22.6%
23.0%
Age 65 and older
15.2%
14.7%
Race
White
63.9%
74.9%
Black
27.9%
17.0%
Hispanic
5.3%
4.9%
Education
High School or more
84.5%
84.4%
Bachelor’s or more
25.1%
23.8%

Table 5.2. Demographic characteristics of continuously enrolleda adult beneficiaries in South
Carolina and Tennessee.
South Carolina
Tennessee
Sample Size
19,043
50,695
p-value
Benzodiazepine use
Filled benzodiazepine
3,515
18.46%
8,782
17.32%
<0.01
prescription
Sex
Female
9,727
51.08%
25,738
50.77%
0.47
b
Age
Median age (IQRc)
44
(35 – 53)
44
(34 – 52)
<0.01
Race
White
15,165
79.64%
42,875
84.57%
<0.01
Black
2,257
11.85%
3,332
6.57%
<0.01
Hispanic
421
2.21%
1,199
2.37%
0.23
Other
1,053
5.53%
2,987
5.89%
0.07
Education
High school diploma or
8,422
44.23%
25,003
49.32%
<0.01
less
Some college or college
9,911
52.05%
24,604
48.53%
<0.01
degree
ICD-9 Diagnosis
Anxiety
2,205
11.58%
6,310
12.45%
<0.01
Depression
2,165
11.37%
6,559
12.94%
<0.01
Insomnia
1,489
7.82%
3,854
7.60%
0.34
a
Continuously enrolled defined as ≥1090 days eligibility between Jan 1, 2007 & Dec 31, 2009
b
Median age was evaluated for the year 2007
c
Interquartile range
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Table 5.3. Interrupted time series analysis examining the percentage of South Carolina and
Tennessee beneficiaries filling a benzodiazepine prescription by month.
South Carolina
Tennessee
95%
95%
Confidence
Confidence
Coefficient p-value
Interval
Coefficient p-value
Interval
Monthly rate of increase
in benzodiazepine in
2007
0.05
<0.01
0.03, 0.07
0.04
<0.01
0.03, 0.06
Monthly rate of increase
in benzodiazepine in
2008 & 2009
0.04
<0.01
0.02, 0.05
0.03
<0.01
0.03, 0.04
Change in the rate of
increase of
benzodiazepine use
-0.01
0.43
-0.03, 0.01
-0.01
0.25
-0.03, 0.01
Change in the level one
month after PDMP
implementation
-0.11
0.35
-0.34, 0.12
-0.13
0.13
-0.30, 0.04
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Table 5.4. Odds of filling a benzodiazepine prescription between January 2007 and December
2009 among continuously enrolled adult beneficiaries in South Carolina and Tennessee.
Variable
Odds Ratio
p-value
95% Confidence Interval
PDMP
No operational PDMP
Ref.
PDMP operational
0.98
0.37
0.94 – 1.02
State of Residence
Tennessee
Ref.
South Carolina
1.29
<0.01
1.18 – 1.40
Sex
Male
Ref.
Female
2.45
<0.01
2.26 – 2.66
Race
White
Ref.
Black
0.35
<0.01
0.30 – 0.42
Other
0.58
<0.01
0.49 – 0.67
Age
Age 44 and under
Ref.
Age 45 and over
1.64
<0.01
1.54 – 1.73
Diagnosis of a Psychiatric Disorder
No psychiatric disorder diagnosis
Ref.
Anxiety
31.39
<0.01
28.58 – 34.48
Depression
4.68
<0.01
4.27 – 5.13
Insomnia
5.65
<0.01
5.09 – 6.28
Economic Climate
Unemployment ratea
0.98
<0.01
0.97 – 0.99
Time Trend
Monthb
1.02
<0.01
1.02 – 1.03
a
Unemployment rate interpretation is the effect of a one percentage point increase in the
unemployment rate
b
Month interpretation is the effect of time progressing forward one additional month
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Table 5.5. Odds of South Carolina adult beneficiaries filling a benzodiazepine prescription
after the implementation of the state’s PDMP.
Variable
Odds Ratio p-value
95% Confidence Interval
Presence of PDMP
No operational PDMP
Ref.
PDMP operational
0.92
0.09
0.83 – 1.01
State of Residence
Tennessee
Ref.
South Carolina
1.26
<0.01
1.12 – 1.41
Sex
Male
Ref.
Female
2.49
<0.01
2.29 – 2.71
Race
White
Ref.
Black
0.35
0.29 – 0.42
Other
0.57
<0.01
0.48 – 0.66
Age
Age 44 and under
Ref.
Age 45 and over
1.65
<0.01
1.55 – 1.75
Diagnosis of a Psychiatric Disorder
No psychiatric disorder diagnosis
Ref.
Anxiety
30.55
<0.01
27.78 – 33.60
Depression
4.64
<0.01
4.23 – 5.10
Insomnia
5.40
<0.01
4.85 – 6.00
Economic Climate
Unemployment ratea
0.98
<0.01
0.97 – 0.99
Time Trend
Monthb
1.02
<0.01
1.02 – 1.03
DDDc Estimators
PDMP * SC * Female
0.92
0.04
0.85 – 0.99
PDMP * SC * Black
1.03
0.73
0.89 – 1.18
PDMP * SC * Other
1.08
0.34
0.92 – 1.26
PDMP * SC * Over 45
0.95
0.19
0.88 – 1.03
PDMP * SC * Anxiety
1.15
<0.01
1.06 – 1.25
PDMP * SC * Depression
1.05
0.25
0.97 – 1.14
PDMP * SC * Insomnia
1.26
<0.01
1.15 – 1.37
a
Unemployment rate interpretation is the effect of a one percentage point increase in the
unemployment rate
b
Month interpretation is the effect of time progressing forward one additional month
c
Difference in difference in difference estimators
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Table 5.6. Linear combinations of effect estimates comparing odds of subgroups of South
Carolina adult beneficiaries filling a benzodiazepine prescription before and after PDMP
implementation.
Odds of filling a
Odds of filling a
Comparison of odds
benzodiazepine
benzodiazepine
after the South Carolina
prescription before prescription after South PDMP implementation
South Carolina PDMP
Carolina PDMP
to before
p-value
p-value
p-value
Variable
(95% CI)
(95% CI)
(95% CI)
3.13
2.65
0.85
Female
<0.01
<0.01
<0.01
(2.70, 3.64)
(2.19, 3.20)
(0.77, 0.92)
0.44
0.41
0.94
Black
<0.01
<0.01
0.47
(0.36, 0.54)
(0.32, 0.54)
(0.80, 1.11)
0.71
0.70
0.99
Other
<0.01
0.01
0.92
(0.58, 0.87)
(0.54, 0.92)
(0.83, 1.18)
2.07
1.81
0.87
Age 45 and over
<0.01
<0.01
<0.01
(1.81, 2.37)
(1.51, 2.16)
(0.80, 0.95)
38.40
40.64
1.06
Anxiety
<0.01
<0.01
0.28
(32.90, 44.83)
(32.99, 50.05)
(0.95, 1.17)
5.84
5.63
0.96
Depression
<0.01
<0.01
0.57
(5.02, 6.80)
(4.51, 7.03)
(0.85, 1.09)
6.79
7.85
1.16
Insomnia
<0.01
<0.01
0.02
(5.79, 7.96)
(6.29, 9.80)
(1.03, 1.30)
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Figure 5.1. Percent of sample who filled a benzodiazepine prescription each month during the
study period among continuously enrolled, privately insured beneficiaries in South Carolina
and Tennessee.
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Figure 5.2. Relative effect of South Carolina PDMP on percentage of sample population filling
a benzodiazepine prescription.
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Appendix 5.1. Number and percentage of continuously enrolled beneficiaries in South
Carolina and Tennessee who filled a benzodiazepine prescription by month.
South Carolina
Tennessee
Sample Size
19,043
50,695
2007
January
578 3.04%
1545 3.05%
February
527 2.77%
1458 2.88%
March
613 3.22%
1597 3.15%
April
585 3.07%
1569 3.09%
May
625 3.28%
1608 3.17%
June
626 3.29%
1600 3.16%
July
638 3.35%
1693 3.34%
August
649 3.41%
1710 3.37%
September
616 3.23%
1647 3.25%
October
683 3.59%
1771 3.49%
November
644 3.38%
1715 3.38%
December
641 3.37%
1730 3.41%
2008
January
680 3.57%
1770 3.49%
February
649 3.41%
1723 3.40%
March
675 3.54%
1739 3.43%
April
704 3.70%
1788 3.53%
May
696 3.65%
1804 3.56%
June
676 3.55%
1771 3.49%
July
681 3.58%
1898 3.74%
August
718 3.77%
1860 3.67%
September
698 3.67%
1901 3.75%
October
740 3.89%
1919 3.79%
November
678 3.56%
1857 3.66%
December
740 3.89%
1926 3.80%
2009
January
743 3.90%
1926 3.80%
February
693 3.64%
1851 3.65%
March
795 4.17%
2009 3.96%
April
739 3.88%
1943 3.83%
May
777 4.08%
1969 3.88%
June
787 4.13%
1992 3.93%
July
785 4.12%
2028 4.00%
August
760 3.99%
2079 4.10%
September
810 4.25%
2042 4.03%
October
810 4.25%
2160 4.26%
November
785 4.12%
2062 4.07%
December
837 4.40%
2180 4.30%
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Appendix 5.2. Interrupted time series analysis examining the percentage of South Carolina
and Tennessee beneficiaries filling an opioid prescription by month.
South Carolina
Tennessee
95%
95%
Confidence
Confidence
Coefficient p-value
Interval Coefficient p-value
Interval
Monthly rate of increase
in benzodiazepine in
2007
0.04
0.03
0.00a, 0.08
0.02
0.25
-0.02, 0.07
Monthly rate of increase
in benzodiazepine in
2008 & 2009
0.03
<0.01
0.02, 0.04
0.03
<0.01
0.02, 0.05
Change in the rate of
increase of
benzodiazepine use
-0.01
0.73
-0.04, 0.03
0.01
0.68
-0.03, 0.05
Change in the level one
month after PDMP
implementation
-0.08
0.67
-0.45, 0.03
0.11
0.55
-0.25, 0.48

Appendix 5.3. Relative effect of South Carolina PDMP on percentage of sample population
filling an opioid prescription.
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CHAPTER 6: A NATIONWIDE STUDY OF THE IMPACT OF PRESCRIPTION DRUG MONITORING
PROGRAMS ON THE DISPENSING OF BENZODIAZEPINES AMONG COMMERCIALLY INSURED
ADULTS.
INTRODUCTION
For the millions of American afflicted with symptoms of anxiety and insomnia
benzodiazepines are a generally safe and effective pharmacologic treatment option.
Benzodiazepines are the most frequently prescribed psychotropic drug class.11 In 2012 they
were the 10th most prescribed drug class in the United States with approximately 94 million
prescriptions dispensed.12 Benzodiazepines are considered a safer alternative compared to
other sedative-hypnotics drugs, such as barbiturates and meprobamate,2,3,6 however the
potential remains for benzodiazepines to be abused due to their addictive nature. Due to
evidence regarding the abuse potential of benzodiazepines they are classified as a Schedule IV
controlled substance (CS).
The role of benzodiazepines in the United States prescription drug abuse epidemic is
prominent. National estimates of drug-related visits to emergency departments collected by the
Drug Abuse Warning Network105 (DAWN) for the year 2011 reported that between 2004 and
2011 the number of emergency department visits for the non-medical use of benzodiazepines
increased 149% from 143,500 to 357,800. Additionally, this report identified benzodiazepines as
the second leading cause of all emergency department visits concerning nonmedical use of
pharmaceuticals, as they were involved in 28.7% of all emergency department visits for this
cause. Another recent study by Cai et al.106 examining data from DAWN between 2004 and 2008
reported that benzodiazepines were identified in approximately 26% of all opioid related
emergency department visits. These estimates suggest that benzodiazepine misuse and abuse
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can lead to serious adverse effects on individuals and caution must be exercised with their
prescribing and use.
To address the prescription drug abuse epidemic in the United States, individual states
have taken the lead in creating and implementing prescription drug monitoring programs
(PDMPs) with the purpose of identifying and mitigating prescription drug abuse and diversion.
These programs permit healthcare providers, including prescribers and pharmacists, the ability
to request and receive a patient’s controlled substance (CS) prescription history with quick
turnaround, allowing treatment decisions to be made at the point of care. Reports detailing a
patient’s CS prescription history can be accessed upon request, or proactively distributed to
authorized PDMP users, depending upon the regulations of the individual state’s program.
Pharmacies, along with dispensing physician and veterinarian offices submit CS dispensing data
to the PDMP on a regular basis as mandated by state law. The majority of states require CS
dispensing data to be submitted at least every seven days with some states requiring daily or
“real-time” reporting.80 Prescription data submitted to PDMPs follows a standard format and
includes patient name, prescriber name, date of dispensing, and name, strength, and quantity of
the CS medication dispensed. As of December 2014, 49 states have an operational PDMP.
Missouri and Washington DC do not currently have a PDMP, however, Washington DC does
have pending legislation.80
While all PDMPs were designed to facilitate collection, analysis, and reporting of
prescription CS use, in practice they take several different forms based upon individual state
legislation and differ in terms of objectives, design, and operations.229 Housing agencies of
PDMPs vary between states with the majority of PDMPs housed within and agency having
primarily a public health mission (e.g. health professional boards, departments of health);
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however some states house their PDMP within a law enforcement agency and while others are
part of another housing authority.80 The housing agency of the PDMP may have an effect on the
overall mission of the program and how authorized PDMP users interact with the system. For
example, states that house their PDMP within a law enforcement agency may perceive
prescription drug abuse as a safety concern and those who abuse and divert CS as criminals
while a state that houses their PDMP in a public health department may view prescription drug
abuse and diversion as a condition for which people need programs and treatment options to
help them overcome their problem. Variation also exists across states in terms of groups
authorized to access the PDMP system and subsequent reports. In most states healthcare
professionals including prescribers and pharmacists are authorized to receive the information
contained within PDMP reports, however, access among law enforcement personnel is less
uniform.80 States also differ in the CS Schedules monitored. While all state PDMPs track the
dispensing of Schedule II CS, some states also monitor Schedules III, IV, and V. Some state
PDMPs also have the authority to monitor non-CS under certain circumstances.82 The frequency
with which CS prescription dispensing data is transmitted to the PDMP is another source of
variation between programs with the majority of states require CS dispensing data to be
submitted at least every seven days, however, some states require daily or “real-time”
reporting.80
Policies designed to curtail the abuse, misuse, and diversion of prescription drugs (i.e.,
PDMPs) should be evaluated to determine if they are effectively meeting their objectives.
Assessments of these policies are also necessary to ensure patient safety (i.e., permitting access
to CS medication for appropriate medical care). To date, studies regarding current PDMP
legislation have primarily focused on the impact concerning opioid analgesic prescribing and
use. Emphasis on this medication class is understandable as opioid analgesics are the primary
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contributor to the increasing trend of drug overdose deaths in the US.92-94 The role of other CS
medications, specifically benzodiazepines, has also been found to contribute substantially to the
rise in unintentional poisoning deaths.92,95-97
Previous studies assessing the impact of benzodiazepine monitoring have concentrated
on the New York triplicate prescription program (TPP) from the early 1990s. In 1989, New York
became the first state the track the prescribing, dispensing, and utilization of benzodiazepines
when they were added to the list of medications to be targeted by the state’s TPP with the goal
of reducing diversion for illicit use and inappropriate prescribing.63-65 Evaluations of the
effectiveness of the New York TPP policy change suggested that immediately following
implementation there was a significant and sustained reduction in overall benzodiazepine
use.65,73,74 There were also concerns that this policy change may have induced a ‘chilling effect’
by restricting access to benzodiazepine therapy among patients with chronic psychiatric
disorders, and/or a legitimate need for the medication were also highlighted. A 2003 evaluation
by Wagner and colleagues72 examined new benzodiazepine use among patients recently
discharged from the hospital for either an acute cardiac event or cancer. Benzodiazepines are
often prescribed to relieve anxiety associated with acute myocardial infarction and in cancer
patients to reduce anticipatory anxiety and anxiety related effects associated with the
administration of chemotherapy.2 The study found new benzodiazepine use among New York
Medicaid beneficiaries recently discharged from the hospital for acute cardiac events and cancer
declined 72.5% and 69.4%, respectively during the two-year observation period after the
benzodiazepine triplicate regulation was implemented. Additionally, Simoni-Wastila et al.73
studied patients who had a diagnosis of schizophrenia, epilepsy, or bipolar disorder, where
benzodiazepines represent an effective first-line or adjunct treatment option, and demonstrated
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a nearly 50% decline in benzodiazepine use six months after the policy change. Patients with a
seizure disorder experienced a 60% decline, the largest among the conditions assessed.
Despite the prominent role of benzodiazepines in the US prescription drug epidemic,
there is a notable absence of the studies evaluating how current PDMP legislation impacts
benzodiazepine behaviors. Of the 49 operational PDMPs as of December 2014, 48 have the
authority to monitor Schedule IV CS which includes benzodiazepines.80,83 The aim of this study is
to understand the impact of PDMPs on the dispensing of benzodiazepines by quantifying the
impact of having a PDMP become operational on the percentage of beneficiaries who fill a
benzodiazepine prescription, estimating the relationship between the presence of a PDMP
monitoring Schedule IV CS an the likelihood of filling a benzodiazepine prescription, testing for
evidence of a chilling effect in the presence of a PDMP, and identifying the association between
the presence of a PDMP monitoring Schedule IV CS and potentially inappropriate
benzodiazepine dispensing.
METHODS
Data were extracted from a large private insurance claims database for the time period
between January 2007 and December 2009 for continuously eligible beneficiaries (≥1090 days)
from all 50 states and the District of Columbia who were between 19 and 64 years of age
throughout the duration of the study period. The claims database includes patient sociodemographic information and codes related to interactions with the healthcare system.
Benzodiazepine dispensing during the study period was represented by a claim for any
benzodiazepine during a given month of the study period and identified using national drug
codes. Psychiatric disorders for which benzodiazepines are indicated or commonly prescribed
including anxiety103 (ICD-9 codes: 300.xx, excluding 300.4), insomnia103 (307.41, 307.42, and
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780.52), and depression174 (296.2x, 296.3x, 300.4, and 311) were also identified in the database.
These conditions were used as a proxy for legitimate benzodiazepine use to test of the presence
of a chilling effect. Beneficiaries were considered to have a specific psychiatric disorder if they
had a claim in any position at any time during the study period with a diagnosis including one of
the ICD-9 diagnostic codes listed above.
The operational status of PDMPs was considered monthly. The monthly time period was
chosen because PDMP implementations take immediate effect (i.e., beginning on a specified
date all dispensing of monitored CS must be reported to the system). The use of monthly time
periods also allowed for the observation of short-term (<12 months) and long-term (≥12
months) trends related to the dispensing of benzodiazepines associated with the
implementation of a PDMP. To be considered operational PDMPs had to be actively collecting
CS dispensing data and authorized users able to generate CS dispensing reports. For the purpose
of this study, states were divided into categories based on their PDMP status during the study
period. States that had an operational PDMP and also monitored Schedule IV CS the entire
duration of the study were grouped together as were states that did not have an operational
PDMP or did not monitor Schedule IV CS throughout the study period. States that had a PDMP
become operational or started monitoring Schedule IV CS during the study period were
considered individually as the dates the PDMPs became operational varied. The month each
state’s PDMP became operational was excluded from all analyses as some benzodiazepine
prescriptions written prior to the PDMP becoming operational may not have been filled
immediately. The exclusion of this time period is consistent with the methods applied by RossDegnan et al.65 to evaluate the impact of the New York TPP on benzodiazepine use.
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To evaluate if having a PDMP monitoring Schedule IV CS become operational impacted
the proportion of beneficiaries who filled a benzodiazepine prescription, interrupted time series
methods were employed. States were considered for individual analysis if they had a PDMP
become operational during the study period, had a minimum observation period of 12 months
before and after PDMP implementation to allow for adequate trend analysis and, on average,
had more than 30 beneficiaries fill a benzodiazepine prescription each month. Time series
analyses using autoregressive integrated moving average (ARIMA) models estimated changes in
the level and trend, in addition to 95% confidence intervals (CI), of the percent of beneficiaries
in each state who filled a benzodiazepine prescription during each of the months prior to and
after the PDMP became operational. A change in level is described by Ramsay et al.230 as the
difference between the observed level at the first intervention time point and that predicted by
the pre-intervention time trend, and a change in trend as the difference between post- and preintervention slopes. States that did not have the operational status of their PDMP change
throughout the study period were used as controls to account for any underlying secular trends
that may have concurrently affected the dispensing of benzodiazepines. States that did not have
a PDMP monitoring Schedule IV CS in place throughout the study and those states that did were
evaluated separately to determine if other underlying and unobserved factors related to either
having or not having an operational PDMP monitoring Schedule IV CS may have partially
accounted for the results observed in the state implementing the PDMP.
Panel data methods using random effects were employed to examine the effect PDMPs
monitoring Schedule IV CS had on the likelihood of beneficiaries filling a benzodiazepine
prescription during the study period. Random effects models were used to control for factors
unobserved in the data that may have impacted the dispensing of benzodiazepines (i.e.,
alternate prescription drug abuse policies, changes in news coverage surrounding prescription
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drug abuse, changing attitudes towards treatments for anxiety, depression, and insomnia).
Multivariate logistic regression models adjusted for presence of a PDMP, sex, age, race,
presence of psychiatric disorders, state and month specific unemployment rates, and time in
months were used to estimate the adjusted odds ratio (AOR) and associated 95% CI of filling a
benzodiazepine prescription. The covariates, with the exception of the monthly unemployment
rates and the time trend variable, were operationalized as indicator variables. Age was
segregated into two categories based on the study population’s median age, 19 to 44 and 45 to
64, and was calculated based on the beneficiary’s year of birth. Race was divided into four
categories: white, black, Hispanic, and other race. State and month specific unemployment rates
acquired from the US Bureau of Labor Statistics227 were used to adjust for the economic climate
that was especially volatile during the study period and included in the model because
unemployment has previously been shown to be associated with benzodiazepine use.164 The
unemployment variable was operationalized as a continuous variable representing the
percentage of the states’ workforce who were without a job, actively seeking employment, and
available for work during a given month. The monthly time trend variable was operationalized
as an ordinal variable taking the values 1 through 36, with 1 representing January 2007 and 36
representing December 2009, and included to capture the effects that trend in one direction
over time.
The first multivariate logistic regression model used a linear form to determine factors
that influence the likelihood of filling a benzodiazepine prescription among beneficiaries in the
study population. This model took the form of
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Where
state

is the odds of filling a benzodiazepine prescription for beneficiary residing in
in month . The variable

in month . The matrix

indicates the presence of an operational PDMP in state

identifies demographic characteristics for beneficiary including sex,

race, and age, and the matrix

represents the presence of a psychiatric disorder diagnosis

including anxiety, depression, and insomnia for beneficiary and the occurrence of a
combination of these psychiatric disorders. The variable
for state

in month and

is the unemployment rate

is the monthly time trend variable. Finally, is a normal

independent identically distributed (i.i.d.) error term.
To better understand the effect of PDMPs on the likelihood of filling a benzodiazepine
prescription an interaction model was estimated. This model estimated the effect of PDMPs in
conjunction with the beneficiary specific predictor variables to understand how subgroups
within the population are potentially differentially impacted by the presence of a PDMP. The
interaction model utilized took the form of

Linear combinations of coefficients estimated the likelihood of filling a benzodiazepine
prescription among subgroups within the population in the presence of an operational PDMP
monitoring Schedule IV CS. The odds of filling a benzodiazepine prescription in the presence of a
PDMP monitoring Schedule IV CS was compared to the likelihood of doing so in the absence of
such a program.
A third multivariate regression model was estimated to determine if the presence of a
PDMP alone, or if instead, individual program characteristics has the greatest impact on
benzodiazepine dispensing. This model analyzing PDMP characteristics took the form of

106

In this model
CS in state

represents the presence of an operational PDMP monitoring Schedule IV

in month . The matrix

denotes the housing agency of the PDMP in state

in

month . Housing agencies were grouped together based on the primary focus of the agency in
which the PDMP was housed. For the purpose of this analysis housing agencies were
categorized as “health focused” (e.g., departments of public health), “safety focused” (e.g., law
enforcement agencies or agencies with a safety focused mission), and “licensing boards” (e.g.,
Boards of Pharmacy). Health focused agencies were identified by observing if the work ‘health’
was in the name of the housing agency. Likewise, safety focused agencies were identified if the
word ‘safety’ or ‘protection’ was present in the housing agency’s name. Law enforcement
housing agencies were initially considered separately from safety focused agencies. Due to lack
of variation between states housed in law enforcement agencies the variable was dropped from
the model. The decision was made to combine safety focused agencies and law enforcement
agencies as their primary mission is to protect and serve the public. Licensing boards were
evaluated separately because even though they may be health centric their primary purpose is
to serve the profession they represent. Controlled substance Schedules monitored by the PDMP
are represented by the matrix . The authority to monitor non-controlled substances are
denoted in matrix . Groups authorized to access the PDMP and obtain information from the
system are represented by the matrix . Groups of authorized users included in this analysis are
pharmacists and law enforcement agents who were able to access the system without requiring
a warrant. Physicians were not included to avoid the issue of collinearity as all states with a
PDMP monitoring Schedule IV CS also allowed physician access to the system. Finally, the
matrix characterizes the frequency with which CS dispensing was required to be reported to the
PDMP and includes monthly, bi-monthly, weekly, and daily reporting frequencies.
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Statistical significance was considered using the Wald χ2 p-value associated with the
interaction term. The a priori level of significance for all analyses was set at 0.05. Data use was
approved by the University of Kentucky Institutional Review Board. Statistical analyses was
conducted using Stata 13.0 (StataCorp., College Station, TX).
RESULTS
A total of 2,827,874 beneficiaries met the inclusion criteria of this study. Baseline
characteristics and benzodiazepine utilization are described in Table 6.1. The population was
divided evenly between males and females (48% vs. 52%) and the median age assessed in 2007
was 44 years (interquartile range (IQR) 35-52). Nearly two-thirds (63%) of the population had
received at least some college education or had earned a college degree. The study population
was also predominately white (74%) with blacks (5%) Hispanics (8%) and beneficiaries of other
races (12%) comprising only one-quarter of the sample. Anxiety and depression diagnoses were
each found in 12% of the study population with 6% of beneficiaries having had received an
insomnia diagnosis during this timeframe. Throughout the study period the proportion of
beneficiaries who filled a benzodiazepine prescription in each month increased steadily (Figure
6.1) with a total of 443,380 (16%) unique beneficiaries having filled at least one prescription for
a benzodiazepine.
Overall, 19 states had an operational PDMP monitoring Schedule IV CS during the entire
study period. Eighteen states did not have an operational PDMP throughout the study duration.
Four states had an operational PDMP in place during the study period but did not monitor
Schedule IV CS. An additional nine states had a PDMP become operational during the study, and
one state had a PDMP in place during the entire study period but began monitoring Schedule IV
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CS during the study period. A description of the states and their PDMP status from January 2007
through December 2009 are presented in Table 6.2.
Interrupted Time Series Analysis
Tables 6.3a-6.3f present results from the interrupted time series analyses. All values in
the tables are interpreted as percentages. The first column of results in each of the tables shows
the rate of increase in the trend of benzodiazepine dispensing before and after the PDMP was
implemented in the state of interest, the change in the rate of benzodiazepine dispensing after
the PDMP was implemented compared to before, and the change in the level of benzodiazepine
dispensing in the month immediately following the implementation of the PDMP compared to
the month immediately preceding the PDMP implementation. The second column of the results
shows the results of the interrupted time series analysis for states without an operational PDMP
monitoring Schedule IV CS throughout the duration of the study period. The last column shows
the results for states that did have a PDMP in place monitoring Schedule IV CS during the entire
study period. These last two columns were analyzed and included to determine if other
underlying and unobserved factors related to either having or not having an operational PDMP
monitoring Schedule IV CS may have partially accounted for the results observed in the state of
interest.
Among the states that had a PDMP become operational during the study period, six
(Arizona, Connecticut, Illinois, Iowa, Louisiana, and South Carolina) met the requirements for
individual trend analysis. Of these states only Iowa experienced a changed in the trend of
beneficiaries who filled a benzodiazepine prescription after their PDMP became operational.
Prior to January 2009 when the PDMP was implemented in Iowa, the percentage of beneficiaries
in that state who filled a benzodiazepine prescription was increasing by a rate of 3% (0.03; 95%
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CI: 0.02, 0.04; p<0.01; Table 6.3d) each month. After the PDMP was implemented the
percentage of beneficiaries who filled a benzodiazepine prescription increased at a rate of 6%
each month (0.06; 95% CI: 0.04, 0.08; p<0.01). The observed increase in the slope of the trend
line of Iowa beneficiaries filling a benzodiazepine prescription after the PDMP became
operational was determined to be statistically significant (0.03, 95% CI: 0.01, 0.05; p<0.01). At
the same time there was no change observed in the percent of beneficiaries who filled a
benzodiazepine prescription in states with an operational PDMP monitoring Schedule IV CS
throughout the study period (0.00; 95% CI: 0.00, 0.01; p=0.31) or without an operational PDMP
monitoring Schedule IV CS throughout the study period (-0.01; 95% CI: -0.03, 0.00; p=0.12).
A change in the level of beneficiaries who filled a benzodiazepine prescription was
observed in Connecticut and Iowa. In the August 2008, the first month after the Connecticut
PDMP became operational, there was a statistically significant decrease the proportion of
beneficiaries who filled a benzodiazepine prescription (-0.15; 95% CI: -0.30, -0.01; p=0.04). At
the same time, no change in the level was observed in states that throughout the study period
monitored Schedule IV CS (-0.01; 95% CI: -0.13, 0.11; p=0.89) or did not monitor Schedule IV CS
(-0.02; 95% CI: -0.18, 0.15; p=0.84). A similar finding was observed in Iowa where in February
2009, the first month after the PDMP became operational, there was a statistically significant
decrease in the proportion of beneficiaries who filled a benzodiazepine prescription (-0.28; 95%
CI: -0.48, -0.08; p=0.01). Additionally, there was no observed change in the level of beneficiaries
who filled a benzodiazepine prescription among states that throughout the duration of the
study period monitored Schedule IV CS (-0.04, 95% CI: -0.12, 0.05; p=0.39) or did not monitor
Schedule IV CS (-0.12; 95% CI: -0.25, 0.01; p=0.08).
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Results from the interrupted time series analyses also suggest that while the beginning
of Schedule IV monitoring in Illinois and PDMP implementation in South Carolina occurring in
January 2008 did not have a direct effect on the trend or level of the proportion of beneficiaries
who filled a benzodiazepine prescription (Tables 6.3c and 6.3f), states that did not have a PDMP
monitoring Schedule IV CS throughout the study period had a statistically significant increase in
the level of the proportion of beneficiaries who filled a benzodiazepine prescription during this
timeframe (0.26; 95% CI: 0.16, 0.37; p<0.01). Also of note was that states that did not monitor
Schedule IV CS throughout the study period experienced a decline in the rate of increase of the
proportion of beneficiaries who filled a benzodiazepine prescription during the same timeframe
when the PDMPs in Arizona, Connecticut, and Louisiana became operational, however, a similar
change in these states was not observed (Tables 6.3a, 6.3b, and 6.3e).
In most states that implemented a PDMP monitoring Schedule IV CS during the study
period the relative effect of the program, based on pre-PDMP predicted values, was not
statistically significant (Figures 6.3a-6.3f). Two states, Connecticut (Figure 6.2b) and Iowa (Figure
6.2d), had significant reductions in the proportion of beneficiaries who filled a benzodiazepine
prescription. In each instance the significance of this effect was negated after only three
months. In Connecticut the PDMP resulted in a 5.26% (95% CI: -9.71%, -0.35%; p=0.04)
reduction in the proportion of beneficiaries who filled a benzodiazepine prescription in the first
month after implementation based on pre-PDMP predicted values. This was followed by a 5.22%
(95% CI: -9.93%, 0.00%; p=0.04) and 5.17% (95% CI: 10.11%, 0.00%; p=0.05) reduction in the
second and third months before becoming insignificantly different from pre-PDMP predicted
values. In Iowa the relative effect of the PDMP in the first month based on pre-PDMP predicted
values was a 9.74% (95% CI: -15.96%, -2.11%; p=0.01) reduction in the proportion of
beneficiaries who filled a benzodiazepine prescription. This was followed by a 7.96% (95% CI: -
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14.14%, -1.22%; p=0.02) and 6.74% (95% CI: 12.63%, 0.00%; p=0.05) reduction in the
subsequent months before the relative effect of the PDMP was no longer significant.
Multivariate Logistic Regression Analysis
In the overall study population, the odds of filling a benzodiazepine prescription were
influenced by the presence of an operational PDMP monitoring Schedule IV CS, sex, race, age,
presence of a psychiatric disorder, the unemployment rate, and time (Table 6.4). The odds of
filling a benzodiazepine prescription were two times greater for females compared to males
(AOR: 2.07; 95% CI: 2.04-2.10) and 2.5 times higher for beneficiaries 45-64 years of age than
beneficiaries 19-44 (AOR 2.52; 95% CI: 2.49-2.55). Having received a diagnosis for a psychiatric
disorder during the study period also significantly increased the likelihood of filling a
benzodiazepine prescription during the study period. Among beneficiaries having received a
diagnosis of anxiety, the odds of filling a benzodiazepine prescription were 48 times greater
(AOR: 47.92; 95% CI: 46.84-49.02) compared to beneficiaries without a diagnosis. Having
received a diagnosis for insomnia increased the likelihood of filling a benzodiazepine
prescription 10 times (AOR: 10.23; 95% CI: 10.00-10.46) and among those with depression the
odds of filling a benzodiazepine prescription were nearly 10 times greater than those without a
diagnosis (AOR: 9.91; 95% CI: 9.70-10.13). Additionally, the time trend variable included in the
model suggests that as time progressed during the study period, the odds of a beneficiary filling
a benzodiazepine prescription in a given month were also increasing (AOR: 1.02; 95% CI: 1.021.02).
Conversely, beneficiaries identified and black, Hispanic, or other race were less likely
than white beneficiaries to have filled a benzodiazepine prescription during the study period.
The odds of Hispanic (AOR: 0.63; 95% CI: 0.61-0.64) and beneficiaries of other race (AOR: 0.64;
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95% CI: 0.63-0.65) filling a benzodiazepine prescription were only about 60% of that of white
beneficiaries while black beneficiaries were only half as likely to fill a benzodiazepine
prescription compared to their white counterparts (AOR: 0.49; 95% CI: 0.48-0.51). Beneficiaries
diagnosed with multiple psychiatric comorbidities were significantly less likely to fill a
benzodiazepine prescription than beneficiaries without any diagnosis of a psychiatric disorder
(AOR: 0.22; 95% CI: 0.21-0.22). Also, the presence of an operational PDMP monitoring Schedule
IV CS lowered the odds of filling a benzodiazepine prescription. When such a PDMP was present
the odds of filling a benzodiazepine prescription were only 92% (AOR: 0.92; 95% CI: 0.92-0.93) of
that compared to instances where one was not.
Results from the interaction model determining whether PDMPs have a differential
impact on specific subgroups of beneficiaries by interacting the PDMP indicator variable with
beneficiary specific predictor variables are presented in Table 6.4. Adjusted for the covariates
described previously, results from the interaction model infer that the presence of a PDMP
monitoring Schedule IV CS differentially impacts the likelihood that specific subgroups within
the population fill a prescription for a benzodiazepine. For the reference group of white males,
between the ages of 19 and 44, and absent a diagnosis of anxiety, depression or insomnia, the
presence of a PDMP monitoring schedule IV CS decreased the likelihood of filling a
benzodiazepine prescription to 97% (AOR: 0.97; 95% CI: 0.95-0.98) of what they were when one
is not present or monitoring Schedule IV CS. For females, non-white beneficiaries, and those
between 45 and 64 years of age, the odds were further decreased. When a PDMP was
operational and monitoring Schedule IV CS females were only 95% (AOR: 0.95; 0.94-0.97) as
likely to fill a benzodiazepine prescription compared to the reference group, blacks 93% (AOR:
0.93; 95% CI: 0.90-0.97), Hispanics 91% (AOR: 0.91; 95% CI: 0.88-0.94), beneficiaries of another
race 92% (AOR: 0.92; 95% CI: 0.89-0.94), and those between 45 and 64 years of age 90% (AOR:
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0.90; 95% CI: 0.88-0.91). Conversely, those beneficiaries who had received an anxiety diagnosis
were 12% more likely (AOR: 1.12; 95% CI: 1.10-1.14) to fill a benzodiazepine prescription when
there was an operational PDMP monitoring Schedule IV CS than the reference group.
Beneficiaries who had been diagnosed with insomnia had 11% (AOR: 1.11; 95% CI: 1.08-1.13)
greater odds of filling a benzodiazepine prescription in the presence of a PDMP monitoring
Schedule IV CD than the reference group, and beneficiaries diagnosed with depression were 2%
more likely (AOR: 1.02; 95% CI: 1.00-1.05) to fill a benzodiazepine prescription.
Linear combinations of effect estimates (Table 6.5) demonstrate that in the presence of
a PDMP monitoring Schedule IV CS, females, beneficiaries identified as black, Hispanic, or other
race, those 45 and older, and who had multiple psychiatric disorder diagnoses experienced
reduced odds of filling a benzodiazepine prescription. In the presence of a PDMP monitoring
Schedule IV CS the odds of filling a benzodiazepine prescription for females was 92% (AOR: 0.92;
95% CI: 0.90-0.94) what they were when no program was operational. For blacks the odds were
reduced to 90% (AOR: 0.90; 95% CI: 0.86-0.94), Hispanics 88% (AOR: 0.88; 95% CI: 0.85-0.91),
beneficiaries of other races 89% (AOR: 0.89; 95% CI: 0.86-0.91), and those 45 and older only had
87% (AOR: 0.87; 95% CI: 0.85, 0.88) of the odds of filling a benzodiazepine prescription in the
presence of PDMP monitoring Schedule IV CS compared to when no program was operational.
Of note, females (AOR: 1.94; 95% CI: 1.90-1.98) and those 45 and older (AOR: 2.27; 95% CI: 2.222.31) were still approximately two times more likely to fill a benzodiazepine prescription in the
presence of a PDMP monitoring Schedule IV CS than their male and younger counterparts.
However, the presence of a PDMP monitoring Schedule IV CS further reduced the odds of black
(AOR: 0.45; 95% CI: 0.43-0.47), Hispanic (AOR: 0.57; 95% CI: 0.55-0.59), and beneficiaries of
other race (AOR: 0.59; 95% CI: 0.57-0.60) filling a benzodiazepine prescription to nearly half that
of white beneficiaries. Likewise, those with multiple psychiatric disorder diagnoses were only
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94% (AOR: 0.94; 95% CI: 0.91-0.98) as likely to fill a benzodiazepine prescription when there was
a PDMP monitoring Schedule IV CS further reducing the odds of filling a benzodiazepine
prescription to only 20% (AOR: 0.21; 95% CI: 0.20-0.22) of those absent any psychiatric disorder
diagnosis.
In the presence of a PDMP monitoring Schedule IV CS, beneficiaries who had received
an anxiety or insomnia diagnosis during the study period experienced greater odds of filling a
benzodiazepine prescription compared to when no program was operational. Beneficiaries who
had received an anxiety diagnosis were 8% (AOR: 1.08; 95% CI; 1.06–1.11) more likely to fill a
benzodiazepine prescription. Likewise, those who had been diagnosed with insomnia
experienced a 7% increase (AOR: 1.07; 95% CI: 1.04–1.10) increase in their odds of filling a
benzodiazepine prescription.
Characteristics of PDMPs during the study period between January 2007 and December
2009 are presented in Table 6.7. Results from the model testing whether the presence of a
PDMP alone or instead individual characteristics of the program affect benzodiazepine
dispensing are reported in Table 6.8. The findings indicate that it is individual characteristics of
the PDMP, and not the presence of the PDMP alone, that have an effect on the likelihood of
filling a benzodiazepine prescription. The model found that beneficiaries residing in a state
where the PDMP was housed in a safety focused agency were less likely (AOR: 0.70; 95% CI:
0.68, 0.73) to fill a benzodiazepine prescription. There was no observed effect on the likelihood
of filling a benzodiazepine prescription in states were the PDMP was housed in a health focused
agency (AOR: 0.97; 95% CI: 0.93, 1.01) or a licensing board (AOR: 1.00; 95% CI: 0.97, 1.04).
Authorized access to a beneficiary’s CS history report by pharmacists and law enforcement
officials resulted in an increase in the odds of filling a benzodiazepine prescription. When
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pharmacists were allowed to access CS history reports, in addition to submitting CS dispensing
records, there was a 24% increase (AOR: 1.24; 95% CI: 1.21, 1.27) in the odds of filling a
benzodiazepine prescription. When law enforcement officials hand the ability to access a
beneficiary’s CS history report there was a 3% increase (AOR: 1.03; 95% CI: 1.01, 1.05) in the
odds of filling a benzodiazepine prescription. Regarding the CS Schedules monitored by the
PDMP, there was no effect observed on the odds of filling a benzodiazepine prescription when
the program only monitored Schedule II & III CS (AOR: 1.03; 95% CI: 0.99, 1.06) or Schedule II-IV
CS (AOR: 1.01; 95% CI: 0.95, 1.07) compared to Schedule II CS monitoring only. When the CS
Schedules monitored included Schedule II-V there was a 17% increase (AOR: 1.17; 95% CI: 1.12,
1.24) in the likelihood of filling a benzodiazepine prescription. The addition of the authority to
monitor non-controlled substances, however, resulted in a decrease in the odds of filling a
benzodiazepine prescription (AOR: 0.91; 95% CI: 0.89, 0.93). When compared beneficiaries in
states with PDMPs that only required CS dispensing to be reported monthly, those residing in
states that mandated bi-monthly (AOR: 0.87; 95% CI: 0.85, 0.88) or daily (AOR: 0.74; 95% CI:
0.66, 0.83) experienced decreased odds of filling a benzodiazepine prescription. However, a 10%
increase in the odds (AOR: 1.10; 95% CI: 1.07, 1.13) of filling a benzodiazepine prescription was
found among those residing in states where weekly reporting of CS dispensing to the PDMP was
required.
DISCUSSIONS
In this sample of continuously eligible adult beneficiaries in the United States, PDMPs
monitoring Schedule IV CS impacted benzodiazepine dispensing. The findings of the interrupted
time series analyses suggested that in the month following the PDMP implementations in
Connecticut and Iowa there was a significant decrease in the level of the percentage of each
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states’ beneficiaries who filled a benzodiazepine prescription. Results also indicated that in the
year after the PDMP in Iowa became operational the proportion of beneficiaries who filled a
benzodiazepine prescription each month was increasing at a faster rate than it was prior to the
PDMP going into effect. This finding was at least partially negated by the decrease in the level of
the proportion of beneficiaries who filled a benzodiazepine prescription which resulted in the
relative effect of the PDMP being a significant reduction in the proportion of beneficiaries who
filled a benzodiazepine prescription in the first three months following implementation with no
significant difference detected thereafter.
The PDMP implementation in Connecticut and Iowa created a shock to the system and
the trend of benzodiazepine dispensing to beneficiaries as the percentage of the population
who filled a benzodiazepine prescription was significantly lower in the month following the
PDMP implementation compare to the month prior to the program. The relative effect of these
shocks in each of these two states were only observed for three months before the observed
percentage of the population who filled a benzodiazepine prescription approached their
predicted values as no PDMP been implemented. These results from Connecticut and Iowa in
conjunction with the other states that had a PDMP implemented during the study period
suggest that with regards to benzodiazepine dispensing PDMP implementation may have a
modest short-term effect on the percentage of the beneficiaries who fill a prescription, however
there is not significant long-term impact as healthcare providers and patients will adjust to the
new policy and the proportion of beneficiaries who fill a benzodiazepine prescription will
approach their pre-PDMP predicted values.
Furthermore, benzodiazepine dispensing was indirectly impacted in some states by the
implementation of a PDMP monitoring Schedule IV CS. In Illinois and South Carolina, two states
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that began monitoring Schedule IV CS in January 2008, having the PDMP become operational
may have prevented the rate of benzodiazepine dispensing from increasing at a faster rate.
States that did not monitor Schedule IV CS during 2008 and 2009 experienced an increase in the
trend of the proportion of beneficiaries who filled a benzodiazepine prescription in each month
whereas there was no evidence of a change in the trends observed in Illinois and South Carolina.
This result suggests that there may have been an unobserved factor occurring at this time that
was associated with an increasing proportion of beneficiaries who filled a benzodiazepine
prescription but the effect of this factor was mitigated by the presence of a PDMP as states that
had a PDMP throughout the study period, in addition to Illinois and South Carolina, did not have
a significant change in the trend of the proportion of beneficiaries who filled a benzodiazepine
prescription between January 2008 and December 2009 compared to January through
December of 2007.
Of interest is the finding after PDMPs were implemented in Arizona, Connecticut, and
Louisiana there was no evidence of a change in the trend regarding the proportion of
beneficiaries who filled a benzodiazepine prescription each month, however, in states that did
not have a PDMP monitoring Schedule IV CS during this time experienced a decline in the trend.
One explanation is that there was an alternative intervention occurring concurrently that
targeted states without Schedule IV CS monitoring, as states that had a PDMP in place
throughout also did not experience a decline in the trend of benzodiazepine dispensing.
Results from the linear logistic regression model found an association between an
operational PDMP monitoring Schedule IV CS and a reduction in the odds of filling a
benzodiazepine prescription. Furthermore, the interaction model provided evidence that PDMPs
may differentially influence the likelihood of filling a benzodiazepine prescription among certain
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subgroups within the population. Females, blacks, Hispanics, beneficiaries of other races, those
between the ages of 45 and 64, and those with more than one psychiatric condition were
significantly less likely to fill a benzodiazepine prescription during the study period when
Schedule IV CS were being monitored by a PDMP. Even with having an operational PDMP,
females and beneficiaries between 45 and 64 remained more likely to fill a benzodiazepine
prescription than their male and younger counterparts, a finding that is in line with existing
evidence demonstrating that in the general US population, benzodiazepines are more likely to
be prescribed to females and older individuals.166 The finding that having an operational PDMP
was associated with black, Hispanic, and beneficiaries of other races being even less like to fill a
benzodiazepine prescription is consistent with findings reported by Pearson et al.74 who found
Medicaid beneficiaries residing in predominately black, Hispanic, or mixed race neighborhoods
were consistently more likely to have their benzodiazepine therapy discontinued after they
were added to the list of medications monitored by the New York TPP.
No evidence of a chilling effect was detected among beneficiaries who received a
diagnosis of anxiety or insomnia during the study period. Moreover, the odds of beneficiaries
with these diagnoses filling a benzodiazepine prescription were greater when a PDMP
monitoring Schedule IV CS was operational. As benzodiazepines are indicated to manage
symptoms associated with these conditions, this suggests that PDMPs, as they pertain to
benzodiazepines, do not induce a chilling effect by restricting access to pharmacotherapy
options among those with a diagnosis of anxiety or insomnia, two conditions where
benzodiazepine therapy is appropriate. An explanation for this finding is that prescribers and
dispensers may have felt more confident in their decisions surrounding benzodiazepine use in a
patient with these conditions in the presence of a PDMP. This potential increase in confidence
may be because the information contained within a patient’s CS history report could give a more
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comprehensive depiction of the patient’s CS use history and allow for a quick determination of
the appropriateness of benzodiazepine in the patient ad their propensity to abuse or divert the
medication.
Of interest was the result that patients with multiple psychiatric diagnoses were
significantly less likely to fill a benzodiazepine prescription than those without any psychiatric
diagnoses, and furthermore, the presences of a PDMP monitoring Schedule IV CS further
depressed these odds. This finding indicates that benzodiazepines are not prescribed and
dispensed to patients with more severe and complex psychiatric illness. This could be because
alternate therapeutic options are being utilized in these patients as severe psychiatric disorders
have been acknowledged as a risk factor for substance use disorders.231 The finding that PDMPs
monitoring Schedule IV CS further reduces the likelihood of filling a benzodiazepine prescription
indicates that prescribers and dispensers may be using a patient’s CS history report to identify
those most at risk of inappropriate benzodiazepine use.
After adjusting for individual characteristics of PDMPs, it was determined that it is
individual characteristics of these programs, and not the presence of the program itself, that
impact the likelihood of filling a benzodiazepine prescription. An interesting finding was that
safety focused housing agencies of PDMPs were associated with a significant decrease in the
likelihood of filling a benzodiazepine prescription. This finding may be due to increased
reluctances of prescribing and dispensing benzodiazepines, and other CS, by healthcare
providers due to fears of investigations and prosecutions related to CS prescribing and
dispensing behaviors. Also of interest was that more frequent reporting requirements, with the
exception of weekly reporting, was associated with lower odds of filling a benzodiazepine
prescription. During the timeframe of this study only North Dakota had a mandate requiring
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dispensers to report daily their CS dispensing records. Therefore, the finding of weekly reporting
of CS dispensing requirements being associated with an increase in the odds of filling a
benzodiazepine prescription may be related to healthcare providers feeling they had a
comprehensive insight into the patient’s history of CS behaviors and thus an increase confidence
in the prescribing and dispensing of benzodiazepines to their patients.
Of note is the result that law enforcement access to PDMPs was associated with a slight
increase in the odds of filling a benzodiazepine prescription. This categorization does not take
into account the types of law enforcement officials who have access to information from the
PDMP or the process necessary for them to acquire that information. For example, in some
states law enforcement officials may be required to be pursuing an active investigation in order
to obtain a CS history report while in other states only a select few law enforcement officials are
allowed to directly access and obtain CS history reports from the PDMP. These officials are then
responsible for disseminating that report or the information contained within to other law
enforcement officials as needed. These variations in laws pertaining to law enforcement access
should be considered when evaluating the meaningfulness of this particular finding.
Limitations to this study exist. First, this study employs data for a nationally
representative sample extracted from private insurance claims database and may not accurately
represent the overall US population. Due to the utilization of a claims database this study could
not account for prescription medications acquired from sources outside the healthcare system
or paid for using cash. Additionally, this study utilized diagnostic codes for psychiatric
comorbidities for which benzodiazepines are indicated and/or commonly prescribed as proxies
for appropriate benzodiazepines use. While these proxies may not encompass all facets of
appropriate benzodiazepine use they are consistent with the goals of PDMPs in mitigating
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prescription drug abuse and its consequences while maintaining access to those with a
legitimate need for CS medications. Also, this study did not account for the number of
benzodiazepine prescriptions filled or the quantity and dosage of these prescriptions. However,
as the aim of this study was to understand the impact of PDMPs on the likelihood of filling a
benzodiazepine prescription among privately insured beneficiaries this information was not
required. Differences may exist between what was written in PDMP legislation and what was
practiced. For example, even though some states had the authority to monitor non-controlled
substances they may not have been actively doing so. Additionally, variability in the
operationalization of PDMPs housed within the same type of housing agency is possible, (e.g.,
types of PDMP requestor accounts, requirements for determining the necessity of requesting a
report) and may impact the observed findings, however, decisions on how individual PDMPs are
operationalized are made in order to achieve the overall goals and mission of the program,
which are likely similar among programs housed within the same type of agency.
The findings presented in this study indicated that PDMPs monitoring Schedule IV CS
have an impact on the dispensing of benzodiazepines. Using an interrupted time series model
evidence was provided that indicated having a PDMP monitoring Schedule IV CS become
operational directly and indirectly impacted benzodiazepine dispensing trends. The presence of
a PDMP monitoring Schedule IV CS was found to decrease the likelihood of filling a
benzodiazepine prescription, especially for those beneficiaries who were female, black,
Hispanic, of another race, between 45 and 64 years of age, or who had multiple psychiatric
disorders. On the other hand, beneficiaries diagnosed with only anxiety or insomnia during the
study period experienced an increase in their odds of filling a benzodiazepine prescription
suggesting that for beneficiaries diagnosed with these conditions there was no “chilling effect”
induced by a PDMP. Furthermore, specific characteristics of PDMPs were found to have a
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significant effect on the odds of filling a benzodiazepine prescription, and should be considered
when amending current PDMPs laws in order to assist effort of mitigating the prescription drug
abuse crisis.
The findings in this study provide support for PDMPs as an effective tool to address the
prescription drug abuse epidemic in the US as it pertains to benzodiazepines. Future studies
regarding the relationship between PDMPs and benzodiazepines should explore clinical
outcomes experienced by those who have their benzodiazepine therapy discontinued to better
understand the economic and societal costs associated with PDMPs. Future policy amendments
should focus on reducing the potential for disparities in benzodiazepine access among
vulnerable groups within the population. As PDMPs become a more widely utilized tool to
combat prescription drug abuse and diversion more research is needed to understand their
clinical utility and ensure they do no obstruct access to legitimate pharmacotherapies.
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Table 6.1. Demographic characteristics of continuously enrolled, commercially insured adults
in the United States.
Number of beneficiaries (%)
Sample size
2,827,874
Benzodiazepine utilization
Filled benzodiazepine prescription
443,380 (16%)
Gender
Male
1,354,884 (48%)
Female
1,472,990 (52%)
Age
Mediana (IQR)
44 (35-52)
Education
High school diploma or less
955,281 (34%)
Some college or college degree
1,787,429 (63%)
Race
White
2,085,190 (74%)
Black
146,165 (5%)
Hispanic
240,090 (8%)
Other
331,325 (12%)
Psychiatric disorder diagnosis
Anxiety
325,107 (12%)
Depression
352,750 (12%)
Insomnia
175,090 (6%)
Multiple psychiatric disorder diagnoses
206,112 (7%)
a
Median age was evaluated for the year 2007

124

Table 6.2. Prescription drug monitoring programs tracking the dispensing of Schedule IV
controlled substances for the period January 2007 – December 2009.31
PDMP became
No PDMP operational PDMP operational but
operational during
PDMP operational
throughout study
Schedule IV CS not
study period (date of
throughout study period
period
monitored
PDMP implementation)
Alabama
Alaska
Massachusetts
Arizona
California
Arkansas
Pennsylvania
(October 2008)
Hawaii
Delaware
Rhode Island
Colorado
Idaho
District of Columbia
Texas
(July 2007)
Indiana
Florida
Connecticut
Kentucky
Georgia
(July 2008)
Maine
Kansas
Illinoisa
Michigan
Maryland
(January 2008)
Mississippi
Minnesota
Iowa
Nevada
Missouri
(January 2009)
New Mexico
Montana
Louisiana
New York
Nebraska
(November 2008)
Ohio
New Hampshire
North Carolina
Oklahoma
New Jersey
(July 2007)
Tennessee
Oregon
North Dakota
Utah
South Dakota
(September 2007)
Virginia
Washington
South Carolina
West Virginia
Wisconsin
(January 2008)
Wyoming
Vermont
(January 2009)
a
Prior to Jan. 2008 Illinois had a PDMP in place but only electronically monitored Schedule II CS
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Table 6.3a. Interrupted time series analysis examining the percentage of beneficiaries filling a
benzodiazepine prescription by month (Arizona).
States with no PDMP States with a PDMP
throughout the study throughout the study
Arizona
period
period
Coefficient
Coefficient
Coefficient
p-value
p-value
p-value
95% Confidence
95% Confidence
95% Confidence
Interval
Interval
Interval
Monthly rate of increase in
beneficiaries filling a
0.02
0.04
0.02
benzodiazepine
<0.01
<0.01
<0.01
prescription prior to PDMP
0.02, 0.03
0.04, 0.05
0.01, 0.03
Monthly rate of increase in
beneficiaries filling a
benzodiazepine
0.03
0.03
0.02
prescription after PDMP
<0.01
<0.01
<0.01
implementation
0.02, 0.03
0.03, 0.05
0.02, 0.03
Change in the rate of
increase of beneficiaries
filling a benzodiazepine
0.00
-0.01
0.00
prescription pre/post
0.29
0.04
0.51
PDMP
0.00a, 0.01
-0.03, 0.00a
-0.01, 0.01
Change in the level one
-0.06
-0.08
-0.01
month after PDMP
0.17
0.11
0.43
implementation
-0.14, 0.03
-0.17, 0.02
-0.30, 0.13
a
Confidence interval contains 0.00 due to rounding
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Table 6.3b. Interrupted time series analysis examining the percentage of beneficiaries filling a
benzodiazepine prescription by month (Connecticut).
States with no PDMP States with a PDMP
throughout the study throughout the study
Connecticut
period
period
Coefficient
Coefficient
Coefficient
p-value
p-value
p-value
95% Confidence
95% Confidence
95% Confidence
Interval
Interval
Interval
Monthly rate of increase in
beneficiaries filling a
0.03
0.04
0.02
benzodiazepine
<0.01
<0.01
<0.01
prescription prior to PDMP
0.02, 0.04
0.03, 0.05
0.01, 0.03
Monthly rate of increase in
beneficiaries filling a
benzodiazepine
0.03
0.02
0.02
prescription after PDMP
<0.01
<0.01
<0.01
implementation
0.02, 0.04
0.01, 0.03
0.02, 0.03
Change in the rate of
increase of beneficiaries
filling a benzodiazepine
0.00
-0.02
0.00
prescription pre/post
0.65
0.01
0.70
PDMP
-0.02, 0.01
-0.03, -0.01
-0.01, 0.01
Change in the level one
-0.15
-0.03
0.01
month after PDMP
0.04
0.72
0.82
implementation
-0.30, 0.01
-0.16, 0.11
-0.11, 0.14
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Table 6.3c. Interrupted time series analysis examining the percentage of beneficiaries filling a
benzodiazepine prescription by month (Illinois).
States with no PDMP States with a PDMP
throughout the study throughout the study
Illinois
period
period
Coefficient
Coefficient
Coefficient
p-value
p-value
p-value
95% Confidence
95% Confidence
95% Confidence
Interval
Interval
Interval
Monthly rate of increase in
beneficiaries filling a
0.03
0.03
0.02
benzodiazepine
<0.01
<0.01
<0.01
prescription prior to PDMP
0.02, 0.04
0.02, 0.03
0.01, 0.04
Monthly rate of increase in
beneficiaries filling a
benzodiazepine
0.02
0.02
0.02
prescription after PDMP
<0.01
<0.01
<0.01
implementation
0.01, 0.03
0.02, 0.03
0.02, 0.03
Change in the rate of
increase of beneficiaries
filling a benzodiazepine
-0.01
0.00
0.00
prescription pre/post
0.26
0.59
0.91
PDMP
-0.02, 0.01
-0.02, 0.01
-0.01, 0.01
Change in the level one
-0.08
0.20
-0.03
month after PDMP
0.30
<0.01
0.65
implementation
-0.22, 0.07
0.09, 0.31
-0.15, 0.10
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Table 6.3d. Interrupted time series analysis examining the percentage of beneficiaries filling a
benzodiazepine prescription by month (Iowa).
States with no PDMP States with a PDMP
throughout the study throughout the study
Iowa
period
period
Coefficient
Coefficient
Coefficient
p-value
p-value
p-value
95% Confidence
95% Confidence
95% Confidence
Interval
Interval
Interval
Monthly rate of increase in
beneficiaries filling a
0.03
0.04
0.02
benzodiazepine
<0.01
<0.01
<0.01
prescription prior to PDMP
0.02, 0.04
0.03, 0.04
0.02, 0.02
Monthly rate of increase in
beneficiaries filling a
benzodiazepine
0.06
0.03
0.03
prescription after PDMP
<0.01
<0.01
<0.01
implementation
0.04, 0.08
0.02, 0.04
0.02, 0.03
Change in the rate of
increase of beneficiaries
filling a benzodiazepine
0.03
-0.01
0.00
prescription pre/post
<0.01
0.18
0.38
PDMP
0.01, 0.05
-0.02, 0.01
-0.01, 0.01
Change in the level one
-0.28
-0.11
0.00
month after PDMP
0.01
0.06
0.95
implementation
-0.48, -0.08
-0.22, 0.01
-0.08, 0.08
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Table 6.3e. Interrupted time series analysis examining the percentage of beneficiaries filling a
benzodiazepine prescription by month (Louisiana).
States with no PDMP States with a PDMP
throughout the study throughout the study
Louisiana
period
period
Coefficient
Coefficient
Coefficient
p-value
p-value
p-value
95% Confidence
95% Confidence
95% Confidence
Interval
Interval
Interval
Monthly rate of increase in
beneficiaries filling a
0.03
0.04
0.02
benzodiazepine
<0.01
<0.01
<0.01
prescription prior to PDMP
0.02, 0.04
0.03, 0.05
0.01, 0.03
Monthly rate of increase in
beneficiaries filling a
benzodiazepine
0.04
0.03
0.02
prescription after PDMP
<0.01
<0.01
<0.01
implementation
0.04, 0.05
0.02, 0.04
0.02, 0.03
Change in the rate of
increase of beneficiaries
filling a benzodiazepine
0.01
-0.01
0.00
prescription pre/post
0.45
0.04
0.51
PDMP
-0.01, 0.03
-0.03, 0.00a
-0.01, 0.01
Change in the level one
-0.13
-0.11
-0.03
month after PDMP
0.14
0.02
0.57
implementation
-0.31, 0.04
-0.22, -0.02
-0.13, 0.07
a
Confidence interval contains 0.00 due to rounding
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Table 6.3g. Interrupted time series analysis examining the percentage of beneficiaries filling a
benzodiazepine prescription by month (South Carolina).
States with no PDMP States with a PDMP
throughout the study throughout the study
South Carolina
period
period
Coefficient
Coefficient
Coefficient
p-value
p-value
p-value
95% Confidence
95% Confidence
95% Confidence
Interval
Interval
Interval
Monthly rate of increase in
beneficiaries filling a
0.05
0.03
0.02
benzodiazepine
<0.01
<0.01
<0.01
prescription prior to PDMP
0.03, 0.07
0.02, 0.03
0.01, 0.04
Monthly rate of increase in
beneficiaries filling a
benzodiazepine
0.04
0.02
0.02
prescription after PDMP
<0.01
<0.01
<0.01
implementation
0.02, 0.05
0.02, 0.03
0.02, 0.03
Change in the rate of
increase of beneficiaries
filling a benzodiazepine
-0.01
0.00
0.00
prescription pre/post
0.43
0.59
0.91
PDMP
-0.03, 0.01
-0.02, 0.01
-0.01, 0.01
Change in the level one
-0.10
0.20
-0.03
month after PDMP
0.38
<0.01
0.65
implementation
-0.33, 0.13
0.09, 0.31
-0.15, 0.10
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Table 6.4. Odds of filling a benzodiazepine prescription between January 2007 and December
2009 among continuously enrolled adult beneficiaries in the United States.
Variable
Odds Ratio
p-value
95% Confidence Interval
PDMP
No operational PDMP monitoring
Ref.
Schedule IV CS
PDMP operational and
0.92
<0.01
0.92 – 0.93
monitoring Schedule IV CS
Sex
Male
Ref.
Female
2.07
<0.01
2.04 – 2.10
Race
White
Ref.
Black
0.49
<0.01
0.48 – 0.51
Hispanic
0.63
<0.01
0.61 – 0.64
Other
0.64
<0.01
0.63 – 0.65
Age
Age 44 and under
Ref.
Age 45 and over
2.52
<0.01
2.49 – 2.55
Diagnosis of a Psychiatric Disorder
No psychiatric disorder diagnosis
Ref.
Anxiety
47.92
<0.01
46.84 – 49.02
Depression
9.91
<0.01
9.70 – 10.13
Insomnia
10.23
<0.01
10.00 – 10.46
Multiple psychiatric diagnoses
0.22
<0.01
0.21 – 0.22
Economic Climate
Unemployment ratea
1.00
0.03
1.00 – 1.00b
Time Trend
Additional monthc
1.02
<0.01
1.02 – 1.02
a
Unemployment rate interpretation is the effect of a one percentage point increase in the
unemployment rate
b
Confidence interval includes 1.00 due to rounding
c
Month interpretation is the effect of time progressing forward one additional month
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Table 6.5. Odds of filling a benzodiazepine prescription among subgroups within a population
of continuously enrolled adult beneficiaries in the United States between January 2007 and
December 2009.
Variable
Odds Ratio
p-value
95% Confidence Interval
PDMP
No operational PDMP monitoring
Ref.
Schedule IV CS
PDMP operational and
0.97
<0.01
0.95 – 0.98
monitoring Schedule IV CS
Sex
Male
Ref.
Female
2.11
<0.01
2.08 – 2.14
Race
White
Ref.
Black
0.50
<0.01
0.49 – 0.52
Hispanic
0.64
<0.01
0.63 – 0.66
Other
0.66
<0.01
0.65 – 0.68
Age
Age 44 and under
Ref.
Age 45 and over
2.62
<0.01
2.59 – 2.66
Diagnosis of a Psychiatric Disorder
No psychiatric disorder diagnosis
Ref.
Anxiety
45.99
<0.01
44.90 – 47.10
Depression
9.83
<0.01
9.60 – 10.05
Insomnia
9.85
<0.01
9.61 – 10.09
Multiple psychiatric diagnoses
0.22
<0.01
0.21 – 0.23
Economic Climate
Unemployment rate
1.00
0.05
1.00 – 1.00a
Time Trend
Additional month
1.02
<0.01
1.02 – 1.02
Interaction variables
PDMP * Female
0.96
<0.01
0.94 – 0.97
PDMP * Black
0.93
<0.01
0.90 – 0.97
PDMP * Hispanic
0.91
<0.01
0.88 – 0.94
PDMP * Other
0.92
<0.01
0.89 – 0.94
PDMP * Age over 45
0.90
<0.01
0.88 – 0.91
PDMP * Anxiety
1.12
<0.01
1.10 – 1.14
PDMP * Depression
1.02
0.03
1.00a – 1.05
PDMP * Insomnia
1.11
<0.01
1.08 – 1.13
PDMP * Multiple psychiatric
0.98
<0.01
0.94 – 1.01
diagnoses
b
Confidence interval includes 1.00 due to rounding
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Table 6.6. Linear combinations of effect estimates comparing odds of subgroups within a
population of continuously enrolled adult beneficiaries in the United States filling a
benzodiazepine prescription with and without the presence of a PDMP monitoring Schedule
IV controlled substances.
Odds of filling a
Odds of filling a
Comparison of odds of
benzodiazepine
benzodiazepine
filling a benzodiazepine
prescription when no prescription when a
prescription when a
PDMP monitoring
PDMP monitoring
PDMP monitoring
Schedule IV CS is
Schedule IV CS is
Schedule IV CS is
present
present
present to without
(p-value)
(p-value)
(p-value)
Variable
(95% CI)
(95% CI)
(95% CI)
2.11
1.94
0.92
Female
<0.01
<0.01
<0.01
(2.18 – 2.14)
(1.90 – 1.98)
(0.90 – 0.94)
0.50
0.45
0.90
Black
<0.01
<0.01
<0.01
(0.49 – 0.52)
(0.43 – 0.47)
(0.86 – 0.94)
0.64
0.57
0.88
Hispanic
<0.01
<0.01
<0.01
(0.63 – 0.66)
(0.55 – 0.59)
(0.85 – 0.91)
0.66
0.59
0.89
Other
<0.01
<0.01
<0.01
(0.65 – 0.68)
(0.57 – 0.60)
(0.86 – 0.91)
2.62
2.27
0.87
Age 45 and over
<0.01
<0.01
<0.01
(2.59 – 2.66)
(2.22 – 2.31)
(0.85 – 0.88)
45.99
49.74
1.08
Anxiety
<0.01
<0.01
<0.01
(44.90 – 47.10)
(48.31 – 51.22)
(1.06 – 1.11)
9.83
9.72
0.99
Depression
<0.01
<0.01
0.15
(9.60 – 10.05)
(9.44 – 10.01)
(0.96 – 1.01)
5.78
10.55
1.07
Insomnia
<0.01
<0.01
<0.01
(5.67 – 5.89)
(10.23 – 10.88)
(1.04 – 1.10)
0.22
0.21
0.94
Multiple psychiatric
<0.01
<0.01
<0.01
disorder diagnoses
(0.21 – 0.23)
(0.20 – 0.22)
(0.91 – 0.98)
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Table 6.7. Characteristics of prescription drug monitoring programs 2007-2009.31,32
Reporting
State
Housing Agency Authorized Users Schedules Monitored
Frequency
Prescribers
Alabama
Health Focused
II-V
Weekly
Pharmacists
Prescribers
Arizona
Licensing Board
II-IV
Weekly
Pharmacists
Prescribers
California
Safety Focused
Pharmacists
II-IV
Monthly
Law Enforcement
Prescribers
Colorado
Licensing Board
II-V
Bi-monthly
Pharmacists
Prescribers
Connecticut
Safety Focused
II-V
Weekly
Pharmacists
Prescribers
Hawaii
Safety Focused
II-IV
Monthly
Pharmacists
Prescribers
II-IV
Idaho
Licensing Board
Pharmacists
Non-controlled
Monthly
Law Enforcement
substances
II-III
Prescribers
(until Dec 31, 2007)
Illinois
Health Focused
Pharmacists
Bi-monthly
II-V
Law Enforcement
(starting Jan 1, 2008)
Prescribers
Indiana
Licensing Board
II-IV
Bi-monthly
Law Enforcement
Prescribers
Iowa
Licensing Board
II-IV
Bi-monthly
Pharmacists
Prescribers
Kentucky
Health Focused
Pharmacists
II-V
Weekly
Law Enforcement
Prescribers
Louisiana
Licensing Board
II-IV
Bi-monthly
Pharmacists
Prescribers
Maine
Health Focused
II-IV
Bi-monthly
Pharmacist
Prescribers
Massachusetts
Health Focused
II
Monthly
Pharmacists
Prescribers
Michigan
Licensing Board
Pharmacists
II-V
Monthly
Law Enforcement
II-IV
Prescribers
Mississippi
Licensing Board
Non-controlled
Monthly
Pharmacists
substances
II-V
Prescribers
Nevada
Licensing Board
Non-controlled
Monthly
Pharmacists
substances
Prescribers
New Mexico
Licensing Board
Pharmacists
II-IV
Monthly
Law Enforcement
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Table 6.7. Characteristics of prescription drug monitoring programs 2007-2009 (cont’d).
New York
Health Focused
Prescribers
II-V
Monthly
Prescribers
North Carolina
Health Focused
II-V
Monthly
Pharmacists
Prescribers
II-V
North Dakota
Licensing Board
Pharmacists
Non-controlled
Daily
Law Enforcement
substances
II-V
Prescribers
Ohio
Licensing Board
Non-controlled
Bi-monthly
Pharmacists
substances
Prescribers
Oklahoma
Safety Focused
II-V
Monthly
Pharmacists
Prescribers
Tennessee
Licensing Board
Pharmacists
II-V
Weekly
Licensing Boards
Prescribers
Pennsylvania
Safety Focused
II
Monthly
Pharmacists
Rhode Island
Licensing Board Law Enforcement
II-III
Monthly
Prescribers
South Carolina
Health Focused
Pharmacists
II-IV
Monthly
Law Enforcement
Prescribers
Texas
Safety Focused
Pharmacists
II
Monthly
Law Enforcement
Prescribers
Utah
Licensing Board
II-V
Monthly
Pharmacists
Prescribers
Vermont
Health Focused
II-IV
Weekly
Pharmacists
Prescribers
Virginia
Licensing Board
II-IV
Bi-monthly
Pharmacists
Prescribers
West Virginia
Licensing Board
II-V
Weekly
Pharmacists
II-V
Prescribers
Wyoming
Licensing Board
Non-controlled
Monthly
Pharmacists
substances
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Table 6.8. Characteristics of PDMPs that impact the dispensing of benzodiazepines.
Variable
Odds Ratio
p-value
95% Confidence Interval
PDMP
No operational PDMP
Ref.
Operational PDMP
0.96
0.21
0.91 – 1.02
Housing Agency
Licensing agency
1.00
0.83
0.97 – 1.04
Health focused agency
0.97
0.06
0.93 – 1.01
Safety focused agency
0.70
<0.01
0.68 – 0.73
Groups Authorized to Access
No pharmacist access
Ref.
Pharmacists
1.24
<0.01
1.21 – 1.27
No law enforcement access
Ref.
Law Enforcement Officials
1.03
<0.01
1.01 – 1.05
Schedules Monitored
Schedule II only
Ref.
Schedule II & III
1.03
0.13
0.99 – 1.06
Schedules II-IV
1.01
0.80
0.95 – 1.07
Schedule II-V
1.17
<0.01
1.12 – 1.24
Reporting Frequency
Monthly
Ref.
Bi-monthly
0.87
<0.01
0.85 – 0.88
Weekly
1.10
<0.01
1.07 – 1.13
Daily
0.74
<0.01
0.66 – 0.83
Authority to monitor non-controlled substances
Non-controlled substance
Ref.
monitoring not authorized
Authority to monitory non0.91
<0.01
0.89 – 0.93
controlled substances
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Figure 6.1. Percentage of study population who filled a benzodiazepine prescription in each
month between January 2007 and December 2009.
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Figure 6.2a. Relative effect of PDMP implementation on the proportion of beneficiaries filling
a benzodiazepine prescription (Arizona).
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Figure 6.2b. Relative effect of PDMP implementation on the proportion of beneficiaries filling
a benzodiazepine prescription (Connecticut).
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Figure 6.2c. Relative effect of PDMP implementation on the proportion of beneficiaries filling
a benzodiazepine prescription (Illinois).
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Figure 6.2d. Relative effect of PDMP implementation on the proportion of beneficiaries filling
a benzodiazepine prescription (Iowa).
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Figure 6.2e. Relative effect of PDMP implementation on the proportion of beneficiaries filling
a benzodiazepine prescription (Louisiana).
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Figure 6.2g. Relative effect of PDMP implementation on the proportion of beneficiaries filling
a benzodiazepine prescription (South Carolina).
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